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ABSTRACT 
Single nucleotide polymorphism (SNP) is a variation of a single nucleotide in the 
genome. Some of these variations can cause a change of single amino acid in the 
corresponding protein, resulting in single amino acid variation (SAV).  SAVs can lead to 
profound alterations of the corresponding biological processes and thus can be associated 
with many human diseases. This dissertation focuses on integration of existing and 
development of new computational approaches to model the effects of SAVs with the goal 
to reveal molecular mechanism of human diseases. Since proton transfer and pKa shifts are 
frequently attributed to disease causality, the proton transfers in the protein-nucleic acid 
interactions are investigated and along with development of a new computational approach 
to predict the SAV’s effect on the protein-DNA binding affinity. The SAVs in four proteins: 
Lysine-specific demethylase 5C (KDM5C), Spermine Synthase (SpmSyn), 7-
Dehydrocholesterol reductase (DHCR7) and methyl CpG binding protein 2 (MeCP2) are 
extensively studied using numerous computational approaches to reveal molecular details 
of disease-associated effects. In case of MeCP2 protein, the effects of the most commonly 
occurring disease-causing mutation, R133C, was targeted by structure-based virtual 
screening to identify the small molecules potentially to rescue the malfunctioning R133C 
mutant.   
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CHAPTER ONE 
 
INTRODUCTION 
 
 
Importance of modelling the molecular effect of single amino acid variation: 
 
    Human genetic variations result in natural differences among the humans or may cause 
diseases[1]. Genetic variations originate from subtle differences in DNA and it is well 
know that humans share 99.5% of DNA code and only the rest 0.5% results in the 
uniqueness of individuals. However, despite of low occurrence, common genetic variations 
may contribute significantly to human’s susceptibility to common diseases[2-4]. Thus, 
understanding common human genetic variations and associated functional impact is a very 
important part of any genetic study and has great potential for direct clinical applications[5, 
6]. 
    Genetic differences can be manifested at different levels as a Single Nucleotide 
Polymorphism (SNPs), which is a change of single nucleotide or as non-synonymous SNP 
(nsSNP), manifested as amino acid change in the corresponding transcribed product. My 
dissertation focused on substitutions of single amino acid in the corresponding protein.  
Following the literature, such a change is termed single amino acid variation (SAV) [4, 7-
9]. The SAV can affect the corresponding protein’s function and thus may be associated 
with many human diseases[10-13]. Predicting disease associated SAV’s effect and 
discriminating disease-causing and harmless SAV is of crucial importance for the early 
diagnostics and medicine [5, 14-17]. However, predicting the effect of disease-associated 
SAV is not a trivial problem[18, 19], prompting many researchers to develop predictive 
algorithms and tools[6, 18-23]. 
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Disease-causing SAV can cause malfunctioning of the corresponding protein [13, 18, 
24-26]. Some disease-causing SAVs affect protein stability, resulting in unfolded 
dysfunctional protein [11, 25, 27, 28]. Other disease-causing SAVs that occur in protein 
binding interface may disrupt the protein interaction network by altering the affinity of 
interacting partners [24, 29, 30]. The effects on protein folding and binding can be accessed 
via the changes of folding free energy (G) and binding free energy (G). Many 
computational and experimental efforts were carried out to determine the changes of 
folding and binding free energies due to SAVs [30-34].  Roughly speaking, current existing 
methods can be categorized into sequence-based approaches, structure-based approaches 
and first principle approaches. Sequence-based approaches utilized machine learning 
models to perform fast predictions but highly depend on the training datasets. Structure-
based approaches consider the potential function or knowledge-based scoring function 
delivered from protein structural information.  First principle approaches, such as the free 
energy perturbation (FEP) and the thermodynamic integrations (TI) are the most rigorous, 
but require intensive calculations, which limit their applicability for large-scale analysis. 
The experimental studies are relatively limited due to the highly cost in time and expense. 
Thus, integration of existing in silico approaches can help us better understand the 
molecular mechanism of the disease-associated SAVs, which is crucial for the personalized 
medicine and identification of potential drugs for treatment. Besides, further development 
of accurate approaches is also highly in demand for understanding the mechanism of 
diseases and protein design. Especially for large scales-analysis of mutations’ effects, 
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computational approaches can complement the experimental measurement and provide fast 
predictions (Chapter III).   
 
Rescue the effects of disease associated single amino acid variation: 
    With the rapid development of computer techniques, computer-aided approaches have 
been currently widely applied in aiding early-stage drug discovery in both industrial and 
academic projects [35-38].  By discovering the potential compounds that target and affect 
the function of the specific proteins, the biological process can be modulated to mitigate or 
eliminate the disease-causing effects [36, 38].  Advances in human genome projects have 
provided vast target proteins for drug discovery projects [39, 40]. Meanwhile, 
breakthroughs in structural biology have offered in-depth structural information of more 
and more targets and elucidated the disease mechanisms at molecular level [41-44]. Such 
advances have further stimulated the application of computational approaches to integrate 
the available structural information, functional mechanism and physical-chemical 
properties to drug discovery [37, 45].  Discovery of compounds to mitigate or eliminate 
the disease-causing effects induced by a specific amino acid mutation is the main goal of 
Personalized Medicine [1]. 
Importance of elucidating and clustering the mutations’ effects in drug design: 
    In terms of a drug-design process targeting specific disease-causing mutations, 
elucidation of mutations’ effects is of great importance, especially for the approaches 
requiring information about target protein structure. Alone with aforementioned 
computational approaches, it can be integrated into the drug design pipeline (Fig. 1.1). For 
example, free energy calculation methods are used to determine the dominant effects of 
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mutations, whether affecting protein stability, protein binding or both.  With the in-depth 
analysis of mutations’ effects at molecular-level, the disease-causing mutations in the 
target proteins can be further clustered by their major effects such as destabilizing 
mutation, dimerization-affecting mutation, conformational-affecting mutation or catalytic 
mutation [41, 46-48]. Such type of classification can help designing drugs for certain 
groups of mutations with similar effects and thus being applicable to broader spectrum of 
patients.  
Structure-based approach in drug design: 
     Structure-based drug design (SBDD) is the computational approaches that rely on 
knowledge of the 3D structure of the biological targets to identify or design the potential 
chemical structure suitable for clinical tests[45, 49] (Fig 1.1). With the explosion of 
genomic, functional and structural information in last decades, vast of biological targets 
with 3D structure have been identified and stimulated the applications of structure-based 
approaches in current design pipeline. SSDB is popular for virtual screening to filter the 
drug-like compounds from a large library of small molecules, including widely applied 
approaches such as docking and structure-based pharcorphore [38]. While the established 
high-throughput screening (HTS) allows for automatic testing of vast compounds (up to 
millions), the low success rate and high cost limits its applications. Alternatively, one can 
use computational approaches to reduce the numbers of compounds subjected to testing 
[36, 50]. 
Ligand-based approaches in drug design: 
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    In the cases of lacking structural information of target protein, the aforementioned 
structure-based approaches may not be suitable for drug design. Alternatively, ligand-
based drug design (LBDD) can be applied for such cases [51]. Ligand-based methods only 
focus on the analysis of physico-chemical properties of known ligands that interact with 
the target of interests. Most popular approaches are quantitative structure activity 
relationship (QSAR) models and ligand-based pharmacophore modeling [51]. In terms of 
drug design targeting the mutant proteins, LBDD could be efficient for novel discovered 
mutations which effects have not yet been investigated (Fig. 1.1). 
    With the advances in understanding of structural and functional characteristics of 
biological targets, structure-based approaches have gained popularity. However, it should 
be pointed out that combining both ligand and structure-based approaches is expected to 
provide significant advantages [52, 53].   
 
 
Figure 1.1 Schematic presentation of drug discovery process to mitigate the effects of 
disease-causing mutations. 
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CHAPTER TWO 
MODELLING THE EFFECTS OF SINGLE AMINO ACID VARIATION  
 
Modelling of SAVs’ molecular effects in KDM5C protein: 
 
PART1: Mutations in KDM5C ARID-domain and their association with Syndromic 
Claes-Jensen-Type Disease: 
 
1. Introduction 
    Epigenetic processes regulate gene expression and are essential for development and 
differentiation of cells [1]. Histone proteins are the major components of chromatin, acting 
as spools around which DNA winds. Particularly, histone lysine methylation is an 
important epigenetic process which regulates chromatin structure and gene transcription 
[54, 55]. Due to this, loss of balance of histone lysine methylation has been found to have 
a profound effect on the diverse biological processes and to be involved in many diseases, 
including cancer development [56-58]. 
    This work focuses on a particular histone protein, the KDM5C protein of 1560 aa, which 
is a member of the SMCY homolog family. The KDM5C protein specifically reverses tri- 
and di-methylation of Lys4 of histone H3 (H3K4), helps maintain the dynamic balance of 
histone H3K4 methylation states, and also plays a crucial role in functional discrimination 
between enhancers and core promoters [59-61]. It is a multi-functional protein, which 
contains highly-conserved domains, including ARID/Bright, JmjN, JmjC, C5HC2 zinc 
finger, and two PHD zinc finger domains (Figure 2.1). These domains were shown to have 
specific functions alone or to function in concert with the other KDM5C domains. Thus, 
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the ARID (A–T rich interaction domain) is a helix–turn–helix motif-based DNA-binding 
domain, which is highly conserved in all eukaryotic proteins and plays important roles in 
development, tissue-specific gene expression, and cell growth regulation [62, 63]. The 
DNA sequence binding preference is still unclear for the ARID domain of KDM5C. The 
other domain, JmjC, catalyzes demethylation of H3K4me3 to H3K4me1 [59]. The JmjN 
domain and its interaction with the JmjC catalytic domain are important for the KDM5C 
function [64]. The N-terminal PHD zinc finger is a histone methyl-lysine binding motif 
and was shown to have a preferential binding to histone H3K9me3 [59, 65]. 
 
Figure 2.1 KDM5C protein domains. The numbers indicate approximate domain 
boundaries. The known disease-associated missense mutations are provided as well. 
    Previous studies have shown that many mutations in the KDM5C gene cause X-linked 
mental retardation (XLMR), the syndromic Claes-Jensen-type disease [59, 66, 67]. Mental 
retardation (MR) generally causes significant limitations both in intellectual functioning 
and in adaptive behavior, covering the social and practical skills that originate before the 
age of 18 years [68]. The estimated prevalence of MR among the general population is 
around 1%–3% [67, 69]. The frequency of mutations in the KDM5C gene approximately 
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accounts for 2.8% to 3.3% of families with XLMR [70]. Thirteen missense mutations 
associated with XLMR, the syndromic Claes-Jensen-type disease in KDM5C have been 
reported to date and affected individuals with KDM5C mutations show a mild-to-severe 
range of intellectual disability. Most of mutations are located in JmjC domain, ZF domain 
(C5HC2 zinc finger domain), and inter-domain regions and affect the demethylation 
activity [59, 60]. The severity of associated XLMR is roughly related to the cellular 
demethylase activities of KDM5C mutants [71]. In this study, we focus on the mutations 
in the ARID domain. Two MR associated mutations (A77T and D87G) are reported in the 
ARID domain [66, 72]. The D87G mutation causes mild to moderate MR including 
aggressive behavior, epileptic seizures, and speech impairment, while the A77T results in 
severe MR including speech impairment, short stature, seizures, microcephaly, hyper 
reflexia, and aggressive behavior [66, 72]. However, recent work has shown that the D87G 
has a minimal effect on KDM5C demethylase activity in vivo [71] indicating that the 
disease-associated effect is not demethylation. Combined with the lack of data for the 
molecular effect of A77T mutation, it can be concluded that the disease-associated effects 
of both A77T and D87G mutations are unknown. In this work, we extend the list of 
mutations, which will be investigated, to include three currently non-classified missense 
mutations in the ARID domain. The non-classified mutations are R108W(rs146232504), 
N142S(rs377166019), and R178H(rs201805773), taken from the NCBI dbSNP database 
[73]. They were identified from population cohorts participating in the NHLBI Exome 
Sequencing Project [74]. This project is designed to identify genetic variants in coding 
regions of the human genome that are associated with heart, lung, and blood diseases, and 
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the group included 200,000 individuals. However, there is no data about the linkage of 
these mutations with a particular disease. This motivates us to investigate the molecular 
mechanism of all abovementioned mutations, disease-associated and non-classified, and to 
infer plausible XLMR linkages with some of the non-classified mutations. The allele 
frequency of the mutations R108W, N142S, R179H are 0.00001151, 0.00001159, and 
0.0002497 taken from the ExAC database [75]. The frequency of the other two mutations 
is not currently available in the database. 
    Disease-associated mutations are often found to alter protein structure, dynamics and 
interaction, and cause deficiency of important protein functions [76-80]. Investigating 
mutations’ effects is important for understanding the molecular mechanisms of disease-
associated mutations and discriminating disease-causing and harmless mutations. Protein 
stability and protein interactions can be quantified by folding free energy change (∆∆G) 
and binding free energy change (∆∆∆G). In this study, we analyze the effects of diseasing-
associated and currently non-classified mutations on ARID domain stability and ARID-
DNA binding affinity utilizing webservers, third-party software, molecular dynamics (MD) 
and free energy perturbation (FEP) methods. Additionally, our free energy calculations 
results are further validated by experiments. Urea-induced unfolding monitored by circular 
dichroism spectroscopy is used to determine the unfolding free energy of the wild-type 
ARID domain, and the two disease-associated mutants A77T and D87G. 
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2. Results 
2.1. Protein Stability Changes due to Mutations 
    We applied the free energy perturbation theory (FEP) to analyze two disease associated 
(A77T, D87G), and three non-classified (R108W, N142S, R179H), mutations. The 
calculated folding and binding free energy changes caused by mutations are shown in Table 
2.1 It can be seen that the energy changes are predicted to be relatively small, being less 
than 1 kcal/mol in the majority of cases, with the notable exception of FEP calculated 
folding free energy changes involving Arg residue. A similar effect of over-predicting the 
magnitude of the change of the folding free energy involving the Arg group was noticed in 
another study [46]. Further investigations are needed to reveal the source of the over-
estimation of the changes caused by Arg mutants, but for completeness, these calculated 
energies will be used as they are in the present study. The average folding free energy 
changes predicted by webservers and third-party software are all relatively small, being 
less than 1 kcal/mol. The FEP calculated binding free energy changes indicate that 
mutations R108W and R179H cause relatively large changes compared to other mutations. 
 
Mutation 
NeEMO 
(Folding) 
PopMusic 
(Folding) 
I-Mutant 
(Folding) 
DUET 
(Folding) 
CUPSAT 
(Folding) 
Foldx 
(Folding) 
FEP 
(Folding) 
Folding 
(Average) 
FEP 
(Binding) 
A77T −1.03 −0.22 −0.75 −0.76 −0.29 −1.40 0.13 −0.74/−0.62 −0.35 
D87G −0.16 −0.49 −0.47 −0.729 −0.16 −0.60 −0.28 −0.43/−0.41 0.73 
R108W −0.36 −0.86 −1.32 −0.26 0.28 −0.18 −11.29 −0.45/−1.99 −1.44 
N142S −0.21 −0.27 −0.09 −0.02 0.17 −0.3 −0.98 −0.12/−0.24 0.64 
R179H −0.71 0.06 −0.15 −0.72 0.28 0.746 −8.78 −0.08/−1.32 −3.06 
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Table 2.1. The calculated binding and folding free energy changes due to mutations in 
kcal/mol. ∆∆G > 0 indicates stabilization, while ∆∆G < 0 shows destabilization. The 
“Folding (average)” column shows the average folding free energy changes calculated 
using the average folding free energy changes predicted by FEP, webservers, and third-
party software (left), and folding free energy changes predicted by webservers and third-
party software (right). The changes of the binding free energy were obtained only with FEP, 
since no reliable third-party tool currently exist. 
    As mentioned above, the mutations were predicted to have a small effect on both the 
folding and binding free energy (excluding the FEP results for Arg-involving mutations). 
This suggests that the disease-associated effect may not be related to these energies but 
may be linked to structural distortion or change of the internal dynamics/flexibility of the 
ARID domain caused by the mutations. Therefore, we review the structural features of the 
mutation sites below and elaborate on their possible linkage with the predicted effect of 
folding and binding free energy. 
2.2. Effect of Mutations on Protein Structure  
    To analyze the mutations’ plausible effect on the protein structure, here we investigated 
the side chains and backbone conformational changes resulting from mutations and discuss 
them with respect to structural integrity of the ARID domain and its interactions with DNA. 
The mutant is introduced into the structure using the Mutator Plugin, Version 1.3 in VMD 
[81] After that, the mutant structures were subjected to 10,000 steps of energy minimization 
to relax the structure and remove possible conflicting contacts. The structures are then 
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visualized in UCSF chimera [82]. The side chain conformation of the residues within 5 Å 
of the WT position or MT position, are shown in Appendix Figures B-1 and B-2, 
respectively. Appendix Figure B-1 shows side chain conformation of two disease-
associated mutations mapped on the KDM5C ARID domain. The A77T mutation involves 
substitution of a hydrophobic Ala by a polar Thr and is located in a short turn of the ARID 
N-terminal. The mutation site is far away from the DNA binding interface and it is solvent-
exposed. Neither the wild-type A77 nor the mutant T77 were found to be involved in any 
specific interactions (Appendix Figure B-1a,b) The mutation D87G is located in Helix 1 of 
the ARID domain and a charged residue, Asp, is substituted by a small residue, Gly. This 
mutation site is also far away from the DNA binding interface and it is totally solvent-
accessible. The wild-type residue, D87, is not involved in any specific interaction and its 
side chain faces the water (Appendix B Figure B-1 c,d). Based on these structural 
observations and the results of folding free energy calculations, it can be summarized that 
these mutations do not solely affect the stability and the structure of the ARID domain. 
Similarly, since the mutation sites are far away from DNA, the binding interface, and the 
binding free energy is not predicted to be affected, one can assume that the mutations have 
minimal effect on ARID-DNA recognition. 
    Appendix Figure B-2 shows the side chains and backbone conformations of non-
classified mutations mapped onto the ARID domain. The R108W is a positively-charged 
residue, Arg, substituted by an uncharged hydrophobic residue, Trp. This mutation occurs 
in the loop between Helix 1 and Helix 2 and is located close to the DNA binding interface 
(Appendix Figure B2-a,b). Since the mutation drastically changes the physico-chemical 
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property of the wild-type residue, it can be anticipated that this mutation may cause 
significant conformational changes. To address this possibility, we performed 20 ns MD 
simulations of the ARID domain and DNA complex and it was found that R108 does not 
form a direct hydrogen bond with DNA. Thus, the wild-type residue, R108, is probably not 
involved in specific interactions with DNA but may provide long-range steering towards 
the negatively-charged DNA. Figure 2.2 shows the electrostatic potential of WT KDM5C 
ARID domain and the ARID doman with mutation R108W generated by DelPhi software 
[83-85]. It can be seen that the electrostatic potential at the mutation site is changed from 
positive to negative upon the mutation. Since the DNA is highly negatively-charged, this 
electrostatic potential change nearby the DNA binding interface will probably decrease the 
ARID–DNA binding affinity and specificity, which is consistent with predictions of the 
protein binding free energy changes. Further, salt bridge analysis indicated that the R108 
forms a transient salt bridge with the neighboring amino acid, E74. Figure 2.3b shows the 
distance between the oxygen atom of E74 and the nitrogen atom of R108 in the MD 
simulation of the ARID domain and DNA complex. Using a cut-off distance of 4 Å as an 
indication of formation of a salt bridge, it was found that such a salt bridge is formed in 
17.4 ns out of 20 ns (87% of the simulation time). Thus, the mutation R108W will delete 
the salt bridge and will probably affect the protein’s stability, which is consistent with 
prediction of the protein folding free energy changes. The other mutation, N142S, occurs 
in a loop between Helix5 and Helix6, and results in a polar uncharged residue, Asn, 
substituted by another polar uncharged, but smaller, residue, Ser (Appendix Figure B-2c,d). 
Such a mutation preserves the biophysical characteristics of the mutation site and is 
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expected not to affect the stability and structural integrity of the ARID domain. The 
mutation R179H involves a positively-charged residue, Arg, substituted by a polar residue, 
His. It is located in the loop of the ARID domain C-terminal, which is far from the DNA 
binding interface and is totally solvent-exposed (Appendix Figure B-2e,f).  
 
Figure 2.2 (a) Electrostatic potential of the WT KDM5C ARID domain; and (b) the 
electrostatic potential of the KDM5C ARID domain with mutation R108W. The mutation 
site is marked with a red circle. The positive potential region is colored with bule and the 
negative potential region is colored with red. 
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Figure 2.3 (a) Part of the ARID domain zoomed at the salt bridge Glu74-Arg108; and (b) 
salt bridge analysis for Arg108 and Glu74 in the KDM5C ARID domain: N–O distance 
shows the distance between oxygen atom of Glu74 and nitrogen atom of Arg108 in the 20 
ns simulation. The cutoff distance of forming salt bridge is 4 Å and marked with red line 
in the graph. 
2.3. Residue Conservation via Multiple Sequence Alignment 
    Further, we investigate the conservation pattern of the KDM5C ARID domain amino 
acid positions based on the sequence alignment of human ARID domain proteins. The 
alignment (Appendix Figure B-3) shows that the two disease-associated mutations (A77T 
and D87G) are conserved in the KDM5 family and D87 is conserved in ARID1, ARID2, 
and ARID3 families, as well. All non-classified mutations are not conserved in the 
alignment, including the alignment of only KDM5 family members. However, position 108 
is predominantly taken by positively-charged residues, either Arg or Lys. Thus, a 
substitution to hydrophobic, uncharged Trp may not be tolerable. Combined with the 
predicted large change of the folding free energy and the change of the electrostatic 
potential, R108W mutation is predicted to be disease-associated. The other two non-
classified mutations, N142S and R179H, occur at sites that are not conserved and there is 
no pattern to indicate the conservation of physico-chemical property of the wild-type 
residue. Even more, the substitutions Asn to Ser and Arg to His are found to exist in some 
family members (ARID3 and ARID4A), which suggest that such substitutions are tolerable. 
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    Overall, the most highly conserved parts of the ARID domain are located on Loop1, 
Helix2, Helix3, Helix4, Loop2, and Helix5. Recent study showed that the KDM5A ARID 
domain binds DNA through the motif CCGCCC and the DNA binding interface includes 
Loop1 and a helix-turn-helix DNA binding motif formed by Helix4, Loop2, and Helix5 
[86]. More specifically, six key residues (Pro103, Lys112, Gly123, Gly124, Trp134, and 
Tyr 157) are conserved in all human ARID-containing proteins, which indicates their 
importance for protein function.  
2.4. Evolutionary Conservation and Protein Interacting Investigation Using the ConSurf 
Server and IBIS Server 
    The ConSurf server is a bioinformatics tool for estimating the evolutionary conservation 
of amino/nucleic acid positions in a protein/DNA/RNA molecule based on the 
phylogenetic relations between homologous sequences. The ConSurf server result (Figure 
2.4) shows that the N-terminal of the ARID domain is one of the most highly-conserved 
parts in the ARID domain, which is probably essential for protein’s function. We also 
predict the protein interacting partners and binding sites in the KDM5C ARID domain 
using the NCBI Inferred Biomolecular Interactions Server(IBIS) [87].The results show that 
Asp87 is a plausible zinc ion binding site. This binding sites is not verified experimentaly, 
but offer an implication that the N-terminal of ARID may be involved in some currently-
unknown function. 
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Figure 2.4. Evolutionary conservation analysis of the ARID domain using the ConSurf 
Server. The conservation grades are color-coded onto each amino acid of the KDM5C 
ARID domain. 
2.5. Experimental Results 
The mutations A77T and D87G affect the overall structure of the ARID domain slightly, 
but the percentage of each secondary structure of the mutants was in the same range as the 
wild-type (Table 2.2). In general, the effects of both A77T and D87G are the increase of 
the unordered structure percentage of the protein. While in the A77T mutation, the 
proportion of the structure shifted from alpha helix and turns to unordered; in D87G the 
shift came from of alpha helix and beta strand. 
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 Helix Strand Turns Unordered 
WT 14% 31% 20% 35% 
A77T 13% 31% 19% 38% 
D87G 13% 30% 20% 38% 
Table 2.2 Percentage of secondary structures of ARID proteins analyzed by using 
CONTINNLL [88] with the online tool Dichroweb [89]. 
The results from the urea denaturation experiments (Table 2.3 and Appendix Figure B-
4) indicate that both mutations caused a lower integrity protein structure (lower ∆G, easier 
to denature) than the wild-type, where the A77T is relatively more stable compared to 
D87G (but the difference is very small). There is a difference of the free energy of 
unfolding value of the ARID wild-type and the mutants. The two different methods to 
calculate the ∆∆G yields different value but the trends are the same, where the two mutants 
are less stable than the ARID wild-types, and D87G is less stable than A77T. The ∆∆G of 
the mutants A77T and D87G obtained by urea-induced unfolding monitored by CD are in 
the same order of magnitude compared to the in silico folding free energy predictions 
(Table 2.1). 
 
Protein 
∆𝑮𝒂𝒑𝒑
𝑯𝟐𝑶 
(kcal·mol−1) 
∆∆𝑮𝒂𝒑𝒑
𝑯𝟐𝑶 
(kcal·mol−1) 
[urea]½ 
(M) 
∆∆𝑮𝒂𝒑𝒑,𝟐
𝑯𝟐𝑶  
(kcal·mol−1) 
ARID WT 3.51 ± 0.32  3.99 ± 0.02  
A77T 2.41 ± 0.05 1.10 3.07 ± 0.02 0.70 
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D87G 1.82 ± 0.01 1.70 2.99 ± 0.03 0.76 
 
Table 2.3 Results from an analysis of urea denaturation curves for ARID Wild-Type, A77T, 
and D87G variants. 
3. Methods and Experimental Section 
3.1. Structures 
    The ARID domain contains 90 amino acids and its sequence is mapped onto the KDM5C 
protein sequence from position 79 to 169. There is an NMR structure of the KDM5C ARID 
domain (PDB ID: 2JRZ) [90] in the Protein Data Bank (PDB) [91], which was used for 
modeling the ARID domain stability. The modeling of the effect of mutations on ARID-
DNA interactions requires the 3D structure of ARID-DNA complex, which is not available 
in the PDB and was generated in silico. For this purpose, we applied structural alignment 
between the KDM5C ARID domain (PDB ID: 2JRZ) and all available ARID-DNA 
complexes in PDB. The lowest RMSD value (2.22 Å) calculated from structural alignment 
(the alignment between the DNA binding interface of the KDM5C ARID domain and the 
ARID domain in the available complex structures) was found for the solution structure of 
the dead ringer ARID-DNA complex (PDB ID: 1KQQ) [92]. The dead ringer and the 
KDM5C ARID domains’ structural similarity (showed the lowest RMSD value (2.22 Å) 
calculated from structural alignment) was the highest for the residues situated at the 
protein-DNA interface, which suggested that the binding mode is preserved (Appendix 
Figure B-5). Thus, the model ARID-DNA complex was built by superimposing the 
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KDM5C ARID domain onto the dead ringer ARID-DNA complex and replacing the dead 
ringer ARID domain with the KDM5C ARID domain. Then, we saved the structure of the 
KDM5C ARID domain and DNA with untransformed coordinates as our model using the 
UCSF Chimera [82]. The DNA sequence in the model was kept the same as in the dead 
ringer ARID-DNA complex since the KDM5C ARID was not reported to show a DNA 
binding preference.  
3.2. ARID Folding and Binding Free Energy Changes 
    We calculated the folding free energy change (∆∆G) and the binding free energy change 
(∆∆∆G) based on free energy perturbation theory (FEP) [93, 94]. The free energy 
calculations of five mutations (A77T, D87G, R108W, N142S, and R179H) were performed 
with the NAMD program, version 2.9 [95] using alchemical transformations via the so-
called dual topology approach [95, 96], where both the initial and final states were defined 
concurrently. Periodic boundary conditions and a 12 Å cutoff distance for non-bonded 
interactions were applied in the system. Each FEP simulation was run using a 
CHARMM22 force field [97] and each mutation was carried out with one 18 ns run and 
four 5 ns runs. The initial protein structure used for each run was randomly taken from the 
trajectory of a 10 ns long equilibration. The results obtained with 18 ns and 5 ns runs were 
very similar and most of the 5 ns runs showed good convergence comparable with the 
convergence of 18 ns run. This motivated us to carry the rest of the FEP using 5 ns 
simulations. Then, the output of FEP simulations was analyzed with the ParseFEP Plugin, 
Version 1.9 [98] in Visual Molecular Dynamics (VMD) [81]. Also, it has to be pointed out 
that Gly is a very particular case in FEP calculations since the library of hybrids contains 
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the dual topologies for amino acids with a true side chain and the alpha carbon of Gly atom 
has to be modified in the transformation. For that reason, most patches cause problems and 
mutating glycine caused some angle and dihedral parameters to be duplicated, possibly 
modifying backbone conformational preferences [99]. Similar problems were also 
observed in our FEP calculation and, here, the FEP calculations of D87G were carried out 
for 1 ns with 0.5 fs time steps. For completeness, these calculated energies of D87G are 
used as they are in the present study. 
The calculations of the effects of mutations on the folding free energy were performed 
utilizing the thermodynamic cycle we have developed in the past [20, 24, 100, 101] 
(Appendix Figure B-6a). The main assumption in this model is the unfolded state, which 
is considered to be made of two structural segments: (i) a structural three-residue segment 
centered at the mutation site; and (ii) the rest of the protein being mutation-independent 
[20, 24, 100]. This allows for canceling mutation-independent components of the unfolded 
state. Thus, the folding free energy change due to a mutation was calculated with the 
following equation: 
∆∆𝐺𝑓𝑜𝑙𝑑𝑖𝑛𝑔 =  ∆𝐺𝑓𝑜𝑙𝑑𝑖𝑛𝑔_𝑊𝑇 − ∆𝐺𝑓𝑜𝑙𝑑𝑖𝑔_𝑀𝑇 = 𝐺𝑓𝑜𝑙𝑑𝑒𝑑_𝑊𝑇 − 𝐺𝑢𝑛𝑓𝑜𝑙𝑑𝑒𝑑_𝑊𝑇
3 −
                                                  𝐺𝑓𝑜𝑙𝑑𝑒𝑑_𝑀𝑇 + 𝐺𝑢𝑛𝑓𝑜𝑙𝑑𝑒𝑑_𝑀𝑇
3                                   (2.1) 
  
,where G3unfolded_X is the free energy of the unfolded state of the three-residue segments at 
the center of mutation site, and x stands for WT or MT, respectively. 
The effect of mutations on the binding free energy was calculated with the following 
thermodynamic cycle (see refs for more details [20, 102-105]) (Appendix Figure B-6b), 
and the corresponding equation is provided below:  
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∆∆𝐺𝑏𝑖𝑛𝑑𝑖𝑛𝑔 =  ∆𝐺𝑏𝑖𝑛𝑑𝑖𝑛𝑔_𝑊𝑇 − ∆𝐺𝑏𝑖𝑛𝑑𝑖𝑛𝑔_𝑀𝑇 = 𝐺𝑏𝑜𝑢𝑛𝑑𝑒𝑑_𝑊𝑇 − 𝐺𝑢𝑛𝑏𝑜𝑢𝑛𝑑𝑒𝑑_𝑊𝑇 −
                                                             𝐺𝑏𝑜𝑢𝑛𝑑𝑒𝑑_𝑀𝑇 + 𝐺𝑢𝑛𝑏𝑜𝑢𝑛𝑑𝑒𝑑_𝑀𝑇                                  (2.2) 
,where the unbounded state means the protein is taken away from its partner and bounded 
state means the protein forms a complex with its partner protein. 
3.3. Utilizing Webservers and Third Party Software 
    Third-party methods were also used to predict protein folding free energy change, 
including webservers and stand-alone computer algorithms. The webservers used to predict 
the folding free energy changes upon single point mutations include NeEMO [106], 
PopMusic [107], I-Mutant 2.0 [108], DUET [109], and CUPSAT [110]. Additionally, a 
computer algorithm, FoldX 3.0 Beta3 [111, 112], was used to predict the folding free 
energy changes upon single-point mutations. Currently, no reliable third-party software or 
a functioning webserver for predicting binding free energy changes are available. 
3.4. Molecular Dynamics Simulation 
    We carried out MD simulations to investigate mutations’ effects on the dynamics on the 
ARID domain. The simulations were set up within the NAMD program, version 2.9 [95], 
using the CHARMM22 force field [97]. The PDB structure taken from Protein Data Bank 
[91] was used as the initial structure. To relax conflicting contacts, energy minimization 
was performed using the conjugate gradient energy minimization of 10,000 steps. The 
protein was solvated in a water box with a layer of water extending 10 Å in each direction 
before the minimization and equilibration with periodic boundary conditions. Temperature 
and pressure in the simulation were set to 298 K and 1 bar. Each mutation was repeated for 
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three 100 ns runs using 2 fs time steps. The trajectory files were analyzed by using VMD 
plugins [81] in order to obtain the RMSD, RMSF, and salt bridges. 
3.5. Electrostatic Potential Calculation 
    The DelPhi program was used to perform the electrostatic potential calculations using 
the following parameters: scale = 2 grid/Å; percentage of protein filling of the cube = 70%; 
dielectric constant = 2 for the protein and 80 for the solvent; and water probe radius = 1.4 
Å. We outputted the DelPhi-calculated potential map into a file in CUBE format, which 
was further opened and analyzed in UCSF Chimera. 
4. Discussion and Conclusion 
    The KDM5C ARID domain binds to DNA and the formation of an ARID-DNA complex 
is important for the KDM5C function in humans [62, 64, 86]. Our analysis shows that 
A77T and D87G have minimal effect on the ARID domain’s DNA binding, which 
indicates that the disease-associated mechanism is probably not due to the alteration of 
DNA binding. It is also interesting that both of the disease-associated mutations are located 
onto the N-terminal of the ARID domain and both of the mutations are far away from the 
ARID domain’s DNA binding interface. We speculate that some not-yet-discovered 
function of the KDM5C protein is associated with the ARID domain’s N-terminal. To test 
this, we analyzed the KDM5C ARID domain using the ConSurf Server [113-116].The 
Consurf results support our speculation and show that both of the disease-associated 
mutations are located in the most highly-conserved part of the ARID domain and possibly 
cause a change in an important function of the protein. Additionally, D87 is predicted to 
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be a plausible zinc ion binding site and further supports that some currently-unknown 
function is linked to N-terminal of the ARID domain. 
    Previous studies show that KDM5C is a muti-functional protein and inter-domain 
interactions are identified among the JmjN domain, N-PHD domain, and JmjC domain [59, 
64, 71]. The interaction between the JmjC domain is important for the demethelytion 
activity. The N-PHD domain and JmjC domain can bind to the same histone tail at Lys4 
and Lys9. Both of pathogenic mutations happen in the N-terminal of the ARID domain and 
are close to the linker part between the ARID and JmjN domains. This suggests that A77T 
and D87G may be involved in some unknown interaction among JmjN, ARID, PHD, and 
JmjC domains. Currently, only the ARID domain structure is available and the arrangement 
of the KDM5C domain is unknown. 
    Our study also evaluates three non-classified mutations’ effects on the KDM5C ARID 
domain. Among them, the R108W causes a loss of a salt bridge, slightly affecting protein’s 
stability and ARID-DNA binding affinity. Therefore, we speculate that R108W is a 
disease-associated mutation based on altering structural features rather than on the 
calculated free energy changes. In addition, as demonstrated, R108W changes the 
electrostatic potential near the DNA binding site which may affect the specificity of ARID-
DNA binding.  
    In our work, protein binding and folding energy changes were calculated with FEP, 
webservers, and third party software. Limitation about the technical issues in FEP 
calculations are observed for the Arg- and Gly-involved mutations, possibly causing less 
reliable predictions. Therefore, other methods, including webservers and third-party 
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software were also applied in the free energy calculation to compare with the FEP results. 
Furthermore, the experimental results of the mutants A77T and D87G are obtained by urea-
induced unfolding methods, showing the same order of magnitude compared to the folding 
free energy calculation. Another limitation about this work is that our speculation about 
the unknown function in the N-terminal of the ARID domain has not been experimentally 
verified and, currently, the only known function about the ARID domain is the DNA 
binding interaction. However, our work implicates that the sites 77 and 87 may be involved 
in some other function or interaction different from cognate ARID-DNA binding. This 
provides motivation for future studies to further investigating other functions of KDM5C. 
 
PART2:  Computational model for quaternary structure of Lysine-specific demethylase 
5C (KDM5C) protein 
1. Introduction 
    The epigenetic processes control transcription of genes and result in the widely different 
gene expression patterns in different tissues and organs [117, 118]. The most frequently 
occurring histone modifications involve acetylation, phosphorylation, methylation, 
ubiquitination and crotonylation [119, 120]. Lysine methylation is one of the most 
important histone modifications among them, and has a crucial role in heterochromatin 
formation, X-chromosome inactivation and transcriptional regulation. Histone lysine 
methylation occurs in histones H3 and H4, and this methylation results in lysine residue’s 
three different methylation states (mono-, di-, and tri-), which are associated with different 
nuclear features and transcriptional states[56].  
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    The KDM5C gene (also known as JARID1C and SMCX) is located on the X chromosome 
and encodes a ubiquitously expressed 1,560-aa protein, which plays an important role in 
transcriptional regulation and chromatin remodeling [71]. The KDM5C protein belongs to 
the JARID subfamily of JmjC-containing proteins. The function of JmjC domain is to 
specifically demethylate di- and trimethylated lysine 4 on histone 3 [59]. The KDM5C acts 
as a transcriptional repressor and many mutations in the KDM5C gene has been shown to 
cause X-linked mental retardation (XLMR) and the syndromic Claes-Jensen-type disease 
[48, 59, 67]. Most of disease-causing mutations are located on JmjC domain, ZF domain 
(C5HC2 zinc finger domain) and inter-domain regions. These mutations are expected to 
affect the protein stability and enzymatic activity [59, 121].  
    Overall KDM5C is a multi-functional protein, consisting structurally of several well-
defined domains, including ARID, JmjN, JmjC, ZF, and two PHD zinc finger domains. 
Little experimental data is available about the 3D structure of the entire protein, individual 
domains and the interactions with its partners. The first experimental structure of one of 
the KDM5C domains is the solution structure of ARID domain, released in 2007 [90]. In 
the past, we used it to generate a 3D model of the ARID-DNA complex [48]. Very recently, 
the 3D structure of part of the human KDM5C protein (JmjN, JmjC and ZF domains) was 
released [122]. The same work revealed that ARID and PHD1 domains contribute to the 
histone substrate recognition despite not being directly required for demethylase activity 
[122]. However, there is still no experimental or theoretical 3D structure of KDM5C 
protein which includes JmjN, ARID, JmjC, C5HC2 zinc finger (ZF), and two PHD 
domains.  
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    Several XLMR-associated mutations were shown to reduce KDM5C demethylase 
activity and binding to the H3K9me3 peptide [123]. Specifically, ARID domain is a DNA-
binding domain in which two missense mutations (A77T and D87G) were reported [67]. 
The other domain, the JmjC domain, catalyzes demethylation of H3K4me3 to H3K4me1, 
and three missense mutations (D402Y, S451R and Y642L) are experimentally shown to 
reduce KDM5C demethylase activity [123]. Several pathogenic mutations (A388P, 
R731W and Y751C) were reported in the PHD1 domain (a histone methyl-lysine binding 
motif) and ZF domain and were shown to reduce the demethylase activity as well [123]. 
However, the molecular mechanism of the above-mentioned disease-causing mutations is 
mostly unknown. Perhaps this is due to the lack of experimental or theoretical 3D structure 
of KDM5C protein, which would allow for modeling the effects of mutations on domain 
stability and inter-domain interactions. The goal of this work is to fill this gap by 
developing a 3D structural model of KDM5C quaternary structure and using it to model 
the effects of disease-causing mutations on KDM5C stability, dynamics and inter-domain 
interactions.  It is understood that such multi-functional and multi-domain proteins may 
adopt various domain arrangements in different functional states. Thus, the quaternary 
structure that is reported in this work represents one of several domain arrangements of 
KDM5C that the protein may adopt during its functional cycle.  
 
2. Results and Discussion 
    The results section has three major components, namely a report of building 3D models 
of the corresponding KDM5C domains and arranging them into quaternary structure of 
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KDM5C, and then validating and using the 3D structure of KDM5C protein to predict the 
effect of XLMD-linked mutations. Below we describe the results in sequential order.  
2.1 Modeling quaternary structure of KDM5C protein 
2.1.1 Homology model of KDM5C PHD1 domain 
    As mentioned above, KDM5C is multi-domain protein consisting of well-defined 
domains as JmjN, ARID, PHD, JmjC and ZF domains. For most of them, JmjN, ARID, 
JmjC and ZF domains, there is experimental 3D structure available (Protein Data Bank 
(PDB) ID:2JRZ and 5FWJ)[90]. However, the 3D structure of PHD1 domain is not 
available and must be modeled. For this purpose, we used homology modeling, since high 
homology templates do exist. Thus, the amino acid sequence of KDM5C was submitted to 
the PSI-Blast [124] and the search was performed against the sequences of proteins in PDB 
database [91]. The best template for KDM5C PHD1 domain is the solution structure of 
another PHD domain within JARID family (PDB: 2E6R), with 84% sequence identity 
[125]. Then, we used SWISS-MODEL server [126] to generate the homology model for 
KDM5C  PHD1 domain. 
2.1.2 Quaternary structure of KDM5C catalytic core 
    We began the modeling of quaternary structure of KDM5C protein by taking advantage 
of recently released experimental structure (PDB ID: 5FWJ), which includes JmjN, JmjC 
and ZF domains. The experimental structure revealed a previously known fact that JmjN 
interacts with JmjC domain and that this interaction is crucial for the KDM5C protein 
stability and catalytic function [64, 122]. Furthermore, it is known that the ZF domain is 
required for catalytic activity of JARID proteins [127]. 
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    While it is known that JmjC domain demethylates di- and trimethylated lysine 4 on 
histone 3 (H3K4me2 and H3K4me3) along with the cofactors Ferrous ion (Fe2+) and 
alpha–ketoglutarate (2-oxoglutaric acid), the binding mode of histone peptide to JmjC 
domain is still unknown for the JARID family. Developing such a model is one of the goals 
of this work and we intend to generate it by taking the advantage of the experimental 
structures of other JmjC domain containing proteins. For this purpose, we first collected 
all existing experimental structures of JmjC domain bound to histone peptide. The 
experimental structures include the structure of KDM2A bound to H3K36me1 (PDB ID: 
4QXH) [128], the structure of JMJD2B complexed with H3K9me3 (PDB ID: 4LXL) [129], 
the structure of human JMJD2D/KDM4D in complex with an H3K9me3 peptide (PDB 
ID:4HON) [130],  the structure of KDM6B bound with H3K27me3 peptide (PDB ID: 
4EZH) [131], the structure of KDM7A from C.elegans complexed with H3K4me3 peptide, 
H3K9me2 peptide and NOG (PDB ID: 3N9O) [132], and the complex structure of 
JMJD2A and trimethylated H3K36 peptide (PDB ID:2P5B) [133]. The structural 
alignment was applied using the Chimera [82] for all collected structures. Figure 2.5A 
shows the results of structural alignment and it can be observed that the structures are 
highly conserved among different JmjC containing proteins. The positions of the histone 
peptides are also similar among different proteins, especially for the regions close to the 
bound Lys4 residue.  Therefore, we took the average coordinates of these histone peptide 
backbones, which were manually assigned to the histone 3 peptide residues from 1 to 10. 
The side chain of each residue was generated using the most probable rotamer from the 
Dunbrack backbond-dependent rotamer library [134] as implemented in Chimera [82]. 
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Further, Lys4 and Lys9 in the peptide were modified to H3K4me3 and H3K9me3 using 
Avogadro [135], since in vivo they are methylated as they bind to JmjC and PHD1 domains. 
Finally, auto-optimization was performed for the peptide with Avogadro [135] to correct 
for bad contacts and improper bonds. 
    Since the template experimental structure contains Mn2+ ion and inhibitor MMK instead 
of enzymatic cofactors Fe2+ ion and 2-oxoglutaric acid, the enzymatic cofactors must be 
placed in the model to replace the template cofactors.  This was done by superimposing 
template structure (structure of rice JMJ703 in complex with alpha-KG, PDB ID: 4IGO) 
onto the structure of KDM5C catalytic core and then replacing the template cofactors with 
enzymatic cofactors. The final model of KDM5C catalytic core bound with histone peptide 
and enzymatic cofactors is shown in Appendix Figure 5B. 
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Figure 2.5: (A) Structural alignment of all existing JmjC domains bound to histone peptide. 
The histone peptides are marked in red. The JmjC domains are marked with other colors. 
The C and N terminals of the histone peptide are labeled as C and N, respectively. (B) The 
model of KDM5C catalytic core bound to histone peptide and enzymatic cofactors. The 
histone peptide backbone is shown in green and H3K4me3 is shown in red. Enzymatic 
cofactors Fe2+ ion and 2-oxoglutaric acid are marked with purple and yellow, respectively. 
The C and N terminals of the histone peptide are also labeled. 
2.1.3 Modeling ARID domain’s interactions in quaternary structure of KDM5C 
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    ARID domain is the DNA binding domain of KDM5C protein and a NMR structure is 
currently available (PDB ID: 2JRZ). Also, in our previous work [48], a model of ARID-
DNA complex has been generated. The presence of DNA provides constrains of how ARID 
interacts with the rest of KDM5C domains. It should be noted that the ARID domain is the 
second domain of the KDM5C sequence (after the JmjN domain) and a link consisting of 
23 amino acids connects these two domains.  This provides further constrains of mutual 
orientation and positioning of ARID and JmjN domains. Since the quaternary structure of 
JmjN, JmjC and ZF domains is already available (see above), the next question is to predict 
ARID domain position and orientation with respect to the JmjN, JmjC and ZF domains.  
    Thus, we first applied the ZDOCK server [136] to search possible binding modes of the 
ARID domain to the quaternary structure of JmjN, JmjC and ZF domains. The ten best 
predictions were collected and analyzed. It should be reiterated that JmjN and ARID 
domains are connected via a linker of 23 amino acids. Thus, the first consideration that was 
made in the analysis of the ten best binding modes was to remove binding modes that result 
in ARID position and orientation that makes it impossible for ARID and JmjN to be 
connected by 23-amino acid linker. It should be pointed out that the linker region between 
JmjN and ARID domain is also included in the crystal structure [122] and it is simply 
wrapped around the JmjC domain. It is tempting to use the linker in the experimental 
structure of JmjN, JmjC and ZF domains (PDB ID 5FWJ) as a guide in positioning the 
ARID domain. However, it should be clarified that the linker adopts crystallographic 
conformation in absence of the ARID domain and thus its conformation in 5FWJ may be 
misleading. Due to this, we decided to delete the linker region from the experimental 
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structure and rebuild 3D structure of the linker connecting ARID and JmjC domains using 
the LOOPY program [137]. The results showed that the 23 amino acid linker is not long 
enough to connect JmjN and ARID domain in six out of ten binding modes. Thus, these 
six models were deleted. To compare the rest of the four binding modes, we computed the 
RMSD among them (Table C-1).  The RMSDs among four models is relatively small, 
ranging from 1.80 to 3.46Å. This indicates that these four binding modes are quite similar 
and that the binding interface is almost identical (Appendix Figure B-7A). 
    To further select the best model and test its stability, we run molecular dynamic (MD) 
simulations for each binding mode. Three 10ns parallel runs were performed for each 
model with CHARMM22 force field [97] in NAMD [95].  Default charges of titratable 
residues were assigned, since the pKa analysis predicted no ionization changes in 
physiological pH. We first calculated RMSD of ARID and JmjC domains to observe the 
overall structural change along the simulation time (Appendix Figure B-7B). The RMSD 
ranged from 5 to 7.5 Å and the overall structure became stable after 5ns for all models. To 
further study the binding mode stability, we also calculated the RMSD of the interfacial 
residues of each binding mode. We identified the interfacial residues by calculating the 
solvent accessible surface area (SASA) change of each residue in the complex and unbound 
domains. A residue is defined as an interfacial residue if the SASA change is not equal to 
0. Since the identified interfacial residues were slightly different in each model due to the 
structure difference, we only selected the interfacial residues common in all models for our 
analysis and the RMSD results are shown in Appendix Figure B-7C. The RMSD of 
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interfacial residues ranges from 3.5 to 7 Å and reaches stable value after 5ns simulation 
time.  
    To finalize the model of ARID bound to KDM5C catalytic core, we took the twelve MD 
generated trajectories (Note that for each of the four binding modes we generated three MD 
trajectories) and selected 50% with lowest RMSD among them. The last 5ns of the 
trajectories were taken to calculate the averaged structure using VMD tcl script [138].  The 
averaged structure was subjected to 10,000 steps of energy minimization to relax the 
structure. The finalized model of ARID bound to KDM5C catalytic core is shown in 
Appendix Figure B-7D. 
2.1.4 Modeling PHD1 domain’s interaction in the quaternary structure of KDM5C 
    The KDM5C PHD1 domain is close in sequence to the JmjC domain (the linker is 13 
amino acids long) and it is expected to bind to tri-methylated H3K9 residue (H3K9me3) 
[59, 139]. Indeed, a recent study indicated that the PHD1 domain is not required for the 
demethylase activity but does contribute to the recognition of the substrate peptide [59, 
122]. Currently, there is no available experimental structure of the KDM5C PHD1 domain 
bound to H3K9me3 and KDM5C catalytic core.  
    Above we described the modeling of quaternary structure of KDM5C catalytic core 
bound to histone peptide and ARID domain. Since a homology model of KDM5C PHD1 
domain was already generated (see above), we applied the ZDOCK server [136] to predict 
the binding modes of PHD1 domain and the model of KDM5C catalytic core bound to 
histone peptide. The Z-dock server predicted the ten most plausible binding modes. We 
evaluated them by applying constraint of the linker length between PHD1 and JmjC domain. 
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Since PHD1 and JmjC domains are connected with a 13-residue-long liner (we built a 3D 
structure of the linker connecting the PHD1 and JmjC domains using the LOOPY program 
[137]), we only selected the binding mode in which a stretch of 13 amino acids is able to 
connect the two domains. This resulted in three possible binding modes (Appendix Figure 
B-8A).  The PHD1 domain in all binding models is close to the substrate peptide but adopts 
different orientations.  
    To further test the binding stability in the rest of the three binding modes, we performed 
MD simulations. Since the substrate peptide is very flexible and tends to move away from 
the JmjC catalytic core, the position of H3K4me3 residue was fixed to make the substrate 
peptide stay in the catalytic core during the simulation time. The enzymatic cofactors, Fe2+ 
ion and 2-oxoglutaric acid, were also fixed in the simulation to prevent them from moving 
away from the JmjC catalytic core. Five 10ns parallel runs were performed for each model 
using AMBER ff14SB force field [140] in NAMD [95]. As mentioned above, default 
charges were used for titratable groups since no protonation changes were predicted by the 
pKa analysis. The averaged RMSDs calculated for the complex JmjC domain, substrate 
peptide and the PHD1 domain are shown in the Appendix Figure B-8B. The RMSD 
calculated for model1 and model3 is around 7 Å and the PHD1 domain stays bound with 
the JmjC domain during the simulation time. At the same time, model2 shows much larger 
RMSD values. It was observed that the PHD1 domain moves away from the JmjC domain 
and substrate peptide. Therefore, model2 was removed from our protocol, while model1 
and model3 were subjected to further considerations.  
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    To further select the best binding mode among mode1 and model3, we took advantage 
of experimental data that indicates that PHD1 domain binds substrate peptide at H3K9me3. 
Therefore, we identified all residues in PHD1 domain, which have any atom within 6 Å 
distance from H3K9me3 in the last 2.5ns simulation time (Appendix Figure B-8C). 
Comparing with model1, the analysis of the trajectories indicated that the PHD1 domain 
in model3 is farther away from the H3K9me3. Due to this, we selected model1 for further 
investigations. In particular, we paid attention to plausible stabilizing charge-charge 
interactions between PHD1 domain and peptides. Since the methylation of Lys does not 
neutralize the charge, we searched for acidic residue in PHD1 domain within a distance of 
6 Å from H3K9me3. Thus, we identified two acidic residues:  Glu360 and Glu375. Further 
N-O distance analysis did not indicate stable salt bridges between H3K9me3 and acidic 
residues in PHD1 domain. However, two other salt bridges within PHD1, Glu381–Histone 
ARG2 (H3R2) and PHD1 Glu375–Histone Arg8 (H3R8), were identified (shown in 
Appendix Figure B-8D). It should be mentioned that the structural segment (the linker) 
connecting ARID domain and PHD1 domain was not included in the model due to lack of 
homology template and thus PHD1 domain may appear to be more flexible in the 
simulations than it actually is and cause us to observe less salt-bridges. Noting the 
consistence with experimental data, we took model1 as the most plausible binding mode 
(the structure is shown in Appendix Figure B-8F). 
 
2.1.5 Quaternary structure of KDM5C JmjN, ARID, PHD1, JmjC and ZF domains bound 
with DNA, substrate histone peptide and enzymatic cofactors 
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    In our previous work, we generated the 3D structure of ARID-DNA complex [48]. Here, 
we took advantage of our previous work and included the DNA in the KDM5C quaternary 
structure model discussed above. Combining all the models described above, we finally 
generated the quaternary model of KDM5C protein - including JmjN, ARID, PHD1, JmjC, 
ZF domains, substrate histone peptide, enzymatic cofactors and DNA (Figure 2.6).  
 
Figure 2.6: Finalized model of quaternary structure for the KDM5C including JmjN, ARID, 
PHD1, JmjC and ZF domains bound to DNA, substrate histone peptide and enzymatic 
cofactors. KDM5C JmjN, ARID, PHD1, JmjC, ZF domains, inter domain region, substrate 
histone peptide, enzymatic cofactors and DNA are marked with yellow, pink, green, purple, 
orange, blue, red, orange, red, and gray, respectively. 
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2.2 Validation of KDM5C quaternary structure model 
    In this paragraph we will investigate domain spatial arrangement within the quaternary 
structure of KDM5C model using biophysical considerations (charge complementarity, 
inter-domain salt bridges, binding motif preservation, MD simulations and experimental 
observations) and predictions of interfacial patches. With our work focusing on predicting 
spatial positions of ARID and PHD1 domains within KDM5C quaternary structure, we will 
continue to focus on validating ARID and PHD1 interactions with the rest of the KDM5C 
domains.   
ARID domain: The binding interface is mostly made of ARID domain’s N-terminal and 
C-terminal regions, including Helix1 and Helix6 (Appendix Figure B-9A). Our previous 
evolutionary conservation study showed that the N-terminal of the KDM5C ARID domain 
is the most highly conserved region, indicating its essential function for KDM5C protein 
[48] and thus implicating its involvement in some important interactions. There exists an 
interface of the ARID domain in which the domain binds the DNA. In the model, it is 
Loop1 and a helix-turn-helix DNA binding motif formed by Helix4, Loop2, and Helix5, 
which is typical for DNA binding motifs. In the previous study [48], we demonstrated that 
DNA binding interface is positively charged, which is expected for interface binding to 
negatively charged DNA. Similarly, we calculated electrostatic potential of ARID domain 
and KDM5C JmjC and JmjN domain using Delphi [84].  The binding interface of JmjC 
domain is highly negatively charged while the binding interface of ARID domain is slightly 
positively charged (Appendix Figure B-9B). This indicates electrostatic complementarity 
and further validates the model. Furthermore, we submitted the sequence to cons-PPISP 
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webserver [141, 142], a consensus neural network method for predicting protein-protein 
interaction sites. The webserver predicts the residues which form binding sites for another 
protein. Here, we separately submitted ARID, PHD and JmjC domains to the server to 
predict the interaction sites on each domain. The results are shown in Appendix Figure B-
10D,E. The predicted interaction sites in ARID domain are mostly in the N terminal helix, 
which is highly consistent with our model (Appendix Figure B-10D). We also perfomed 
MD simulations on the model of ARID bound with KDM5C catalytic core (see above). 
The RMSD analysis of the interfacial residues indicated that the binding is stable 
(Appendix Figure B-7C). Lastly we investigated plausible salt bridges formed at the 
interface of ARID and PHD1 domains, because salt bridges are frequently observed at 
transient domain-domain interfaces [143, 144]. Since we had previously performed 5 
parallel runs, we only selected the salt-bridges observed in no less than two runs. The list 
of identified interfacial salt bridges is shown in Table 2.2. It can be seen that ARID 
interface is rich of interfacial salt bridges, indirectly indicating that the interface is correctly 
predicted.  
PHD1 domain: The predicted binding interface between PHD1 and JmjC domains is shown 
in Appendix Figure B-10A and marked with green. It includes a short helix and two loops. 
The KDM5C PHD1 domain binds to H3K9me3 and reduction of its binding decreases 
enzyme activity [59, 139]. This mechanism is still unknown. However, a recent study 
indicated that PHD1 domain contributes to the histone substrate recognition, despite being 
not directly required for demethylase activity [122]. In our model, the PHD1 domain 
simultaneously binds to peptide and JmjC domain. Here we investigated whether PHD1 
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domain binds with the substrate histone peptide alone, or whether it also interacts with 
JmjC domain to help further stabilize its binding to substrate peptide. For this purpose, we 
carried out MD stimulations and monitored RMSDs (Appendix Figure B-8). It is shown 
that the PHD1 domain is highly flexible - the salt bridge formed between the substrate 
peptide and the PHD1 domain were not very stable during the simulations as well 
(Appendix Figure B-8D,E). To better understand this finding, we carried out the same type 
of MD simulations of closely related complexes with experimentally available 3D 
structures. Thus, we collected the experimental structure of the KDM5B PHD1 finger 
(having 61% sequence identity with KDM5C PHD1 domain) in complex with H3K4me0 
[145] and ran 10ns simulation to study the RMSD of PHD1 domain and histone peptide. 
The results showed that the peptide moves away from PHD1 domain around 5ns (Appendix 
Figure B-10B). The overall PHD1 domain is very flexible as well (Appendix Figure B-
10C). Thus, the simulations indicate that the binding between the substrate histone peptide 
and PHD domain alone is not stable. This is perhaps due to the high flexibility of both PHD 
domain and substrate peptide. This advocates that the binding of histone peptide is 
supported by PHD1 interactions with JmjC catalytic core. Indeed, very recent study of 
domain arrangement in KDM5B protein by small-angle X-ray scattering (SAXS) and rigid-
body modeling [122] provided an evidence of the interaction between PHD1 domain and 
JmjC catalytic core. The model derived from SAXS indicates that the PHD1 domain is in 
close contact with the JmjC catalytic core and suggested cooperation between PHD1 and 
the catalytic core in KDM5 enzymes [122].  Considering both these experimental results 
and our model [59, 122], we speculate that the PHD1 domain interacts with the JmjC 
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domain to help stabilize the substrate peptide and itself, and further to position the H3K4 
in the JmjC catalytic core. Furthermore, as we did for the ARID domain, we submitted the 
sequence to cons-PPISP webserver [141, 142]. The cons-PPISP predicted interaction sites 
in PHD domain are located in the binding interface in our model (Appendix Figure B-10E). 
Lastly, we identified interfacial salt bridges at the PHD1 interface (Table C-2). 
2.3 Effects of disease-associated mutations on KDM5C domain’s stability and interactions 
    Currently there are eleven amino acid mutations in KDM5C protein known to be causing 
XLMD. They were investigated to predict their effects on the KDM5C domain’s stability 
and interactions. First we predict the effect on folding free energy (domain stability) using 
various webservers (Table 2.4). The results indicate that most of the disease-associated 
mutations substantially decrease domain stability, particularly mutations A77T, D87G, 
F642L, E698K and Y751C.  Furthermore, mutations D87G and D402Y are located at the 
binding interface of the ARID and JmjC domains and their effect on domain-domain 
interactions was predicted using several webservers (Table 2.5). It can be seen that the 
mutation D87G significantly decreases the binding affinity while D402Y slightly increases 
it. Asp87 is in the binding interface (shown in Figure 2.5A) and participates in two salt 
bridges (Asp87-Lys459, Asp87-Arg460) across the binding interface. Replacing 
negatively charged D87 with small, uncharged residue will alter the salt bridges and reduce 
the ARID-JmjC binding. The other mutation, D402, involves negatively charged residue 
in which the wild type KDM5C is predicted to form a salt bridge with R159 of JmjC 
domain. Preplacing it with neutral residue is expected to alter the salt bridge and to decrease 
binding affinity. However, the mutation is predicted to slightly increase binding affinity of 
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ARID domain to JmjC domain.  Perhaps this is due to the fact that R159 is involved in 
another salt bridge (Table C-2) and the D402-R159 salt bridge does not contribute to inter-
domain interactions. However, this bridge may be essential for forming the wild type 
binding pose. Overall, all investigated mutations are predicted to alter the wild type domain 
stability and inter-domain interactions. 
  
 mCSM SDM DUET SAAFEC Average 
A77T 0.88 2.48 0.83 1.44 1.41 
D87G 0.84 1.9 0.86 5.01 2.16 
A388P 0.44 2.12 0.57 -0.13 0.75 
D402Y 1.03 -0.8 1.04 -7.93 0.42 
S451R 0.52 0.25 0.43 -3.74 0.40 
V504M 0.16 0.88 0.16 -0.14 0.27 
F642L 1.43 1.05 1.56 1.71 1.44 
E698K 0.22 3.27 0.29 4.16 1.99 
L731F 1.5 0.31 1.69 0.01 0.88 
R750W -0.56 -1.74 0.76 1.01 0.40 
Y751C 1.66 -1.76 1.57 1.44 1.56 
 
Table 2.4: Folding free energy change upon mutations (kcal/mol). Positive value indicates 
that the mutation decreases domain stability. The most contradictory predictions are 
underlined and not used. The averaged prediction is shown in the last column.  
 
 
 BeAtMuSiC SAAMBE MutaBind Average 
D87G 1.65 -0.54 0.42 1.04 
D402Y -0.22 -0.66 0.18 -0.23 
 
Table 2.5: Binding free energy change upon mutations (kcal/mol). Positive value indicates 
that the mutation decreases binding affinity. The most contradictory predictions are 
underlined and not used. The averaged prediction is shown in the last column. 
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3. Materials and Methods 
3.1 Sequence alignment and homology modeling 
    The homologues of the KDM5C protein and their domains were retrieved from the 
Protein Data Bank database using the protein basic local alignment search tool [124], 
applying Position-Specific Iterated BLAST. The homologues with the highest sequence 
similarity were used to generate the homology model of KDM5C domains using the Swiss-
Model webserver [126]. 
3.2 Protein docking and inter domain linker building 
    The KDM5C domains interactions were predicted with ZDOCK 3.0.2 [136], which 
searches all possible binding modes in the translational and rotational space between two 
proteins/domains and evaluates each pose using an energy-based scoring function. The 
linker regions were predicted with LOOPY [146], a computer algorithm to predict loop 
conformation provided the amino acid sequence.  
3.3 Molecular Dynamics simulation 
    Molecular dynamics (MD) simulations were performed with the NAMD program, 
version 2.11b [95]. The force field used in the simulation, including the substrate peptide 
and enzymatic cofactors, was Amber force field in the Amber tools 15 [79]. The inpcrd 
and prmtop files were generated with Amber tools 15 [147].  Other simulations, with only 
standard protein residues, were performed with CHARMM22 force field [97]. A 10,000 
steps minimization was performed for all simulations to relax plausible overlaps. 
Generalized Born implicit solvent (GBIS) was applied in the simulations and the time step 
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was set to 2 fs. The temperature in the simulation was set to 298 K. The trajectory files 
were investigated using VMD 1.9.2 [138] with related plugins in order to analyze the 
RMSD, RMSF, and salt bridges. 
3.4 Change of folding and binding free energies upon missense mutations 
    The binding free energy changes upon missense mutations (ΔΔΔG) were predicted with 
webservers including BeAtMuSiC [148], MutaBind [149] and SAAMBE [30, 150]. The 
folding free energy changes upon missense mutations (ΔΔG) were evaluated with mCSM 
[151], SDM [152], DUET [109] and SAAFEC [153] servers. 
3.5 Electrostatic Potential Calculation 
    The DelPhi program was used to perform the electrostatic potential calculations. The 
following parameters were applied in the calculation: scale = 2 grid/Å, percentage of 
protein filling of the cube = 70%, dielectric constant = 2 for the protein and 80 for the 
solvent, and water probe radius = 1.4 Å.  
3.6 pKa shifts analysis 
    To investigate the possibility that some titratable residues may undergo protonation 
change upon formation of quaternary structure of KDM5C, we performed the pKa 
calculations with DelPhiPKa [154, 155], which surface-free Poisson-Boltzmann based 
approach to calculate the pKa values of protein ionizable residues, nucleotides of RNA and 
DNA. We first calculated the pKa’s of titratable residues for unbound ARID, PHD1 
domains and KDM5C catalytic core and then repeated the calculations using quaternary 
KDM5C structure. The pKa shifts are calculated by subtracting the pKas of quaternary 
KDM5C structure and the pKas of individual domains (details are provided in SI).  
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4. Conclusion 
    The KDM5 protein is of significant interest for the biomedical community due to its 
relevance to X-linked mental retardation [70] and importance in oncological drug 
development [156]. KDM5C protein is a multi-functional protein of 1560-aa length and 
3D structure of the entire protein is currently unavailable. Only the 3D structure of ARID 
domain, and very recently of catalytic core, is available [122]. Here we fill this gap by 
reporting a 3D model of KDM5C protein quaternary structure, including JmjN, ARID, 
PHD1, JmjC and ZF domains bound to DNA, substrate histone peptide and enzymatic 
cofactors. The model was used to infer the effect of disease-causing mutations of domain 
stability and domain-domain interactions. From the model, it was demonstrated that the 
mutations significantly alter wild type domain stability and inter-domain interactions. This 
suggests that domain stability and domain spatial arrangement with KDM5C protein are 
essential for its wild type function.   
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Modelling of SAVs’ molecular effects in Spermine Synthase: 
1. Introduction 
    Polyamines are cationic polymers that play multiple important roles in a wide range of 
cell growth and development processes. [157-159]. This study focuses on human spermine 
synthase (SpmSyn), a protein whose function is to convert spermidine (SPD) into spermine 
(SPM). The reactant (SPD) and the product (SPM) are both polyamines, which are essential 
for normal mammalian cell growth and development [160, 161]. A previous study has 
illustrated that mutations in SpmSyn are associated with Snyder–Robinson syndrome 
(OMIM #309583, SRS) [13, 162, 163]. Mutations can affect SpmSyn’s dimer and 
monomer stability and alter the wild-type hydrogen bond network, which is important for 
the enzymatic functionality [13, 101, 164]. All of these alterations cause the disruption of 
SpmSyn function and thus result in an abnormal SPM/ SPD ratio and SRS. SRS is a rare 
form of X-linked intellectual disability characterized by mild to moderate mental 
retardation, asthenic body build (marfanoid habitus), diminished muscle bulk, 
osteoporosis, kyphoscoliosis, dysmorphisms (facial asymmetry, full lower lip, long great 
toes) and nasal or dysarthric speech [162, 163]. Significantly decreased SpmSyn activity 
results in low levels of intracellular SPM and a decreased SPM/ SPD ratio for Snyder–
Robinson syndrome patients. SpmSyn is thus an important drug target to restore the 
protein’s function [24, 164]. 
    SpmSyn consists of two structural domains, C-domain and N-domain, connected via a 
linker-domain. Structural and biochemical analyses have shown that the biological unit of 
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SpmSyn is a homo-dimer instead of a monomer [101, 165]. The C-terminal domain is the 
catalytic domain, which carries out the catalysis of SPD to SPM. In contrast, the N-terminal 
domain is not involved in catalytic function but plays a crucial role for the dimerization. 
Most of the binding interface is formed with the N-terminal domain and deletion of the N-
domain disables dimerization and results in the lack of activity [24, 160]. Missense 
mutations occurring in SpmSyn can directly affect the wild-type properties of the active 
site in the C-domain or alter the binding interface in the N-domain to lower dimer affinity 
[24, 101]. Since the SRS is caused by various molecular mechanisms, combined in silico 
and in vitro investigations are necessary to reveal molecular effects of missense mutations 
in SpmSyn in order to identify drug-like small molecules for disease treatment [24, 164, 
166, 167]. 
    Here, we investigate the molecular effect of five SRS causing mutations located within 
the N-domain of SpmSyn: M35R, G56S, F58L, G67E and P112L. Since these mutations 
are away from the active center of SpmSyn, they are not expected to directly affect the 
catalytic function of SpmSyn, but rather to alter SpmSyn activity indirectly by perturbing 
other biophysical properties. Here we focus on two of them, the stability and the 
dimerization of SpmSyn. 
    Some of the abovementioned mutations were previously investigated; others are 
reported in this work for the first time. Thus, M35R was identified at the Greenwood 
Genetic Center from a patient diagnosed with SRS. The P112L is the SRS-causing 
mutation included in this work due to personal communication with Raymond family. The 
G56S (rs121434610), which occurs at a highly conserved residue within the N-domain 
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region of SpmSyn, greatly reduces SpmSyn activity and leads to severe epilepsy and 
cognitive impairment [168]. The F58L (rs397515549) also greatly reduces SpmSyn 
activity and leads to mental retardation along with severe osteoporosis [169]. The G67E 
(rs397515553) causes an ectopic kidney and early-onset epilepsy in addition to features 
characteristic of Snyder-Robinson syndrome and completely destroys SpmSyn activity in 
the patient’s lymphoblastoid cells [162]. 
2. Results 
2.1. Effect of Missense Mutation on Monomer Stability (in Silico Modeling) 
    Table 2.6 shows the results of monomer stability changes (changes of the folding free 
energy) due to missense mutations calculated with webservers and stand-alone computer 
algorithms. For most of the cases, predictions made with different algorithms are in good 
agreement. The most controversial prediction is made by FoldX, where F58L is predicted 
to stabilize the monomer while other tools give opposite results. The five disease-causing 
mutations are all predicted to decrease monomer stability. Specifically, M35R, G67E and 
G56S are predicted to dramatically decrease monomer stability. 
Mutations PoPMuSiC DUET FOLDX I-Mutant 2.0 SDM SD AV 
M35R −0.93 −0.47 −0.42 −1.81 −2.93 1.06 −1.31 
G56S −1.99 −0.52 −3.50 −2.16 −3.51 1.24 −2.34 
F58L −1.77 −0.95 2.12 −2.72 −0.18 1.84 −0.7 
G67E −1.99 −1.26 −1.36 −0.18 −1.34 0.65 −1.22 
P112L −0.87 −0.06 −0.43 −0.83 −1.04 0.40 −0.65 
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Table 2.6 Predictions of monomer stability change due to missense mutations. The 
calculated folding free energy changes are in kcal/mol. G > 0 indicates stabilization 
while G < 0 indicates destabilization. Average value (AV) of folding free energy 
changes is given in the last column of the table. Standard deviation (SD) is also calculated 
to quantify the variation of energy changes. 
2.2. Effect of Missense Mutation on Monomer Stability (in Vitro Experiments) 
    The patient samples showed a reduced level of SpmSyn protein for all the patients either 
by native or denatured western blot analysis as compared to the control (Figure 2.7). After 
native gel electrophoresis, the dimer form of SpmSyn was only detectable in the lane for 
the G67E alteration. Its level was only detectable upon long exposure.  
    On denatured western blots, the P112L alteration was detected at about 20% of the 
control; F58L was detected at about 7% of the control, and G67E was detected at about 5% 
of the control. M35R and G56S were barely detectable (Table C-3). The implied stability 
order from this data is: WT > P112L > F58L > G67E > G56S > M35R. 
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Figure 2.7 Western blot analysis of SMS levels in patient lymphoblast cell lines. (A) 
Denatured SMS blot. 10 µg of lymphoblast lysate was prepared in Lamelli sample buffer. 
The buffer was parted on a 4%–20% sodium dodecyl sulfate polyacrylamide gel (SDS–
PAGE). Furthermore, the buffer was probed for SMS and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). The control was GAPDH. Densitometry of the blots was 
analyzed using NIH Image J. SMS expression levels of the mutants were normalized to the 
control. (B) Native SMS blot. 10 ug of lymphoblast cell lysate was prepared in native 
sample buffer, separated on a native PAGE gel and probed for SMS and GAPDH. 
Densitometry of the blots was analyzed by NIH Image J. 
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2.3. Effect of Missense Mutation on Dimer Affinity 
Mutations 
BeAtMuSiC 
(AB) 
BeAtMuSiC 
(CD) 
Foldx 
(AB) 
Foldx 
(CD) 
SAAMBE 
(AB) 
SAAMBE 
(CD) 
SD 
(AB) 
MEAN 
(AB) 
SD 
(CD) 
MEAN 
(CD) 
M35R 0.05 0.24 0.17 −0.96 −0.27 −0.19 0.22 0.11 0.60 −0.30 
G56S −1.84 −1.34 −8.64 
−11.8
7 
1.58 −4.12 5.20 −5.24 5.45 −5.78 
F58L −2.74 −2.28 −0.1 −1.26 2.20 7.46 2.47 −1.42 5.35 1.31 
G67E −0.78 −0.83 0.372 0.16 −1.86 9.91 1.12 −0.76 5.93 3.08 
P112L −0.11 −0.17 −4.59 −3.32 −0.38 3.39 2.51 −2.35 3.35 −0.03 
Table 2.7 Predictions of dimer affinity change due to missense mutations. The calculated 
binding free energy changes are in kcal/mol. ∆∆G > 0 indicates stabilization while ∆∆G < 
0 indicates destabilization. The calculation is performed for “AB” dimer and “CD” dimer 
for comparison. The mean value is the average of all calculated results for each mutation. 
SD is also calculated to quantify variation of values. 
 
Table 2.7 shows the results for dimer affinity change (binding free energy change) due 
to missense mutations calculated with webservers and stand-alone computer algorithm. 
The calculations for all investigated mutations are performed using “AB” dimer and “CD” 
dimer. For most cases, the predictions made by different algorithms are in agreement. 
Among disease causing mutations, G56S, F58L, G67E and P112L, are predicted to 
substantially decrease dimer affinity while M35R is calculated to have negligible effect. 
2.4. Result of Multiple Sequence Alignment Analysis(MSA) 
    We investigated the evolutional conservation of the WT residues involved in the 
mutations based on MSA. The SpmSyn proteins used for MSA are taken from ten different 
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species, which include seven mammals and three non-mammals. Figure 2.8 shows the 
result of multiple sequence alignment of SpmSyn among different species. It can be seen 
that the residues involved in SRS are almost totally conserved across all different species, 
indicating that these residues are probably important for protein function. The substitution 
of these highly conserved residues will probably have a large impact on the protein’s 
functionality.  
 
Figure 2.8. Sequence alignment of SpmSyn among different species. The mutation sites 
considered in this study are represented in bold letters and the position of the residue in 
human SpmSyn is shown at the top. The mammals considered in this study are represented 
in bold letters. Multiple sequence alignment (MSA) is performed with Cobalt Constraint-
based Multiple Protein Alignment Tool (COBALT). 
3. Discussion 
    Dimerization is essential for the normal function of SpmSyn and the N-terminal domain 
plays a crucial role in the dimerization. In this work, we investigated the molecular effect 
of five mutations which causes SRS located within the N-domain of SpmSyn, focusing 
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mainly on the stability and the dimerization of SpmSyn. To analyze the effects of these 
mutations on SpmSyn stability and binding affinity, we investigated the structural features 
of the side chains involved in the mutations and made connections to computational and 
experimental results. We performed such an analysis for each mutation separately. 
Appendix Figure B-11 shows the side chain conformations of the wild type and the mutant 
residue for the five disease-causing mutations studied in this work. 
M35R: The M35R is substitution of a hydrophobic residue Met by a positive charged 
residue, Arg. The M35 site is totally buried in the protein’s interior. As it is shown in 
Appendix Figure B-11a, the structure around M35 site is very well packed and there is no 
room to accommodate the large Arg side chain. In addition, placing a charged residue, Arg, 
in the hydrophobic protein interior is energetically very costly and is typically referred as 
to desolvation penalty. It can be seen (Appendix Figure B-11b) that the mutant R35 does 
not establish any hydrogen bonds or other type of favorable interaction. In terms of binding 
affinity, the M35 site is far away from the interface and a direct effect of the mutation on 
the binding affinity is not expected. This is consistent with the energy calculations and 
experimental observation, which showed that M35R has large effect on the monomer 
stability but negligible effect on the dimer affinity. 
G56S: The mutation G56S is located ina sharp loop connecting two β strands of the N-
domain (Appendix Figure B-11c). The G56 site is almost totally exposed to the water in 
monomer state. However, it is well known that Gly is typically found in tight turns and any 
replacement may cause steric clashes. This is the structural argument for predicting that a 
substitution with a relatively long side chain of Ser is not favorable (Appendix Figure B-
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11d). The G56 is at the periphery of the dimer binding interface and direct effect on binding 
is expected for any residue substitution. This is consistent with the energy calculations 
reported here and in previous work [24, 101], showing that the G56S mutation decreases 
both monomer stability and dimer affinity. The effects were also experimentally confirmed 
[101].  
F58L: The mutation F58L is located in a β strand at the dimer binding interface; (Appendix 
Figure B-11e,f.) The energy calculations predict that the mutation destabilizes the 
monomer and has a large effect on dimer affinity. The experiments show that the mutation 
decreases monomer stability as well. As for the dimer affinity, Phe58 is totally buried at 
the dimer binding interface formed by two β sheets and there is no room for 
accommodating side chain of different volume—thus the substitution ofLeu is predicted to 
greatly decrease dimer affinity. 
G67E: The mutation G67E is a substitution of a neutral residue Gly by a negative charged 
residue, Glu, and is located in a sharp loop connecting two β strands of N-domain 
(Appendix Figure B-11g). Similar to the effect of the above mentioned mutation G56S, the 
replacement of Gly by Glu, which is a negative charged residue with long side chains and 
does not form any favorable interactions (Appendix Figure B-11h) , in a tight turn in 
structures will cause steric clashes and probably destabilize the protein. This predicted 
effect is consistent with the energy calculation that G67E significantly destabilizes the 
monomer stability. The experiments also confirm the computational prediction. In terms 
of dimer affinity, G67E is at the periphery of the dimer binding interface and the prediction 
is that G67E mutation will also destabilize the dimer. 
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P112L: The last disease causing mutation, P112L is also located at the binding interface 
(Appendix Figure B-11i,j). The P112 site is totally exposed to the water in the monomeric 
state. However the substitution is predicted to decrease stability of the monomer. The same 
is observed experimentally. Furthermore, the P112L is predicted to have a large effect on 
the dimer affinity as well. It can be seen that P112 site is located at a turn between two β 
strands and the specific characteristics of Pro residue cannot be mimicked by any other 
amino acid. This is consistent with the energy analysis indicating that P112L mutation will 
significantly destabilize the dimer. 
    From an evolutionary stand-point, the five disease-causing mutations are in sequence 
positions that are highly conserved across different species in multiple sequence alignment 
analyses, indicating that they are important for SpmSyn function. 
Overall, the study revealed the molecular mechanism of the five SRS-causing mutations: 
It was shown that all mutations greatly affect SpmSyn stability and dimerization. Thus, the 
disease-causing effect alters the structural integrity of SpmSyn and thus, the protein is 
either unfolded, and therefore subjected to degradation, or present in very small quantities 
with impaired ability to form a dimer. The functional result of either of these events would 
be a dysfunctional protein resulting in SRS. 
4. Materials and Methods 
4.1. Protein Structure 
    The wild type structure of human SpmSyn (PDB ID: 3C6K)[165] was downloaded from 
Protein Data Bank (PDB) [91]. The structure contains four chains and the biological unit 
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is taken as a homo-dimer made of chain “A” and “B” or Chain “C” and “D”. Since there is 
a small structural difference between the “AB” dimer and the “CD” dimer, both structures 
are used for energy calculation for comparison. The mutant structure was generated in 
silico by side chain replacement with VMD Mutator Plugin, Version 1.3 [81]. 
4.2. Protein Binding and Folding Free Energy Prediction 
    Webservers and stand-alone computer programs were applied to assess monomer 
folding free energy change and dimer affinity change due to mutations. The webservers 
used for energy calculation included BeAtMuSiC [148], NeEMO [106], PopMusic [107], 
I-Mutant 2.0 [108], SDM [152], DUET [109] and CUPSAT [110]. Also a computer 
algorithm, FoldX 3.0 [111, 112] was used to predict the folding free energy changes and 
dimer affinity change upon single point mutations. Another program developed in our lab, 
SAAMBE [30], was also used to calculate dimer affinity change. 
4.3. Multiple Sequence Alignment  
To investigate the evolutional conservation of the above mentioned mutations, multiple 
sequence alignment (MSA) was performed with Cobalt Constraint-based Multiple Protein 
Alignment Tool (COBALT) [170] among different species. The sequence of different 
species was downloaded from UniProtKB/Swiss-Prot Database [171] with FASTA format 
and include seven mammals: human (Homo sapiens; UniProtKB/Swiss-Prot: P52788), 
mouse (Mus musculus; UniProtKB/Swiss-Prot: P97355), bovin (Bos taurus; 
UniProtKB/Swiss-Prot: Q3SZA5), rat (Rattus norvegicus; UniProtKB/Swiss-Prot: 
Q3MIE9), calja (Callithrix jacchus; UniProtKB/Swiss-Prot: U3FPX7), pantr (Pan 
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troglodytes; UniProtKB/Swiss-Prot: P97355), and maceu (Macropus eugenii; 
UniProtKB/Swiss-Prot: B3VFB4) and three non-mammals: danre (Danio rerio; 
UniProtKB/Swiss-Prot: Q9YGC9), ophha (Ophiophagus hannah; UniProtKB/Swiss-Prot: 
V8NLB9), and ictpu (Ictalurus punctatus; UniProtKB/Swiss-Prot: W5U5T7). 
 
Modelling of SAVs’ molecular effects in DHCR7 protein: 
1. Introduction 
Smith-Lemli-Opitz syndrome (SLOS) is an inherited disorder of cholesterol synthesis 
characterized by intellectual disability and multiple malformations, including facial and 
genital abnormalities and syndactyly and was first described by Smith and coworkers 
[172]. The reported incidence of SLOS varies widely depending on the heterogeneity of 
the population studied, the biochemical methods used and the alleles assessed. Current 
estimates of SLOS carrier frequency in Caucasian populations lie between 1% and 3% 
[173-175]. SLOS is more prevalent in individuals of northern and eastern European descent 
and is rarely described in individuals of Asian or African descent [176]. Reports that up to 
80% of affected fetuses, likely those heterozygous for null mutations, die before birth and 
that milder cases of the disease may not be diagnosed, conceivably prevent accurate 
determination of frequency [177-179]. The majority of “classical” SLOS patients are 
compound heterozygotes with one severe null mutation and a second missense mutation 
which retains some enzyme functionality. Milder cases often possess two less severe 
missense mutations [180]. 
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SLOS is linked to mutations in 7-dehydroxycholesterol reductase (DHCR7), which is 
the rate-limiting enzyme in the cholesterol synthesis pathway [181]. DHCR7 reduces the 
C7–C8 double bond of 7-dehydrocholesterol (7DHC), the precursor molecule to 
cholesterol [182]. Cholesterol, though harmful in high levels, is essential to life since it is 
involved in membrane structure and permeability, synthesis of steroid hormones and 
proper fetal development. The loss of functionality of the DHCR7 enzyme in individuals 
with SLOS results in a significant decrease in cholesterol levels and possibly toxic buildup 
of 7DHC and other cholesterol precursors [183]. It was shown that accumulation of 7DHC 
in the brains of rats is associated with intellectual and learning disabilities [13,14]. 
In addition to its role in cholesterol synthesis, 7DHC is also required for vitamin D3 
production. Exposure to sunlight cleaves the C9–C10 bond of 7DHC in the skin, resulting 
in vitamin D3. Vitamin D3 is essential for calcium absorption and bone health [184]. As 
DHCR7 activity decreases the amount of 7DHC available for vitamin D3 synthesis, there 
is a potential heterozygote advantage to carriers of DHCR7 mutations, which typically 
decrease enzymatic activity [185, 186]. This may explain the prevalence of mutations 
originating in areas with decreased sun exposure such as northern Europe and northeast 
Asia [178, 187]. 
The DHCR7 gene maps to chromosome 11q13.2–13.5 [17–19] and consists of nine 
exons with the initiation codon located in exon three. The gene is expressed in all tissues 
with peak expression in adrenal glands, liver and brain [188]. DHCR7 encodes a 475 amino 
acid polypeptide with a molecular weight of 54.5 kDa, which is a transmembrane protein 
located in the endoplasmic reticulum (ER) membrane, the location of cholesterol synthesis. 
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The first DHCR7 mutations were identified in 1998 by several groups and the early 
years of the 21st century resulted in more advanced molecular tests to rapidly identify 
DHCR7 mutations [188, 189]. Most mutations are identified through sequence analysis of 
coding exons and flanking intronic sequences [5,17]. To date, more than 160 DHCR7 
mutations have been reported [176]. The most common mutation with a prevalence of 
~30% of reported SLOS patients is the IVS8AS G > C − 1 splice acceptor site mutation. 
This results in the inclusion of 134 base pairs of intronic sequence into the transcript and a 
non-functional protein. Other common mutations include T93M, W151X, V326L and 
R404C.  
The majority of pathogenic DHCR7 mutations occur in the highly conserved C-
terminus region of the protein. In their molecular model of the DHCR7 protein, Li and 
coworkers predicted two overlapping binding sites: one for docking of the sterol 7DHC 
and one for binding of the coactivator NADPH [190]. As both binding sites are critical for 
proper protein function, it can be speculated that mutations affecting these areas would be 
most likely to result in disease. In support of this hypothesis, Waterham and Hennekam 
conducted a systematic review of published SLOS patients and compared genotype with 
phenotype [176]. They concluded that the most severely affected patients presented with 
two null alleles or two mutations in the 8–9 cytoplasmic loop while a milder phenotype 
was associated with mutations in the 1–2 loop or one mutation in the N- or C-terminus 
[176]. 
In the present study, we obtained variations in the DHCR7 gene from online databases 
and modelled their effects on the corresponding protein to make predictions about SLOS 
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phenotype. We demonstrate that structural and conservation properties are good 
discriminators between pathogenic and non-pathogenic mutations, while folding free 
energy changes (∆∆Gs) are not. This is consistent with previous observations [191] that 
current methodology for computing ∆∆Gs are not accurate enough when applied to 
membrane proteins. Furthermore, based on detailed analysis of selected mutants, we 
predict that the currently non-classified mutation, R228Q, is pathogenic. 
2. Results and Discussion 
2.1. Mapping Missense Mutations onto the 3D Structure of DHCR7 Protein 
The dataset of DHCR7 missense mutations includes three types of mutations: 
pathogenic, non-pathogenic and mutations of unknown effect. The mutations were 
visualized by mapping them onto the DHCR7 structure (Figure 2.9A). Pathogenic 
mutations are predominantly located in transmembrane and ligand-binding regions while 
non-pathogenic mutations are primarily situated outside the membrane. This observation 
indicates that pathogenic mutations occur at protein sites that are either buried or directly 
involved in protein function, which corroborates the findings of previous investigations 
[41, 48, 78, 192]. To investigate the linkage between structural and evolutionary features 
of DHCR7 protein, we obtained the evolutionary conservation score (EC score) for each 
residue from multiple sequence alignment and mapped them onto the 3D structure of 
DHCR7 (Figure 2.9B). The transmembrane and ligand-binding regions appear to be highly 
conserved. Thus, most pathogenic mutations are located in highly conserved positions, 
while non-pathogenic mutations are less conserved. To further quantitatively assess the 
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mutations’ effects, we computed the relative solvent accessible surface area (rSASA), 
evolutionary conservation score (EC score) and folding free energy change (∆∆G) for all 
mutations studied in this work (Table C-4). Pathogenic mutations tend to have lower 
rSASA values and higher EC scores compared with non-pathogenic mutations. However, 
∆∆G results show no obvious tendency to discriminate pathogenic from non-pathogenic 
mutations. The predictions made with different servers frequently contradict each other 
resulting in large standard deviation (SD) when averaging these predictions (Table C-4). 
As DHCR7 is a transmembrane protein and recent work [191] demonstrated that current 
tools of ∆∆G predictions are not accurate when applied to membrane proteins, this may 
explain why ∆∆G fails to discriminate pathogenic from non-pathogenic mutations in this 
case. In addition, we also performed Polyphen predictions on all types of mutations (Table 
C-4). Almost all the pathogenic mutations are predicted to be probably damaging by 
Polyphen. However, Polyphen overestimated the deleteriousness of the non-pathogenic 
mutations. About half of the non-pathogenic mutations were classified as possibly or 
probably damaging. Thus, Polyphen has limited accuracy in discriminating the pathogenic 
mutations from the mutations with unknown effects for this particular protein. 
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Figure 2.9. (A) Visualization of mutations mapped onto DHCR7 protein. Red, orange and 
green colored sites represent pathogenic, unknown effects and non-pathogenic mutations, 
respectively. The membrane boundaries are schematically shown with light blue dashed 
lines; (B) Most highly evolutionarily conserved residues mapped onto DHCR7 protein. 
Residues with EC score > 0.9 are marked with blue and all mutation-affected residues are 
shown with side chain. The membrane boundaries are schematically shown with light blue 
dashed lines. 
2.2. Classification of the Mutations with Unknown Effects Using KNN Model 
One of the goals of this study was to identify biophysical features allowing us to 
distinguish between pathogenic and non-pathogenic mutations, and thus to make 
predictions about unclassified mutations. Above, we outlined several biophysical features, 
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namely rSASA, EC score, PD and ΔΔG, which will be used in conjunction with the K-
nearest neighbors (KNN) method (see Method section). The dataset includes 16 pathogenic 
mutations and 23 non-pathogenic mutations. These 39 mutations were randomly 
partitioned into training dataset (29 mutations) and test dataset (10 mutations) and then 
subjected to the KNN classifications. As the ΔΔG was shown to be less successful in 
distinguishing between pathogenic and non-pathogenic mutations, we performed the KNN 
classification with and without the ΔΔG (Table C-5). The classification shows better 
performance without using the ΔΔG and the accuracy is 100% when K value is within 5 to 
9. Here, we select K = 7 (the median of the K value corresponding to highest accuracy). 
Finally, KNN model with K = 7 and using properties: rSASA, EC score and PD applied to 
classify the mutations with unknown effects (Table 2.8). Thus, we predict that among all 
currently known unclassified mutations, only R228Q is pathogenic. In Table 2.8 we also 
compared our KNN classification results with the predictions from Polyphen. Consistent 
with our results, Polyphen predicted R228Q to be probably damaging. However, Polyphen 
gives contradictory predictions for eight additional mutations (predicted to be probably 
damaging), which are classified as non-pathogenic by our KNN classification. 
Overestimation of mutation deleteriousness was also observed when applying Polyphen to 
the known non-pathogenic mutations (Table C-4). 
 
Mutation KNN Classification Polyphen Mutation KNN Classification Polyphen 
A41V N Benign R228Q P Probably damaging 
I44T N Benign V330M N Probably damaging 
A67T N Possibly damaging V338M N Benign 
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I75F N Benign F361L N Probably damaging 
R81W N Probably damaging T364M N Probably damaging 
A97T N Possibly damaging R367C N Probably damaging 
V126I N Probably damaging G424S N Probably damaging 
V134L N Benign G425S N Benign 
A162V N Possibly damaging R461C N Probably damaging 
Table 2.8. KNN classifications and Polyphen predictions of the mutations with unknown 
effects. P and N represent pathogenic and non-pathogenic mutations, respectively. 
2.3 Case Study of Selected Mutations Using Molecular Dynamics (MD) Simulations 
The above classification and analyses were performed using fast computational 
approaches and were applied to the entire dataset. We selected a subset of mutations for 
extensive MD simulations to investigate the possibility that pathogenic and non-pathogenic 
mutations have different effects on DHCR7 protein conformational dynamics. For this 
purpose, we selected 10 representative mutations including five pathogenic mutations 
(T154R, E288K, T289I, G303R and R404C), two non-pathogenic mutations (R260Q and 
A452T) and three mutations with unknown effects (V134L, R228Q and F361L). These 
mutations are localized to different regions of protein structure. Five mutations (T154R, 
R228Q, E288K, T289I and G303R) are located in the transmembrane region and are buried 
in the membrane, two mutations (F361 and R404C) occur near the ligand-binding site and 
potentially affect ligand binding, and the remaining three mutations (V134, R260Q and 
A452T) are in neither the transmembrane region nor the ligand binding site. 
Since our focus was on protein conformational dynamics, we calculated the 
corresponding RMSDs and RMSFs for the wild type and mutant proteins. The average 
 65 
RMSD data shows no obvious difference between wild type protein and proteins with non-
pathogenic or pathogenic mutations. However, the average RMSF indicates some 
differences between the wild type and mutants. For example, in the mutant A452T, cytosol 
loops (CL) 2 and 4 and transmembrane domain (TM) 10 regions are more rigid compared 
to the wild type (Table 2.9). However, no apparent patterns were identified to differentiate 
pathogenic mutations and non-pathogenic mutations by simply observing the graphs. A 
previous study of the AGAL protein has indicated a correlation between the protein’s 
flexibility and the severity of a mutant’s pathogenicity [193]. Thus, to identify such 
potential correlation in DHCR7 protein, we mapped the pathogenic and non-pathogenic 
mutations on the average RMSF of the wild type proteins (shown in Figure B-12). We 
observed that most pathogenic mutations are located on the low RMSF region while the 
non-pathogenic mutations show the opposite trend. As the low RMSF residues are mostly 
transmembrane, such observed correlation is expected when majority of the pathogenic 
mutations are located on the transmembrane region. In addition, further analysis was 
performed by grouping the residues into different regions and then summing up the RMSF 
of residues in that region to get a region-RMSF. Based on DHCR7 protein structure 
information [194], residues were grouped into regions: TM1 (residues 40–60), TM2 
(residues 94–115), TM3 (residues 145–164), TM4 (residues 176–191), TM5 (residues 
235–256), TM6 (residues 268–288), TM7 (residues 302–326), TM8 (residues 332–352), 
TM9-10 (residues 408–442), CL1 (residues 116–144), CL2 (residues 198–234), CL3 
(residues 289–301), CL4 (residues 354–407) and CTD (residues 443–475). The topology 
of the cytosol loops (CL), the C terminal domain (CTD) and transmembrane domains (TM) 
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mapped with selected mutations are further represented for better visualization of the 
DHCR7 structure (Figure 2.10). 
 
Figure 2.10. The topology of the cytosol loops (CL), the C terminal domain (CTD) and 
transmembrane domains (TM) in DHCR7 structure. Mutation sites are mapped with 
different colors according to mutation type (double color is applied for sites with unknown 
and non-pathologic classification). The unclassified mutation R228Q, which we predict to 
be pathogenic, is highlighted with a red asterisk. 
Table 2.9 shows the region-RMSFs. Pathogenic mutations tend to decrease the 
flexibility in the TM1, TM2 and CL2 regions and increase the flexibility in the TM7 and 
TM9-10 regions. Very little is known about DHCR7 function and structural changes 
occurring during chemical reactions, so we used the above observation to suggest an 
empirical formula that discriminates between pathogenic and non-pathogenic mutations, 
which were subjected to MD simulations (ideally, one should perform such an analysis for 
mutations analyzed in this manuscript, but this is too computationally demanding). For the 
wild type and each mutant, we sum the RMSFs of TM1, TM2 and CL2 and then subtract 
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the RMSFs of TM7 and TM9_10 (last column in Table 2.9). We refer to this quantity as 
cumulative RMSF. The wild type and non-pathogenic mutants have cumulative RMSFs 
larger than 50 Å while all pathogenic mutants have a cumulative RMSF less than or equal 
to 46 Å. Among non-classified mutations, V134L is confirmed to be non-pathogenic, while 
R228Q and F361L show the same cumulative RMSFs as pathogenic mutations. Thus, it is 
encouraging to observe that R228Q is independently confirmed to be pathogenic mutation 
(see KNN classification above), while F361L cannot be classified with high confidence 
and additional investigations are reported in the next section. 
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Table 2.9. RMSF values per structural region (see text for details) for each of the mutants. 
The RMSFs are given in Å units. The last column reports the RMSF calculated as the sum 
of RMSFs of TM1, TM2 and CL2 subtracted by RMSF of TM7 and TM9-10. Values larger 
than 50 Å are underlined. 
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2.4. Analysis of Mutations’ Pathogenic Effects: 
2.4.1. Ligand Binding 
Here, we investigated the possibility that mutations may change DHCR7 functionality 
by altering the binding affinity towards its ligand NADPH. For this purpose, we compared 
the effects of F361L (non-classified) and R404C (pathogenic mutation), both located near 
the NADPH binding site. It is anticipated that NADPH binding will cause structural 
rearrangement of the binding site and the conformational flexibility of the binding pocket 
is essential for proper protein function. We tested the effects of F361L and R404C on 
binding pocket flexibility by comparing them with the wild type protein. This was done 
using the MD trajectories obtained above and computing the residue cross-correlation for 
each trajectory with Bio3D [195]. These types of analyses were successfully used to 
elucidate the effects of a single mutation on the human β2-microglobulin’s protein 
dynamics [196]. For each mutation and wild type, we calculated the average cross-
correlation from three independent MD runs. Finally, the residue cross-correlation changes 
for mutations F361L and R404C are shown in Figure 2.11A,B, which is the subtraction of 
the averaged cross-correlation map between mutant and wild type proteins. Significant 
changes of the cross-correlation coefficient near the NADPH binding site were found for 
R404C, highlighted with a circle in Figure 2.11, but not for F361L. 
We also performed MM/PBSA analysis to investigate the effect of mutations on 
NADPH binding affinity (Figure 2.11D). Mutation R404C results in a large increase of the 
binding affinity by about 15 kcal/mol. As shown in the literature [78, 197, 198], any large 
deviation from wild type characteristics may be deleterious. In this case, R404C mutations 
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contribute to disease by altering the binding affinity of NADPH. Compared to the effect of 
F361L, we observe that binding affinity is much less affected. This, combined with 
correlation analysis, allows us to speculate that F361L is a non-pathogenic mutation. 
 
Figure 2.11. (A–C) The changes in residue cross-correlation for mutations F361L, R404C 
and R228Q; (D) NADHP binding free energy for WT and mutations F361L and R404C. 
2.4.2. Protein Dynamics 
We further analyzed the selected mutations including our predicted pathogenic 
mutation R228Q to identify other pathogenic effects on protein functionality. The residue 
cross-correlation analysis of R228Q (Figure 2.11C) indicates a local conformational 
change near the mutation site. The R228Q mutation makes the corresponding region more 
rigid, resulting in local flexibility changes in CL2. Changes in protein dynamics are also 
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observed in the residue cross-correlation analysis of other pathogenic mutations such as 
E288K and G303R (shown in Appendix Figure B-13), indicating that alterations in DHCR7 
protein dynamics likely contribute to protein dysfunction.  
2.5. Allele Frequency Analysis 
We compared the frequency distribution of pathogenic mutations and frequently-
occurring common mutations among different populations and genders. Figure 2.12A 
displays the top 40 DHCR7 mutations of varying types occurring in more than 50 
individuals archived in the ExAC database. At the same time, Figure 2.12B shows the 
distribution of pathogenic missense mutations chosen for this study within the same set of 
populations. The most frequently-occurring mutations in the general population are found 
in individuals of non-Finnish European descent followed by South Asian and African and 
African American descent (Figure 2.12A). Additionally, individuals of non-Finnish 
European and South Asian descent have the highest frequency of pathogenic mutations as 
shown in Figure 2.12B. African and African American populations have few cases of 
SLOS despite high occurrences of DHCR7 mutations. The low occurrence and frequency 
of mutations in Europeans of Finnish descent is supported by the extremely low number of 
SLOS cases in Finland [199]. 
Interestingly, females in the overall ExAC population possess more DHCR7 mutations 
at higher frequencies than males (Figure 2.12C), while this is an opposite for the pathogenic 
mutations investigated in this manuscript (Figure 2.12D), though no support for this trend 
has been found in the literature. One can speculate that this is linked to sex hormones and 
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is embryo lethal, but the observation that females carry more pathogenic mutations than 
males should be taken with precaution. 
 
Figure 2.12. The frequency distribution of DHCR7 mutations. AFR, AMR, EAS, FIN, 
NFE, SAS and OTH represent African and African American, American, East Asian, 
Finnish, Non-Finnish European, South Asian and other populations, respectively. (A) The 
frequency distribution among different populations of the top 40 DHCR7 mutations of 
varying types occurring in more than 50 individuals archived in the ExAC database; (B) 
The frequency distribution among different populations of pathogenic missense mutations 
chosen for this study; (C) The frequency distribution in males and females of the top 40 
DHCR7 mutations of varying types occurring in more than 50 individuals archived in the 
ExAC database; (D) The frequency distribution in males and females of pathogenic 
missense mutations chosen for this study. 
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3. Materials and Methods 
3.1. Selection of DHCR7 Missense Variants 
The missense mutations investigated in this work were selected using ClinVar [200] 
and ExAC [201] databases. The ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) 
was queried using the search term “DHCR7”. The results were further refined by missense 
mutations consisting of benign (2), likely benign (3), uncertain significance (30), likely 
pathogenic (15), pathogenic (26) and conflicting reports of pathogenicity (3) (as of 13 
November 2017). The ExAC (Exome Aggregation Consortium) Browser 
(http://exac.broadinstitute.org/) was queried using the search term “DHCR7” and the 
entries were sorted by allele frequencies in descending order. The missense variants with 
an allele frequency greater than 0.00001, which were also classified in ClinVar were 
chosen for further in silico analysis. Of the chosen mutations, the variants defined as 
pathogenic or likely pathogenic in Clinvar database are classified as pathogenic mutations 
in this study while the others defined as uncertain significance in Clinvar database are 
classified as mutations with unknown effects. E288K and G303R are previously reported 
SLOS-causing mutations [202, 203] although they are not classified as pathogenic in the 
Clinvar database. Thus, E288K and G303R were treated as pathogenic mutations in this 
study. Overall, 16 pathogenic mutations and 18 mutations with unknown effects are 
classified for this study. 
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3.2. Selection of Non-Pathogenic DHCR7 Mutations 
We first obtained the missense mutations in DHCR7 gene from the ExAC database 
[201], including the whole genome sequencing data from 60,706 unrelated individuals. In 
total, 280 missense mutations in DHCR7 were identified. The ExAC database also provides 
the corresponding allele frequency data from the 1000 Genomes Project and the NHLBI-
GO Exome Sequencing Project (ESP) for each mutation. Individuals participating in the 
1000 Genomes Project were all healthy while the objective of the ESP is discovery of novel 
genes and mechanisms contributing to heart, lung and blood disorders. As our goal was to 
select non-pathogenic mutations from the ExAC database, we applied the following 
selection criteria: (a) mutations with allele frequency >0 in the 1000 Genomes Project; (b) 
mutations with allele frequency of 0 in the ESP. Thus, we classified the mutations 
identified from the healthy population of 1000 Genomes Project but not from the ESP as 
non-pathogenic mutations in this study. In total, 23 non-pathogenic missense mutations 
were identified. 
3.3. Obtaining Allele Frequency and Gender Occurrence 
The allele frequency and gender data of DHCR7 mutations were obtained from EXAC 
database [201]. The most recent database version was downloaded from the FTP site 
(http://exac.broadinstitute.org/downloads) and mutations affecting the DHCR7 protein as 
well as their corresponding allele frequencies and gender data were obtained. The 
frequency of mutation by gender is calculated by the number of carrier females or males 
divided by the total number of carrier individuals. 
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3.4. Generation of the 3D Model for DHCR7 
The 3D structure of the DHCR7 protein was generated by homology modeling due to 
lack of an existing experimental structure. Structure of the integral membrane sterol 
reductase from Methylomicrobium alcaliphilum (PDB: 4QUV) [190] was used as a 
template and subjected to MODELLER [204] for homology modeling. The sequence 
identity between the template and DHCR7 is 37% (sequence alignment is shown in 
Appendix Figure B-14) and thus high structural similarity was observed between the 
generated model and template. The model with lowest DOPE score was selected for this 
study and further subjected to automatic loop refinement with MODELLER [204]. 
3.5. Property Distance (PD) 
To quantify the physical-chemical property differences between the wild type and 
mutant residues, we used the property distance (PD) as a parameter to quantitatively 
describe such changes. In this study, we describe physical-chemical properties of a 
particular residue using a property vector which includes two elements: hydrophobicity 
and charge. The hydrophobicity of the residues are taken from an experimentally 
determined hydrophobicity scale [205, 206]. R and K carry +1 charge while E and D have 
−1 charge. All other residues are considered neutral. PD represents the Euclidean distance 
of the property vector between the wild type and mutant residues (shown in Equation (2.3)). 
The PD between all types of residues are shown as a matrix in Appendix Figure B-15. 
𝑃𝐷(𝑥, 𝑦) = √((𝐻(𝑥) − 𝐻(𝑦))
2
+ (𝑄(𝑥) − 𝑄(𝑦))
2
                                                                       (2.3) 
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,where x and y represent two types of residues; H and Q are corresponding hydrophobicity 
and charge for a particular residue. 
3.6. Evolutionary Conservation Score (EC Score) Calculation 
The DHCR7 sequence from 35 different species were collected from UnitProt [171] 
and subjected to multiple sequence alignment with the T-Coffee webserver [207]. The EC 
score of each residue in the human DHCR7 sequence was calculated using the multiple 
sequence alignment with the following equation: 
𝐄𝐂 𝐬𝐜𝐨𝐫𝐞(𝐢) =  
𝐍(𝐢)𝐢𝐝𝐞𝐧𝐭𝐢𝐭𝐲
𝐍(𝐢)𝐭𝐨𝐭𝐚𝐥
                                                                                             (2.4) 
,where N(i)identity  is the number of the species sharing identical residues in position i of the 
human DHCR7 sequence and N(i)total is the total number of the species in the multiple 
sequence alignment. 
3.7. Folding Free Energy Change (ΔΔG) and Relative Solvent Accessible Surface Area 
(rSASA) Calculation 
Several webservers were used to predict the effect of mutations on protein stability 
(folding free energy change (∆∆G)) using the generated homology model of DHCR7 
protein. The webservers used in this study include DUET [109], Eris [208], mCSM [151], 
SDM [209], Foldx [210] and SAAFEC [34]. The SASA were calculated using VMD [138]. 
As DHCR7 is a transmembrane protein, the membrane was also included when calculating 
the SASA. Thus, only the amino acids exposed to water were treated as exposed and the 
transmembrane regions were treated as buried in the calculation. The rSASA for residues 
were calculated using the following equation: 
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𝑟𝑆𝐴𝑆𝐴(𝑖) =  
𝑆𝐴𝑆𝐴(𝑖)
𝑆𝐴𝑆𝐴(𝑖)𝑚𝑎𝑥
                                                                                       (2.5) 
 
,where SASA(i) is the SASA measured for particular residue i and SASA(i)max is the 
maximum SASA obtained for a free residue (entire residue taken off the protein).  
3.8. Molecular Dynamic Simulations 
The membrane-protein-ligand system was built primarily using the CHARMM-GUI 
[211] tools. The DHCR7 protein with ligand structure was obtained from previous 
homology modeling. Ten mutant (V134L, T154R, R228Q, R260Q, E288K, T289I, F361L, 
G303R, R404C and A452T) structures were derived from the wild type DHCR7 protein 
structure using VMD 1.9.3 [138] mutator package. The protein was embedded in a POPC 
bilayer using the CHARMM-GUI website. The protein was oriented to align with 4QUV 
structure in the OPM [212] database. When the oriented protein was placed into the 
membrane, the z axis of the protein matched the z axis of the membrane. The whole system 
was solvated with 0.15 M KCl. The final system was 89.13 × 89.13 × 96.64 Å3 with a total 
of about 70,800 atoms. 
Molecular dynamic simulation (MDS) was performed using NAMD2.11 [95]. The 
system first underwent energy minimization for 10 ps, then equilibrated through 6 cycles 
where harmonic constraints were applied to keep original positions of: (a) lipid head groups 
(force constants were gradually reduced from 5 kcal∙mol−1∙Å−2 to 0 kcal∙mol−1∙Å−2), (b) 
protein backbone (force constants were gradually reduced from 10 kcal∙mol−1∙Å−2 to 0 
kcal∙mol−1∙Å−2), and (c) protein sidechains (force constants were gradually reduced from 5 
kcal∙mol−1∙Å−2 to 0 kcal∙mol−1∙Å−2). In addition, dihedral restraints were applied to keep 
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cis double bonds and c2 chirality (force constants were gradually reduced from 500 
kcal∙mol−1∙Å−2 to 0 kcal∙mol−1∙Å−2). A 1 fs timestep was used in the first few cycles and 
then switched to 2 fs for wild type whereas much smaller timesteps such as 0.01 fs were 
used for mutants to prevent restraints from failing. In the first two cycles, NVT simulation 
was performed and then switched to NPT simulation in the later cycles. Temperature was 
held at 303.15 K using a Langevin thermostat with a damping coefficient of 10 ps−1 and 
velocity rescaling thermostat. The pressure was maintained at 1 atm using a Langevin 
piston barostat with an oscillation period of 50 fs and a damping time constant of 25 fs. 
Electrostatic interactions between charged atoms were calculated using the particle mesh 
Ewald method. Van der Waals interactions were truncated at 12 Å with a switching 
function applied from 10 Å. RATTLE is used to constrain the length of all bonds involving 
a hydrogen atom. This stage of equilibration lasts for tens of ps to hundreds of ps. Then 
three 10 ns equilibration and 10 ns production runs with no constraints were performed for 
the wild type and each mutant. A 2 fs timestep was used. No velocity rescaling thermostat 
was used. Other conditions are the same as the previous stage. RMSD and root mean square 
fluctuation (RMSF) with the structure at the beginning of the 10 ns run as the reference 
structure were calculated using VMD 1.9.3. 
3.9. MM/PBSA Analysis 
To estimate the binding affinity of the DHCR7 protein with the ligand NADPH, we 
calculated the binding free energy using the MM/PBSA approach. For this purpose, we 
performed three independent 20 ns MD simulations as described above. We took the 
frames with an interval of 20 ps from the last 10 ns and a total of 500 frames were selected 
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from each trajectory. All ions, water and lipids were removed before MM/PBSA energy 
calculations. All the energy terms were averaged over 500 frames for each trajectory and 
the mean and standard deviation of binding free energy were calculated for wild type and 
mutant structures. The internal energy and van der Waals interactions were calculated using 
NAMD2.11b [95] by subjecting the structure to a one step equilibration at 300 K using 
dielectric constant = 2 for protein and = 80 for solvent. The electrostatic components of the 
binding free energy (Coulombic and solvation energy) were calculated by solving the 
Poisson Boltzmann (PB) equation using the Delphi program [84] with dielectric constant 
= 2 for protein and = 80 for solvent. The solvent accessible surface area (SASA) was 
calculated by VMD [138] with the solvent and lipid. The non-polar component of the 
solvation was further calculated with the following widely-used equation: 
𝐺𝑠𝑎𝑠𝑎 =  𝛼 ∙ 𝑆𝐴𝑆𝐴 +  𝛽                                                                                           (2.6) 
, where α = 0.0054 and β = 0.92 kcal/mol. 
3.10. K-Nearest Neighbors (KNN) classIfication 
K-Nearest Neighbors algorithm was used to classify the missense mutations with 
unknown effects in DHCR7 protein. The dataset includes 16 pathogenic missense 
mutations and 23 non-pathogenic missense mutations (non-classified/unknown effect 
mutations were excluded). The dataset was randomly partitioned into a training dataset (29 
mutations) and a testing dataset (10 mutations). The KNN classification was performed 
using R program and various numbers of K values were tested to obtain the best 
performance. 
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4. Conclusions 
We investigated the effects of mutations causing SLOS on the biophysical 
characteristics of DHCR7 protein with the goal of identifying methods allowing the 
discrimination of pathogenic mutations from non-pathogenic mutations. We found that 
pathogenic mutations are located either within the transmembrane region or are near the 
ligand-binding site and are highly conserved between species. In contrast, non-pathogenic 
mutations observed in the general population are located outside the transmembrane region 
and have different effects on the conformational dynamics of DHCR7. Our analyses 
confirmed the inability of folding free energy modeling to deliver reliable results and to be 
used to discriminate pathogenic from non-pathogenic mutations in membrane proteins. 
Future investigations may include modeling the effects of DHCR7 mutations on melting 
temperature (Tm) via MD simulations conducted at different temperatures using the 
methodology adopted from recent work on NBD1 domain [213]. As mentioned in the work 
of Estacio et al. [213], the decrease of Tm may cause the protein to adopt partially 
misfolded states that become targeted for degradation. 
In this work, using three characteristics: solvent exposure of the mutation site, residue 
conservation and physico-chemical descriptors, we were able to distinguish between 
pathogenic and non-pathogenic mutations. This observation, along with extensive MD 
simulations and MM/PBSA modeling, was used to classify R228Q as a pathogenic 
mutation. 
Taken together, these observations suggest that the non-classified mutation R228Q is 
in fact pathogenic. The analyses performed indicate that pathogenic effects may be of 
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different origin, from affecting protein stability and dynamics to altering binding affinity 
and flexibility of the binding site.  
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CHAPTER THREE 
PKA SHIFT AND PROTON TRANSFER IN PROTEIN-NUCLEIC ACID 
INTERACTION AND DEVELOPMENT OF COMPUTATIONAL APPROACH TO 
PREDICT SAV’S EFFECT IN PROTEIN-DNA BINDING 
 
Computational investigation of proton transfer, pKa shift and pH-optimum in 
protein-nucleic acid interaction: 
 
1. Introduction: 
Protein-nucleic acid interactions are common in various biological reactions and play 
a crucial role in cell life [214-216]. These interactions are mediated by various forces and 
effects, such as electrostatic interactions, hydrogen bonding, hydrophobic effect, and base 
stacking [215, 217, 218]. Particularly, electrostatic interaction plays a crucial role in 
protein-nucleic acid binding, since nucleic acids are predominantly negatively charged, 
while the binding protein interface is typically positively charged – this results in charge 
complementarity[219-223]. It has been demonstrated, in the case of protein-DNA 
interactions, that the protein recognizes a specific DNA sequence via formation of 
hydrogen bonds with specific bases (primarily in the major groove) and that the subsequent 
binding results in sequence-dependent deformations of the DNA helix [224, 225]. 
Furthermore, it was shown that the narrow minor groove of DNA strongly enhances the 
negative electrostatic potential of the DNA phosphate groups and thus facilitates the 
binding of positively charged arginine residues [224, 226]. Similarly, stacking, 
electrostatics, and hydrogen bonding play important roles in ssRNA recognition, providing 
affinity and sequence-specificity during the binding process [227].  
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   In the past, existing structures of protein-nucleic acid complexes were utilized to 
predict protein binding hot spots and elucidate the mechanism of the binding [215, 217, 
223, 227, 228]. However, no attempts were made to evaluate the pKa change induced by 
the binding, even though it is well recognized that any binding results in a change of 
electrostatic environment [229, 230]. Thus, the pKa values of the titratable groups may 
shift upon the complex formation and these pKa shifts can be used as an indicator of the 
electrostatic energy contribution to the binding [230-232].  
Most properties of biological macromolecules are pH dependent, and are tuned 
towards a particular cellular or sub-cellular pH [233]. Stability and binding are among the 
basic biophysical characteristics of these macromolecules. It was previously indicated that 
the stability of monomeric proteins is adapted to cellular and sub-cellular characteristic pH 
[217, 234, 235]. Similarly, our past investigations have demonstrated that the pH-optimum 
of binding and the pH-optimum of folding are correlated [231, 236, 237]. At the same time, 
the pH dependence of protein-nucleic acid binding has not attracted much attention.  
 Our work took advantage of a recent development: a Poisson-Boltzmann based 
pKa calculation approach, the DelPhiPKa [154, 155]. The DelPhiPKa is capable of 
performing rapid pKa calculations of protein ionizable residues, and of nucleotides of RNA 
and DNA. Complex structures from a large protein-nucleic acid interaction database 
(NPIDB database) [238, 239] were used for the modeling. Our work aims at revealing 
plausible proton transfers and pKa shifts induced by protein-nucleic acid interactions. 
Furthermore, we investigate whether or not the pH-optimum protein-nucleic acid binding 
is correlated with the stability of the corresponding binding protein.  
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2. Materials and Methods: 
2.1 Protein-nucleic acid structures used in the study: 
Protein-nucleic complex structures were downloaded from the NPIDB database [238, 
239]. The NPIDB is a large protein-nucleic acid interaction database, which contains 5,547 
structures of protein-nucleic acid complexes in the PDB format. The database also includes 
classification of complexes based on the protein domains using Pfam[240] and SCOP[241] 
families.  
Structural analysis of these 5,547 complex structures showed that there are many 
entries with very similar structures. This is due to either a particular protein-nucleic acid 
complex being reported at different experimental conditions, structural resolution, or the 
existence of highly homologous binding domains. These identical or highly similar 
structures would result in common protonation state changes in our analysis, and would 
cause overrepresentation of such protein-nucleic acid interaction types. To eliminate 
structural bias, we took advantage of the existing Pfam and SCOP classification in the 
NPIDB database. One representative structure from each Pfam/SCOP family was elected 
based on the best resolution. We then created two datasets resulting in 112 protein-DNA 
complex structures and 56 protein-RNA complex structures using SCOP classification, 
along with 99 protein-DNA complex structures and 105 protein-RNA complex structures 
using Pfam classification. In this investigation, they are referred as “NPIDB Pfam dataset” 
and “SCOP dataset”. 
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2.2 pKa calculations: 
   The calculations of pKa values were performed with DelPhiPKa [154, 155], which 
is a Poisson-Boltzmann based approach to calculating the pKa values of protein ionizable 
residues and nucleotides of RNA and DNA. The profix program, a software module within 
the JACKAL package (http://wiki.c2b2.columbia.edu/honiglab_public/index 
.php/Software:Jackal_General_Description) was used to generate missing atoms/residues 
of the original structures. The ligands and ions were removed from the structures. For each 
protein-nucleic acid complex, one pKa’s calculation was performed for the entire complex 
structure and then another two calculations were run for the protein and nucleic acid 
component respectively. This provides pKa values of the titratable groups in bound and 
unbound states. The pH range in the calculations was set from 0 to 14 with an interval of 
1.  
 
2.3 Proton uptake and pH dependence of folding and binding energies: 
   We calculated the pH dependence of the stability of the complexes and their monomers 
using the following equation [230, 237, 242]: 
∆𝐺(𝑝𝐻𝑓) = 2.3𝑅𝑇 ∫ (𝑄𝑓(𝑝𝐻) − 𝑄𝑢(𝑝𝐻)) 𝑑(𝑝𝐻)
𝑝𝐻𝑓
𝑝𝐻𝑖
                                                 (3.1) 
,where Qf(pH)  and Qu(pH)  are the total net charge of folded and unfolded states. R is the 
universal gas constant, taken as 8.314J/(mol*K) and T is the temperature (in K). Similarly, 
in the case of pH dependence of binding energy, Qf(pH)   and Qu(pH)   represent the net charge 
of the complex and the sum of the net charges of the unbound protein and nucleic acid 
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components. Typically, the difference of these net charges is referred as “proton uptake or 
release”[242]. 
   The net charge of the folded state for complexes and their components in the pH range 
were calculated with the DelPhiPKa [154, 155]. In this work, the unfolded state was 
modeled as a chain of non-interacting residues [237, 242]. Thus, the net charge of the 
unfolded state was calculated with the Henderson-Hasselbalch equation: 
𝑄𝑢(𝑝𝐻) = ∑
10−2.3𝑦(𝑖)(𝑝𝐻−𝑝𝐾𝑎(𝑖))
1+10−2.3𝑦(𝑖)(𝑝𝐻−𝑝𝐾𝑎(𝑖))
𝑁
𝑖=1                                                                                  (3.2) 
,where the summation is over all titratable groups in the system and y(i) is +1 for basic 
groups and -1 for acidic groups.  
 
2.4 Determination of the interfacial residues and classification of nucleotides in 
DNA/RNA: 
A residue is defined to be interfacial residue if its solvent accessible surface area 
(SASA) changes upon complex formation. The SASA of all residues in the complexes and 
components was calculated using the VMD plugin [138]. The probe radius was taken as 
1.4 Å. For statistical analysis of pKa shifts in DNA and RNA, we classified nucleotides 
into three different types: phosphate group binding type, base group binding type and O-
type [231]. These classifications were based on the different binding modes as described 
below. These different interaction types were identified by calculating the SASA change 
of phosphate and base groups upon the complex formation. In our work, we are focused on 
the effects on the protonation state changes for the N1 and N3 atom in the bases of adenine 
and cytosine [243]. Instead of the entire base group, we only carry out SASA calculations 
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on N1, N3, and two bound carbon atoms. For the phosphate group, the SASA calculations 
were restricted to the P, OP1, and OP2 atoms. Thus, the relative SASA change for each 
group of atoms of interest was calculated as: 
∆𝑟𝑆𝐴𝑆𝐴(𝑟𝑒𝑠𝑖𝑑𝑢𝑒 𝑖) =
|𝑆𝐴𝑆𝐴(𝑟𝑒𝑠𝑖𝑑𝑢𝑒 𝑖 𝑖𝑛 𝑚𝑜𝑛𝑜𝑚𝑒𝑟)−𝑆𝐴𝑆𝐴(𝑟𝑒𝑠𝑖𝑑𝑢𝑒 𝑖 𝑖𝑛 𝑐𝑜𝑚𝑝𝑙𝑒𝑥)|
𝑆𝐴𝑆𝐴(𝑟𝑒𝑠𝑖𝑑𝑢𝑒 𝑖 𝑖𝑛 𝑚𝑜𝑛𝑜𝑚𝑒𝑟)
                                  (3.3) 
 
Finally, the classification of the binding mode was done using the following rules: 
𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒𝑠 = {
 𝑏𝑎𝑠𝑒 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 𝑡𝑦𝑝𝑒, 𝑖𝑓 ∆𝑟𝑆𝐴𝑆𝐴(𝑏𝑎𝑠𝑒) ≥ 25%                                 
𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 𝑡𝑦𝑝𝑒, 𝑖𝑓 𝑜𝑛𝑙𝑦 ∆𝑟𝑆𝐴𝑆𝐴(𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒) ≥ 25%
𝑂 − 𝑡𝑦𝑝𝑒, 𝑖𝑓 ∆𝑆𝐴𝑆𝐴(𝑏𝑎𝑠𝑒)𝑎𝑛𝑑 ∆𝑟𝑆𝐴𝑆𝐴(𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒) < 25%     
                (3.4) 
 
3. Results and Discussion:  
 In the results section, we will first report general frequency patterns of ionizable residues 
in datasets, as well as statistical analysis of pKa shifts induced by the binding. Furthermore, 
different pKa shift origins are classified for all ionizable groups based on different 
chemical-physical properties and binding modes. The pKa shifts among different binding 
modes are then analyzed. Finally, we investigate the pH dependence of the net charge of 
binding, complexes, and their components – and reveal how the optimum pH values are 
correlated (pH-optimum is the pH at which the binding or folding free energy is most 
favorable, see refs [235, 236] for details). Below we describe the results in sequential order.  
 
3.1 The frequency patterns of ionizable residues in the datasets: 
It is expected that proteins binding to negatively charged DNA or RNA should be 
positively charged, so that the electrostatic interactions are able to guide the protein toward 
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its binding partner. To investigate this expectation, we carried out statistical analysis of 
amino acid composition of the proteins in both Pfam and SCOP datasets (Appendix Figure 
B-16). We considered only Arg and Lys residues to be carrying positive charge, as His is 
typically neutral. The acidic groups were Glu and Asp. It can be seen (Appendix Figure B-
16) that the frequency of Arg and Lys residues are almost the same as the acidic residues 
in both datasets. Thus, the total net charge of these binding proteins is close to zero in the 
neutral pH range, which is somewhat unexpected.  
We now expand the analysis to the interfacial ionizable residues. The frequency 
patterns of different residue types were shown in Appendix Figure B-17. In contrast to 
overall amino acid composition (Appendix Figure B-16), the interfacial regions are 
enriched with basic residues, resulting in highly positive charged interfacial patches. This 
confirms our expectations, since both RNA and DNA are highly negatively charged in 
neutral pH. The important role of electrostatics in protein nucleic acid binding is indicated 
by our observations that the overall net charge is almost zero, but interfaces are positively 
charged. It provides guidance for correct orientations of binding partners. It should be 
mentioned that interfaces of DNA binding proteins are typically more positively charged 
when compared with RNA binding protein (Appendix Figure B-17).   
 
3.2 Statistics of pKa shifts induced by the binding:  
Protein-protein binding frequently involves pKa shifts of ionizable groups as 
previously demonstrated both computationally [230, 231, 242, 244] and experimentally 
[242, 245-249]. Here we address the same question for protein-DNA and protein-RNA 
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binding, including the pKa changes of DNA/RNA bases, using computational methods. 
The calculations were done for all interfacial residues and bases separately for the complex 
and monomers alone. The pKa shifts were calculated with the following equation: 
∆𝑝𝐾𝑎𝑧 = 𝑝𝐾𝑎𝑐𝑜𝑚𝑝𝑙𝑒𝑥
𝑧 − 𝑝𝐾𝑎𝑚𝑜𝑛𝑜𝑚𝑒𝑟
𝑧                                                                    (3.5) 
,where Z stands for the ionizable group in the protein or DNA/RNA. 
  The pKa shifts of all interfacial residues were calculated in both Pfam and SCOP 
datasets and the results are shown in Appendix Figures B-18 and B-19. The corresponding 
pKa shifts are reported for all protein acidic interfacial residues, protein basic interfacial 
residues, and nucleic acid ionizable groups (bases) separately. The results are grouped by 
complex type: protein-RNA complex, protein-double stranded DNA (protein-dsDNA) 
complex, and protein-single stranded (protein-ssDNA) complex. This is done to facilitate 
the analysis of the effect of different binding modes. It can be seen (Appendix Figures B-
18 and B-19) that complex formation is predicted to cause positive pKa shifts for both 
acidic and basic protein titratable residues. This is in sharp contrast with the statistical 
observation made for protein-protein complexes[231]. An opposite shift is predicted for 
nucleic acid bases – they are predicted to lower their pKa values upon complex formation. 
These tendencies are similar for all types of complexes (such as protein-RNA, protein-
dsDNA, and protein-ssDNA complexes) and remain similar across both datasets (Pfam and 
SCOP). These pKa shifts originate from the different intrinsic properties of these groups, 
different binding modes, and different structural features (which will be discussed later).  
 Further analysis of the pKa shift distribution indicates that the overall pKa shifts of 
protein basic residues are slightly larger when compared with the pKa shifts of acidic 
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residues. This may indicate that protein basic groups are frequently involved in direct 
interactions with negatively charged phosphate groups of DNA/RNA. Nucleic bases of 
RNA and ssDNA are predicted to undergo larger pKa shifts than those of dsDNA. Perhaps 
this is due to the double helix structure of dsDNA, where the base groups make hydrogen 
bonds with their partners and are buried before binding. Due to this, the base groups of 
RNA and ssDNA are involved in more direct interactions with the corresponding binding 
protein.   
 
3.3 Analysis of the pKa shift origins: 
In this section, we will outline common reasons for predicted pKa shifts and categorize 
them into several distinctive classes. Since protein titratable groups and DNA/RNA bases 
have different physical-chemical properties, the origins of their pKa shifts will be discussed 
separately. 
Protein pKa shifts:  
pKa shifts are caused by various factors, the most prominent being interactions with other 
charges and de-solvation penalty (upon complex formation). Based on the comparison of 
these energy components, we will consider two common scenarios: (a) complex formation 
is not affected by much solvation energy change (small de-solvation penalty) but provides 
strong favorable interactions supporting the charged state of the protein titratable group 
(termed C-type); and (b) complex formation does not greatly affect the solvation energy 
(small de-solvation penalty) while resulting in strong unfavorable interactions suppressing 
the charged state of the protein titratable group (termed N-type). A representative example 
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for the first case, C-type residue, is shown in Figure 3.1A ,depicting a fragment of the 
binding interface of Archaeosine tRNA-Guanine Transglycosylase complexed with 
lambda-form tRNA(PDB: 1j2b) [250]. Upon the complex formation, Lys430 of chain A 
forms a new salt-bridge with the RNA Gua927’s phosphate group. In the unbound state, 
the pKa of Lys430 was calculated to be 10.22, a slight deviation from the standard pKa 
value. In the complex formation, the de-solvation energy slightly increases by 
0.04kcal/mol, since the degree of the burial of the residue does not undergo a large change. 
However, the interaction energy is changed by -1.52kcal/mol – a contribution from the salt-
bridge formed by Lys430 and phosphate group of RNA Gua927. As a result of favorable 
electrostatic interactions between the protein interfacial basic residue and phosphate group 
in RNA, the pKa of Lys430 shifts from 10.22 to 12.47 at the complex formation. This type 
of pKa shift was found in many cases, thus explaining the positive pKa shifts predicted for 
protein interfacial basic residues. The second common scenario is shown in Figure 3.1B 
for the structure of PVUII Endonuclease complexed with cognate DNA (PDB: 3pvi) [251]. 
In unbound protein, the Glu68 residue of chain A is exposed to the water and the side chain 
is stabilized by the interaction with the nearby Lys70. Upon the complex formation, Glu68 
side chain points to the phosphate group of DNA Cyt9. As shown in the corresponding 
Figure, the oxygen-oxygen distance between the Glu68 side chain and DNA Cyt9 
phosphate group is only 3.5 Å. This results in strong unfavorable interactions opposing the 
charged state of Glu68. The existing interactions of the Glu68 and Lys70 are additionally 
weakened in the complex as Lys 70 forms new interactions with a phosphate group. 
According to the energy calculation of DelphiPka, the interaction energy is increased by 
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0.64 kcal/mol and the de-solvation energy is only slightly increased, since the degree of 
the burial of the residue does not change much. As result, the Glu68 pKa value is shifted 
from 3.93 to 5.11. Therefore, we refer to these kinds of residues (which are under 
unfavorable interactions in the complex) as N-type protein residues. As shown in the 
previous statistical analysis of pKa shifts, the majority of the protein acidic residues are 
affected by different degrees of positive pKa shifts. Most of these cases can be classified 
as N-type residues due to the unfavorable electrostatic interactions between the acidic 
residue and the phosphate group of the DNA/RNA nucleotides.    
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Figure 3.1: (A) Fragment of binding interface of Archaeosine tRNA-Guanine 
Transglycosylase complexed with lambda-form tRNA (PDB: 1j2b). (B) Fragment of 
binding interface of PVUII Endonuclease complexed with cognate DNA (PDB: 3pvi). The 
side chains of the residues directly contributing to the electrostatic interactions or H-
bonding are shown with balls and sticks. The protein and DNA/RNA are marked as blue 
and orange for comparison. The distance between the atom pairs are shown in Å. 
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DNA/RNA: 
In this investigation, the pKa values of Cys and Ade bases are predicted for bound 
and unbound states. These bases are typically neutral at physiological pH (pH about 7), but 
can be protonated and positively charged in some cases [154]. As shown from the above 
statistical analysis, the majority of DNA/RNA bases are predicted to undergo negative pKa 
shifts due to the binding. Therefore, the base groups are less likely to be protonated at 
physiological pH values. We will group the common pKa shift scenarios into several 
categories: (a) bases experiencing large de-solvation penalty and forming H-bonding or 
electrostatic interactions (termed B-type), (b) bases experiencing electrostatic interactions 
and negligible de-solvation penalty (termed L-type), and (c) bases experiencing small de-
solvation penalty (O-type). Typically, the B-type residue is a base group in which the 
nucleotide is buried into the binding interface and directly participates in hydrogen bonding 
or electrostatic interactions upon the complex formation. One representative example is 
shown in Figure 3.2A: a CCA-adding enzyme complexed with tRNA (PDB: 3ovb) [252]. 
The atom N3 of the base group of the RNA Cyt33 is predicted to have standard pKa of 
4.35 in unbound RNA. In chain C of the complex, the atom N3 of Cyt33 makes a hydrogen 
bond with the backbone atom of His93 of chain A of the complex. Since the N3 atom plays 
the role of a proton acceptor, such an interaction increases the energy cost of protonation. 
Cys 33 is also buried at the binding interface, and thus the charged form of Cys 33 pays 
the de-solvation penalty. Combining these two effects, the RNA Cys 33 pKa shifts from 
4.56 to 1.14. Another example is shown in the Figure 3.2B: TilS complexed with tRNA 
(PDB: 3a2k)[253]. The base group of RNA Ade36 is buried into the binding interface and 
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surrounded by a pocket of three Arg residues. Although the base group is not directly 
forming interactions with nearby residues, it is still affected by electrostatic interactions of 
the three positively charged Arg residues. This results in a shifting equilibrium towards the 
de-protonated form. The degree of burial for Ade36 is increased upon complex formation, 
resulting in a de-solvation penalty. Finally, the pKa value of Ade36 is predicted to decrease 
from 4.90 to 2.75. 
Another common type of pKa shift, listed above as L-type, is shown in Figure 3.2C. 
This shift occurs in case of restriction endonuclease MspI on its palindromic DNA 
recognition site (PDB: 1sa3)[254]. The Cyt13 of chain D resides in a double strand 
structure, and its base group makes a hydrogen bond with its base pair. The base group of 
Cyt13 is pre-buried in unbound DNA and its degree of burial is almost unchanged in the 
complex. Therefore, Cys13 does not pay a de-solvation penalty upon complex formation. 
However, a nearby positively charged Lys261 protein residue does interact with the base 
of Cyt13. This unfavorable interaction energy is calculated to be about 0.5 kcal/mol, and 
along with other smaller contributions, results in pKa shift of -0.83.  
Finally, the common cases referred to above as “O-type” are represented by many 
other residues that are not involved in strong interactions with charged residues upon 
complex formation. Their pKa shifts are relatively small (|pKa| < 0.5) and are mostly due 
to a de-solvation penalty upon complex formation.  
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Figure 3.2: (A) Fragment of binding interface of CCA-adding Enzyme complexed with 
tRNA (PDB: 3ovb). (B) Fragment of binding interface of TilS complexed with tRNA 
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(PDB: 3a2k). (C) Fragment of binding interface of restriction endonuclease MspI on its 
palindromic DNA recognition site (PDB: 1sa3). The side chains of the residues directly 
contributing to the electrostatic interactions or H-bonding are shown with balls and sticks. 
The protein and DNA/RNA are marked as blue and orange. The distances between atom 
pairs are shown in Å. 
 
3.4 pKa shifts and binding mode: 
In this section we investigate the effect of different binding modes on previously 
discussed pKa shifts. Here, we classify the binding modes into three categories: (a) 
phosphate group binding mode (protein interacts mostly with phosphate groups), (b) base 
group binding mode (protein interacts mostly with base groups), and (c) others (O-type 
mode: categorization is outlined in Method section).        
Appendix Figures B-20 and B-21 show the distributions of pKa shifts in different 
binding modes for both Pfam and SCOP datasets. The most significant pKa shifts are 
predicted for the base group binding mode. In base group binding modes, the base groups 
directly participate in the interactions across the interface and bases are buried at the 
binding interface, thus paying a large de-solvation penalty. According to the above 
categorization strategy, these bases are grouped as B-type nucleotides. Both the de-
solvation penalty and interaction energy oppose the charged form of the bases and thus 
result in significant pKa shifts, lowering the pKa of the bases. Phosphate group binding 
modes result in L-type bases, as the base groups are not at the interface and do not 
experience burial change upon complex formation (but are affected by long-range 
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electrostatic interactions). In the phosphate group binding mode, the bases are predicted to 
have relatively less significant pKa shifts. The rest of these cases are mostly of O-type, and 
are predicted to have the smallest pKa shifts as they are not involved in strong interactions 
and do not experience a de-solvation penalty upon binding. 
 
3.5 pH-optimum of binding: 
Previous studies investigated protein stability and interactions as a function of pH, 
and referred to the pH-optimum as the pH of maximal stability and interactions [235-237]. 
This optimum pH can be obtained by finding the pH value at which the net charge 
difference of the folded and unfolded states, or bound and unbound states, is zero. We 
illustrate this with a particular example from our dataset. The pH dependence of the net 
charge difference and the pH dependence of the binding free energy for a bacteriophage 
lambda cII protein in complex with dsDNA (PDB: 1zs4) [255] is shown in Figure 2.15. 
Three distinctively different pH regions can be clearly identified. The first region is in the 
acidic pH range, where both the net charge difference (Q < 0) and the free energy decrease 
(the free energy of binding becomes more favorable) with an increase in pH. Proton release 
occurs in this pH range upon complex formation or protein folding which involves mostly 
acidic groups. The third region is in the basic pH range, where Q > 0 and the free energy 
increases with the pH (the binding free energy becoming less favorable). Proton uptake 
involving predominantly basic groups occurs in this pH range. The second region is in the 
intermediate pH range, where Q is close to 0 and remains almost unchanged with the 
increase in pH. The titration of acidic or basic groups with non-standard pKa values occurs 
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in this pH range. Since most of the proteins perform their function in this intermediate pH 
range, it is the most interesting pH region for the study. The optimum pH can be determined 
by finding the pH corresponding to the minimum free energy. This is usually located at the 
border of first and third pH regions. As shown in Figure 3.3, the Q in the second region 
is frequently very small, practically close to zero. Thus, the results from this pH region are 
very sensitive to the imperfections of computational protocol and applied methodology. To 
reduce the error in finding the optimum pH, we introduce a threshold value Qt and assume 
that Q = 0 if abs(Q) < Qt . We explored different values for Qt  (from 0.1, 0.2, 0.3 to 
0.4) and the best results (in terms of obtaining the best correlation coefficient, explained 
below) were obtained with the 0.1 value. In cases of very flat intermediate pH regions, the 
pH-optimum was taken to be the center of the intermediate pH range. In Figure 3.3(B) and 
(D), the intermediate pH regions for binding and protein stability both range from pH 4 to 
9. Thus, the optimum pH for the binding and stability of the protein component is taken to 
be 6.5. Several other approaches were explored as outlined below.   
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Figure 3.3: pH dependence of the net charge difference and free energy for a bacteriophage 
lambda cII protein in complex with dsDNA (PDB: 1zs4). (A) and (B) show pH dependence 
of net charge difference (proton uptake/release) and the corresponding pH dependence of 
the binding free energy. (C) and (D) show pH dependence of net charge difference and 
folding free energy of the protein component.  
 
3.6 Correlation of pH-optimum of binding and protein stability: 
Protein-DNA/RNA interaction is a pH-dependent process, with the binding affinity 
reaching a maximum at the pH-optimum. In vivo, the monomers and their complex coexist 
in the same subcellular environment and thus should be adapted to the corresponding 
subcellular pH [233]. Indeed, it was demonstrated that the optimum pH of binding and 
folding are correlated [231, 236]. In this work, we investigate the possibility that the pH-
optimum of protein-DNA/RNA binding is correlated with the pH-optimum of the folding 
of the corresponding binding protein. We do not address the same question for RNA/DNA 
stability, since our approach considers only basic titration of RNA/DNA titratable groups 
and therefore the titration is monotonic with pH.   
The optimum pH was determined by using the above-discussed strategy for both 
SCOP and Pfam datasets, and  was taken as 0.1 in the calculations. A fraction of cases 
did not show clear pH dependence and thus no optimal pH value could be determined. 
Thus, we excluded these cases from the correlation analysis and the rest of the cases (62 
out of 105 cases and 33 out of 56 cases for protein-RNA complexes in Pfam and SCOP 
datasets respectively, as well as 68 out of 99 cases and 91 out of 112 cases for protein-
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DNA complexes in Pfam and SCOP datasets respectively) were subjected to two different 
protocols to assess pH-optimum: (a) pH-optimum is taken to be the middle of the “flat”, 
almost pH independent region and (b) the pH-optimum of binding is taken within the “flat” 
pH region, with selected pH being the closest to folding of the corresponding binding 
protein. The results are summarized in Table 3.1 and the corresponding plots are provided 
in the supplementary material. One can see a weak correlation between the pH-optimum 
of binding and the pH-optimum folding of the corresponding binding protein.  
 
Scenario (a) Scenario (b) 
Complexes 
Type 
Correlation 
coefficient for 
all complexes 
Correlation 
coefficient for 
STDEV<2 
Complexes 
Type 
Correlation 
coefficient for all 
complexes  
Correlation 
coefficient for 
STDEV<2 
Protein-RNA in 
SCOP 
0.71 0.66 Protein-RNA in 
SCOP 
0.78 0.83 
Protein-DNA in 
SCOP 
0.3 0.58 Protein-DNA in 
SCOP 
0.42 0.83 
Protein-RNA in 
Pfam 
0.48 0.56 Protein-RNA in 
Pfam 
0.5 0.77 
Protein-DNA in 
Pfam 
0.24 0.27 Protein-DNA in 
Pfam 
0.41 0.74 
 
Table 3.1 Pearson product-moment correlation coefficient between pH-optimum of 
binding and folding of the corresponding binding protein. Results are shown for both SCOP 
and Pfam classifications and the two scenarios outlined above. For each complexes type, 
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Pearson product-moment correlation coefficient is calculated for all complexes and also 
for complexes in which outliers are excluded (standard deviation > 2 pH units). 
 
4. Conclusion: 
      In this work, we investigated the electrostatic properties, pKa shifts, proton 
uptake/release, and pH-optimum of a large number of protein-DNA/RNA complexes with 
available 3D structures. The analysis of the pKa shifts induced by the complex formations 
indicated a completely different trend in comparison with previous studies on protein-
protein complexes [230, 231, 256]. Protein titratable residues were found to undergo 
positive pKa shift, thus increasing the pKa values of both basic and acidic groups. Such an 
opposite trend (opposite to the trend observed for protein-protein complexes) is due to the 
difference between the electrostatic properties of the corresponding partners. In the case of 
protein-protein complexes, the interfaces are frequently made up of patches of opposite 
polarity and thus the given protein may provide a favorable electrostatic environment for 
both basic and acidic groups [231, 256]. In contrast, most of the binding modes in our 
dataset consist of cases in which the protein binds to phosphate groups of DNA/RNA. Since 
phosphate groups are negatively charged, the electrostatic environment for protein 
titratable groups make the charged state of acidic groups less favorable while promoting 
the charged state of basic groups. This is the main reason for the observed tendency of 
protein-DNA/RNA binding to induce positive pKa shifts of protein titratable groups. In 
contrast, the binding causes pKa values of nucleic acid bases to lower. Most of this effect 
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is due to unfavorable electrostatic interactions with the positively charged interface of the 
corresponding binding protein. 
Very little proton uptake/release was predicted to accompany the binding. For many 
cases in the dataset, the proton uptake/release was almost zero for the pH range of 5 to 8. 
This is also quite different from observations made of protein-protein complexes [229, 230, 
236]. Protein-DNA/RNA binding seems to be less pH dependent than protein-protein 
binding. This likely reflects the fact that protein-protein interactions occur in more diverse 
environments than protein-DNA/RNA binding.  
 A weak correlation was found between the pH-optimum of binding affinity and the 
folding free energy of unbound protein. The correlation is not as significant as correlations 
found for protein-protein binding [229-231, 236]. This may be due to the fact that only 
basic groups of DNA/RNA were treated as titratable residues in our protocol. We anticipate 
that the inclusion of other groups (phosphate groups, for example) could result in a more 
significant correlation. Another reason could be computational protocol, which treats the 
structures of both protein and DNA/RNA as rigid bodies, considers that pKa shift are 
entirely due to electrostatic energy changes, does not include explicit ions and does not 
allow for water penetration at the binding interface. Some of the abovementioned 
deficiencies are intrinsic to continuum approaches [257], others can be handled via 
continuum approach as explicit ion binding [258-260], but were not implemented in this 
study in order to reduce computational cost of modeling such large set of complexes. 
Further insights can be obtained via constant pH molecular dynamics simulations (MD) 
[261, 262]. Recent constant pH MD study proposed “trap-and-trigger” mechanism was 
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proposed to accompany protein binding and to involve structural rearrangement and water 
penetration at the interface [263]. Such structural rearrangements upon molecular 
recognitions are frequently revealed in studies utilizing constant pH MD [264, 265], 
indicating that rigid body approach may induce significant error in modeling pKa’s [257].    
         Overall, our study indicates that electrostatics play a significant role in protein-DNA 
and protein-RNA binding and frequently this binding is accompanied by pKa shifts, 
resulting in little proton uptake/release and weak pH dependence.  
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Development of computational approach in prediction of SAV’s effect on protein 
DNA binding: 
1. Introduction  
Protein-DNA interactions are essential for functions of living cells and are involved in 
many important cellular processes such as transcription, replication, and recombination.  
For example, the expression level of genes is regulated by a wide number of proteins named 
transcription factors, which have DNA-binding domains recognizing a specific sequence 
of DNA [266, 267]. Protein-DNA binding is mediated by many factors such as DNA 
sequence, hydrogen bonds, van der Waals contacts, DNA shape, protonation states, 
flexibility and many others [217, 223, 224, 268-270].  While DNA–backbone interactions 
are important for the stability of protein-DNA complexes, proteins recognize specific DNA 
sequence by forming hydrogen bonds between amino-acid side chains and DNA bases 
[217, 224, 225]. 
Therefore, mutations occurring in DNA binding proteins that alter the physicochemical 
properties of the binding interfaces will affect binding specificity and affinity [271, 272]. 
Such mutations are frequently involved in many diseases like neurological disease, heart 
disease and cancer. Hence, understanding their molecular effects is crucial for deciphering 
disease origins and pursuing treatment [48, 273-275].  
Significant fractions of diseases are caused by the alteration of native binding affinities, 
which can be quantitatively described by the binding free energy change [26, 198]. There 
are many experimental techniques capable of measuring protein-DNA binding free energy 
such as isothermal titration calorimetry (ITC) [276], fluorescence resonance energy 
transfer (FRET) [277], nuclear magnetic resonance(NMR)  [278], surface plasmon 
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resonance(SPR) [279] and many others. However, these experimental methods are usually 
time consuming and non-applicable for large-scale studies. Recently, the available 
experimental data of protein-DNA binding free energy changes caused by amino acid 
substitutions was compiled and organized in a database, the ProNIT database [32]. 
    Computational approaches can complement experimental techniques and permit large-
scale investigations. Among them, the free energy perturbation (FEP) and the 
thermodynamic integrations (TI) are the most rigorous, but require intensive calculations, 
which limit their applicability for large-scale analysis. Alternatively to FEP and TI, 
different physical models and optimized knowledge-based potentials have been developed 
to carry out fast predictions of protein–DNA binding affinities achieving a good correlation 
with experimental measurements [280-284]. A structured based approach, the mCSM 
method, was developed [151, 285] and was shown that it achieves correlation coefficient 
of 0.673 in benchmarking test against ProNIT database. Very recently, mCSM-NA, an 
improved version of mCSM method, achieved correlation coefficient of 0.72 in 
benchmarking against ProNIT database [285].  Even so, the existing approaches for fast 
prediction of protein-DNA binding affinity changes upon mutations are still very limited, 
comparing with approaches developed for protein-protein interactions. 
    The Molecular Mechanics/Poisson Boltzmann Surface Area (MM/PBSA) approach is a 
widely applied method to calculate binding free energies of macromolecules by combining 
molecular mechanics calculations and continuum solvation models [286-288]. The 
MM/PBSA method computes a linear combination of energy terms for molecular 
mechanics, polar and non-polar solvation energy and shows high computational efficiency 
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comparing with the rigorous methods such as FEP and TI methods. In this work, we 
developed a new approach termed SAMPDI (Single Amino acid Mutation binding free 
energy change of Protein-DNA Interaction) to perform fast predictions of binding free 
energy changes of protein-DNA complexes caused by single mutations on the proteins. 
Our approach combines modified MM/PBSA based energy terms with additional 
knowledge-based terms. The method is implemented in a webserver 
(http://compbio.clemson.edu/SAMPDI/), which allows the users to upload the 
corresponding protein-DNA structural file, to specify the mutations and to obtain the 
predicted binding free energy change. 
2. Methods 
2.1 Dataset preparation 
We constructed a dataset, containing experimentally measured binding free energy change 
upon missense mutations and corresponding PDB structures, by combining the ProNIT 
database [32] and data from recent references. We applied three criteria in constructing the 
dataset: 1) Mutations affecting protein DNA binding, but not the quaternary structure of 
the corresponding protein, like dimerization.  2) The binding site of DNA (DNA sequence 
of the interface) used in the experiment is exactly identical to the DNA sequence of the 
corresponding PDB structure. 3) The structures with modified DNA, like methylation were 
removed and not considered in this study. Finally, the constructed dataset for this study 
included 105 missense mutations from 13 proteins. (The constructed dataset used in this 
study is shown in the supplementary material and can be downloaded from URL: 
http://compbio.clemson.edu/downloads) 
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2.2 NAMD Simulation protocols 
The structures of protein-DNA complexes were downloaded from RCSB Protein Data 
Bank (PDB) [289]. The biological units were retained and ligands, except ions, were 
removed from the initial structures. The missing heavy atoms were fixed using the default 
parameters of the profix module in Jackal package 
(https://honiglab.c2b2.columbia.edu/software/Jackal/Jackalmanual.htm). The mutant 
(MT) structures were generated by the VMD Mutator plugin [138] using the topology files 
from CHARMM36 force field [290, 291]. The energy minimization was performed with 
the NAMD program, version 2.11b [95] using the conjugate gradient algorithm. The 
default minimization steps were set to 5000 steps but longer minimization was applied if 
the variation of the total energy was more than 0.5 kcal/mol. In the minimization, the 
Generalized Born implicit solvent (GBIS) model and CHARMM36 force field[290, 291] 
were used. The dielectric constant of the implicit solvent was set to 80 and the various 
values of the protein-DNA dielectric constant were tested (see results section). Finally, the 
minimized structures were used to calculate the relevant energies. 
2.3 Electrostatic energy calculations 
Delphi with the Gaussian-based smooth dielectric function [83, 292, 293] was used to 
calculate the electrostatic component of the binding free energy in the Protein-DNA 
binding interaction using the following parameters: scale = 2 grid/Å; percentage of filling 
for the protein-DNA complex structures = 70%; dielectric constant = 80 for the solvent; 
salt concentration =0.15 mol/L; Gaussian with sigma=0.93, srfcut=20 and non-linear 
Poisson-Boltzmann equation (PBE) (non-linear PBE was used because of the high charge 
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of the DNA). Grid box for protein and DNA monomers were set exactly identical as for 
their complex by specifying the grid box size and center.  
2.4 Binding free energy calculations 
This study combines a modified MM/PBSA approach and knowledge based energy terms 
to calculate the protein-DNA binding free energy change upon single amino acid 
substitution. MM/PBSA is a widely used approach to calculate the receptor-ligand binding 
free energy and the thermodynamic cycle of computing the binding free energy change 
upon single amino acid change is shown in Figure 3.4. In our approach, the unbound 
monomer structures are taken from the corresponding complex, thus assuming no structural 
changes upon the binding (called rigid body approach).  In addition, a set of knowledge 
based energy terms, which are derived from analysis of physicochemical properties of the 
corresponding protein-DNA structures, are combined with the MM/PBSA approach (more 
details are provided in refs [30, 34]). All individual energy terms are combined via 
weighted linear scoring function and optimal weighted coefficients are determined via 
multiple linear regression against experimental data. Below, we will describe the protocols 
of computing each energy terms, including the MM/PBSA and knowledge based ones.  
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Figure 3.4: Thermodynamic cycle for binding free energy change calculations. The side 
chain of wild type and mutant residues are show in green and red color, respectively. 
 
2.4.1 The MM/PBSA-based energy terms 
The MM/PBSA components of the change of the binding free energy are in a linear 
combination of the five components shown in the following equation: 
∆∆𝐺𝑀𝑀/𝑃𝐵𝑆𝐴 = 𝑤0 + 𝑤1 ∙ ∆∆𝐼𝐸 + 𝑤2 ∙ ∆∆𝐶𝐸 + 𝑤3 ∙ ∆∆𝑃𝑆 + 𝑤4 ∙ ∆∆𝑉𝐸 + 𝑤5 ∙ ∆∆𝑁𝑆           (3.6) 
,where IE is the internal energy, CE is the Coulombic energy, PS is the polar component 
of the solvation energy, VE is the van der Waals energy, NS is the non polar component of 
the solvation energy and wi are weight coefficients. The energy difference for each energy 
term is computed using the following equation: 
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∆∆E = (𝐸𝑐𝑜𝑚𝑝𝑙𝑒𝑥
𝑀𝑇 − 𝐸𝑝𝑟𝑜𝑡𝑒𝑖𝑛
𝑀𝑇 − 𝐸𝐷𝑁𝐴
𝑀𝑇 ) − (𝐸𝑐𝑜𝑚𝑝𝑙𝑒𝑥
𝑊𝑇 − 𝐸𝑝𝑟𝑜𝑡𝑒𝑖𝑛
𝑊𝑇 − 𝐸𝐷𝑁𝐴
𝑊𝑇 )                    (3.7)   
,where MT and WT represent the mutant and wild-type structures. The structures of 
unbound protein and DNA are taken from the complex structures. Below we describe each 
energy component (more details can be found in [30]).  
    IE and VE energies were calculated using the NAMD program. Since the rigid body 
approach was applied and no structural changes are considered in the binding, ΔΔIE 
calculated by equation 3.7 will result in zero. In our methodology development, we have 
tried to minimize the complex structure and unbound monomer structure separately to take 
into account the structural changes induced by the binding. However, the results showed 
weaker correlation between the predicted value and experimental data comparing with 
applying the rigid body approach, thus w1 was set to zero. VE energy was obtained with 
NAMD by subjecting the corresponding minimized structure to an one step equilibration. 
CE and PS were calculated using the Delphi program with Gaussian-based smooth 
dielectric function, an accurate and fast Poisson-Boltzmann Equation (PBE) solver [83, 
292]. In Gaussian Delphi, the solute and water phase are treated as an inhomogeneous 
dielectric medium by using a smooth Gaussian-based dielectric function, which showed 
better performance comparing with the traditional two-dielectric model (the traditional two 
dielectric model treats biomolecule and water as two distinctive media with two different 
dielectric constants with a sharp dielectric border between the two media). The 
performance of the traditional two-dielectric model and the smooth Gaussian-based model 
were tested and the Gaussian-based model showed better results as benchmarked against 
experimental data. 
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 NS was calculated via the solvent accessible surface area (SASA) using the equation 3.8. 
The SASA was computed using the NACCESS software with default atom radius 
parameters [294]. The constants α and β in equation 3.8 were incorporated into to the 
weight coefficient in equation 3.6. 
𝑁𝑆 = 𝛼𝑆𝐴𝑆𝐴 + 𝛽                                                                                                            (3.8) 
2.4.2 Knowledge-based energy terms 
Many knowledge-based energy terms were tested in this study among which entropy (S) 
and hydrogen bond (HB) showed highest impact. The impact was evaluated based on the 
p-test indicating that S and HB are the terms showing highest correlation with experimental 
measured binding free energy changes (see supplementary material). Finally, the 
knowledge-based energy terms (ΔΔGKW) are a linear combination of the two components 
shown in the following equation: 
∆∆𝐺𝐾𝑊 = 𝑤1 ∙ ∆∆𝑆 + 𝑤2 ∙ ∆∆𝐻𝐵                                                                                     (3.9)        
where S is the entropy, and HB is the number of hydrogen bonds. The energy differences 
for each term are also computed using equation 3.7. 
The entropy of protein’s residue is calculated using the following empirical formula 
originally developed in our previous work [30]. 
𝑆 = 𝑙𝑛 [𝑟𝑆𝐴𝑆𝐴(𝑖) ∙ (𝑅(𝑖) − 1) + 1]                                                                                (3.10) 
,where rSASA(i) represents the relative solvent accessibility of residue i (calculated by the 
NACCESS software [294]) and small rSASA(i) values (close to 0) indicate that the residue 
is buried and only a few side chain rotamers can be sampled, which results in a small 
entropy contribution; R(i) is the maximum number of the rotamers for residue i  (R(i) for 
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all types of residues are shown in the Table C-6). The entropy change upon mutation is 
calculated by subtraction of the entropy for the wild-type residue and mutant residue.   
     The number of hydrogen bonds (HBs) is calculated using the VMD plugin with a cut-
off distance 3.0 Å and a cut-off angle of 30 degrees. We tried two protocols to compute the 
number of HB: 1) compute the total number of the HBs for the entire structures (including 
intra and inter HBs); 2) only compute the number of HBs near the mutation site and choose 
to count the HBs within 6 Å of the mutation site (different cut-off values were tested and 
6 Å showed the best correlation). The second protocol was applied in our calculation since 
it showed much better correlation with the experimental ΔΔG in the p-test (see 
supplementary material). 
3. Results 
3.1 Finding optimal value of dielectric constant  
In our protocol we used an implicit model to minimize protein-DNA structures and to 
calculate the MM/PBSA energy terms. Different dielectric constant values affect the 
energy minimization and the energy terms calculated with both Delphi and NAMD 
programs. Our previous works showed that selecting an optimal dielectric constant value 
for proteins results in improved correlation coefficient for binding/folding free energy 
calculation [30, 34]. Here, we tested various dielectric constants for the protein-DNA 
complex to identify the optimal value corresponding to the highest correlation coefficient 
against experimental data. Figure 3.5 shows the dependence of correlation coefficient on 
the value of the dielectric constant of the protein-DNA complex. We varied the dielectric 
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constant of protein-DNA from 1 to 5 for NAMD program (this was done for testing 
purposes, while understanding that dielectric constant value of 1 is physically sound) and 
1 to 20 for Delphi program with a step of 1. Multiple linear regression was performed for 
each set of values of dielectric constants using VDW energy, Coulomb energy and the polar 
component of the solvation energy to obtain the correlation coefficient (Figure 3.5). The 
results indicate the dielectric constant value used in NAMD modeling highly affects the 
correlation coefficient (Figure 3.5). Summarizing, the correlation coefficient reaches the 
highest value with a dielectric constant for NAMD =1 and for Delphi =14 and these values 
will be used in our protocol. 
 
Figure 3.5. The correlation coefficient calculated with various dielectric constants used in 
Delphi and NAMD. Panel A shows the correlation coefficient dependence of dielectric 
constant from 1 to 5 in NAMD and 1 to 10 in Delphi while Panel B shows the dependence 
of dielectric constant from 1 to 5 in NAMD and 11 to 20 in Delphi. The size and color of 
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circle are representing the correlation coefficients for a particular dielectric constant 
selection. 
3.2 Determination of optimal values of the weight coefficients  
As discussed in the Method section, the linear function of binding free energy changes 
contains 6 terms and 7 weight coefficients: 
∆∆G = 𝑤0 + 𝑤1 ∙ ∆∆𝐶𝐸 + 𝑤2 ∙ ∆∆𝑃𝑆 + 𝑤3 ∙ ∆∆𝑉𝐸 + 𝑤4 ∙ ∆∆𝑆𝐴𝑆𝐴 + 𝑤5 ∙ ∆∆𝑆 + 𝑤6 ∙ ∆∆𝐻𝐵     (3.10) 
Then, the weighted coefficients are determined from the multiple linear regression (MLR) 
between experimentally measured ΔΔG and calculated binding free energy changes. The 
resulting optimized weight coefficients are shown in Table C-7. The correlation coefficient 
from MLR is 0.72 over 105 cases. The plot of experimentally measured binding free energy 
changes and predicted binding free energy changes is shown in Figure 3.6. 
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Figure 3.6. A plot of experimentally measured binding free energy changes and predicted 
binding free energy changes. The corresponding linear fit and correlation coefficient are 
shown as well.  
3.3 Performance and Validation 
3.3.1 5-fold cross validation 
In our study the datasets used for training and testing are relatively small due to limited 
available experimental data. To address the problem of overfitting, we further performed 
5-fold cross validation by randomly partitioning the dataset into five subgroups of 
approximately equal sizes. For each round, four subgroups are used for training and the 
rest one is used for testing. The results are shown in the Table Appendix C-8 and Figure 
3.7A. The Root Mean Square of the Error (RMSE) in each fold varies a little and the 
resulting average is 0.54 kcal/mol. At the same time, Pearson correlation coefficient (CC) 
varies significantly probably due to the limited number of data points (20 data points for 
each fold and the corresponding CC shows significant variation even if with roughly same 
RMSE). We also analyzed the variation of the weighting coefficients for each energy terms 
in 5-fold cross validation and the results are shown in Appendix Table C-9. The standard 
deviation of the weighting coefficients is relatively small and indicate the variation is not 
significant across each fold. We further compared the average weighting coefficients in 5-
fold cross validation with the previous determined weighting coefficients from MLR and 
the results in Appendix Table C-9 shows that the differences for all the energy terms are 
very small. Overall, the testing indicates that overfitting is not significant. 
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3.3.2 Receiver operating characteristic (ROC) 
To evaluate the performance of SAMPDI, we further performed ROC analysis to 
distinguish large and small effects on binding free energy changes. Here, we classify the 
large effects as |ΔΔG| > 1kcal/mol and small effects as |ΔΔG| < 1kcal/mol. Figure 3.7B 
shows the ROC curve of SAMPDI for 105 experimentally measured binding free energy 
changes. The area under the curve is 0.76, indicating the capability of SAMPDI to 
distinguish different types of mutations.  
 
Figure 3.7. (A) Plot of predicted ΔΔG and experimental ΔΔG in 5-fold cross validation.  
(B) Receiver operating characteristic curve of classification of large effects (|ΔΔG| > 
1kcal/mol) and small effects (|ΔΔG| < 1kcal/mol).  
3.3.3 Multicollinearlity analysis 
It may be anticipated that some energy terms may reflect similar phenomena. To address 
such a possibility, we performed multicollinearlity analysis to study the correlation across 
each term and the variance inflation factors (VIF) from MLR. The results shown in 
Appendix Table C-10 indicate a strong correlation between CE and PS. This is due to the 
well-known fact that the PS originates from the CE. In addition, SASA has relative high 
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correlation with VDW, CE and PS. The rest, the VIFs of SASA, VDW, S and HB are 
within relative low multicollinearlity (VIF < 4). Removing highly correlated terms from 
eq. (5) results in decrease of prediction accuracy, but the change is not large. For example, 
removing the CE in the MLR leads to the decrease of correlation coefficient from 0.72 to 
0.65. Thus, these highly conserved terms were kept in our final protocol to achieve optimal 
accuracy. 
 
 
3.3.4 Case studies: consistent and inconsistent predictions comparing with experimental 
data. 
 To further investigate the factors affecting the predictions, representative examples of 
consistent and inconsistent predictions will be discussed below. The results of six single 
mutations shown in Table 3.2 will be discussed. 
 
Protein PDB 
(Mutation) 
ΔΔG 
(EXP) 
ΔΔG 
(PRED) 
ΔΔSASA ΔΔVE ΔΔCE ΔΔPS ΔΔS ΔΔHB 
1B3T 
(R469A) 
3.4 2.6 260.7 16.0 -61.4 106.9 1.8 -11.0 
1B3T 
(Y518A) 
2.6 2.2 72.6 14.3 1.3 -0.9 1.2 -9.0 
1MSE 
(C130I) 
0.3 0.2 3.6 -2.0 -2.3 3.8 0.0 0.0 
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1MSE E141A -0.1 -0.1 0.8 -1.8 7.6 -19.4 0.0 0.0 
1TN9 K54A 1.3 0.6 -18.0 -3.5 -20.5 38.4 0.9 -2.0 
2A0I E187A 2.1 1.2 24.3 7.4 7.1 -11.5 0.5 0.0 
 
Table 3.2 Cases of consistent and inconsistent predictions. Mutations in protein 1B3T and 
1MSE are the cases of consistent predictions (underlined), while the rest are inconsistent 
prediction cases. The ΔΔGs are in kcal/mol and positive value indicates destabilization 
(lowering protein-DNA affinity) while negative indicates stabilization.  The ΔΔE for each 
terms is shown as MT-WT. 
⚫ Predictions consistent with experimental data: 
Epstein-Barr nuclear antigen 1 (EBNA1) binds to the recognition site of the minimal origin 
of latent DNA replication of Epstein-Barr virus and results in activation of the latent-phase 
replication of the viral genome [295].  Here, we outline two single mutations (R469A and 
Y518A) of a permanganate-sensitive DNA site bound by EBNA1. Both mutations occur 
on the binding interface (PDB: 1B3T, Figure 3.8A) and dramatically destabilize the 
protein-DNA binding according to the experimental measurement (3.4 and 2.6 kcal/mol, 
respectively). The wild type residue R469 interacts with the DNA backbone and forms 
strong electrostatic interactions upon binding. Our calculations predict that a substitution 
to ALA will result in dramatic energy change of 61.44 kcal/mol of CE and 16.02 kcal/mol 
of VE upon binding along with a large effect on the SASA, HB and S (Table 3.2). Taking 
all together we predicted that R469A would cause decrease of 2.6 kcal/mol of binding free 
energy, which is very close to experiment. Another mutation, Y518A is also located at the 
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binding interface, which leads to a large change of VE along with decrease of HB and S. 
For both mutations, the experimental measured free energy changes are dramatic and 
destabilize DNA binding, which is reproduced by the SAMPDI.  Another representative 
example are two single mutations (C130I and E141A) in the structure of a specific DNA 
complex of the Myb DNA-binding domain with cooperative recognition helices (PDB: 
1MSE, Figure 3.8B) [296]. Both mutations are not in the binding interface and 
experimental measurement indicates minimal effects on the binding affinity. As shown in 
our energy calculations (Table 3.2), no large changes were computed for all energy terms 
resulting in minimal binding free energy change predictions, which is consistent with 
experiment.  
 
⚫ Predictions inconsistent with experimental data: 
             The first case is the mutation K54A in the structure of the Tn916 integrase-DNA 
complex. (PDB: 1TN9, Figure 3.8C) [297]. Experimental measurement indicated 
destabilization of binding and our calculation underestimated the binding free energy 
change by 0.72 kcal/mol (Table 3.2). In the wild-type structure, K54 is located in a flexible 
loop and does not directly form H-bond with nearby residue. It is feasible that K54 forms 
H-bonds in unbound protein or other specific interactions, which would not be captured in 
our rigid-body protocol and this could be the reason for discrepancy between experiment 
and modeling. Another case is the single mutation E187A in the complex structure of F 
Factor TraI Relaxase Domain bound to F oriT Single-stranded DNA (PDB: 2A0I, Figure 
3.8D). The experimental data indicates that the mutation destabilizes the binding by 2.12 
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kcal/mol while the effect is underestimated by SAMPDI. The corresponding reference 
[298] reporting the structure of protein-DNA complex indicates that there is significant 
uncertainty for the position of the Glu187 side chain. It is indicated that such a large free 
energy change is unexpected as the Glu187 side chain appears to only contact with Thy1 
5-methyl with its carboxylate [298]. The SAMPDI is a structure-based approach and thus 
strongly depends on the accuracy of the experimental structures. 
            The reasons that in some cases SAMPDI predictions are good or bad, as compared 
with experimental data stem from various sources. It should be reiterated that the SAMPDI 
protocol is a structure-based rigid-body approach and the accuracy is expected to be 
sensitive to the conformational changes upon binding and the resolution of experimental 
structures. Thus, mutations that do not induce large conformation changes are expected to 
be predicted with higher accuracy compared with mutations causing significant 
conformational changes. Another reason could be that the protocol does not take into 
account some non-specified experimental conditions, as non-reported specific ion binding, 
proton release/uptake and many others.  
 122 
 
Figure 3.8. Case study of consistent and inconsistent predictions. The backbone of DNA is 
marked as orange while protein is shown as brown. Mutation site is labeled as red along 
with the side chain of the wild-type residue. (A) The estrogen receptor DNA-binding 
domain bound to DNA (PDB: 1HCQ). (B) DNA complex of the Myb DNA-binding 
domain (PDB: 1MSE). (C) TN916 integrase n-terminal domain/DNA complex (PDB: 
1TN9). (D) F Factor TraI Relaxase Domain bound to F oriT Single-stranded DNA (PDB: 
2A0I).  
 
4. Implementation  
4.1. SAMPDI Webserver architecture  
The design of SAMPDI webserver consists of three components: the user interface, the 
local server and the job backend (The flowchart is shown in Figure 3.9A). The user 
interface is implemented using the HTML (http://compbio.clemson.edu/SAMPDI/), which 
provides users with a webpage interface to upload all required input files and fill in 
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parameters for the free energy calculations. In the webpage, users are firstly asked to upload 
an input PDB file from a local computer. In addition, the job parameters including chain 
ID, mutation position, original amino acid and mutated amino acid are provided by the 
users. Detailed descriptions of all the input parameters are provided as tooltips. Once the 
job is submitted, users are provided with an URL link to the result page, which will 
automatically refresh itself every 30s to return the latest results from the backend. The local 
server part is run on a light-duty computer server, which obtains the PDB files and 
parameters from the user interface. All the jobs in the backend are executed on the Clemson 
University Palmetto Cluster. The jobs are executed using multiple nodes with MPI parallel 
runs to attain the capability for large-scale analysis. Large arrays of independent jobs are 
permitted to be submitted to the server and are sequentially executed on the Palmetto 
cluster according to the order of submission. 
4.2. Webserver performance 
To verify the capability of the SAMPDI server for large-scale analysis, we tested the 
execution time for different sizes of the proteins ranging from tens of residues up to more 
than 1000. The execution time linearly increases with the size of proteins (Figure 3.9B). 
For proteins with less than 200 residues, the results are returned to users within ten minutes. 
Execution time for middle size proteins is about 20 to 30 minutes and reaches maximum 
of an hour for large proteins with about and more than 1300 residues.   
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Figure 3.9. (A) Work flowchart of SAMPDI webserver. (B) Performance of SAMPDI 
webserver showing the execution time for different size proteins. 
5. Discussion 
    Development of computational approaches for large-scale predictions of effect of 
mutations on macromolecular binding is not a trivial problem [30, 151]. There are multiple 
available tools and servers for predicting protein-protein binding affinity changes upon 
single mutations [30, 148, 149, 151, 210, 299]. However, there is still lack of resources for 
predicting affinity changes of protein-DNA complexes. Currently, the only available 
method capable of quantitatively predicting binding affinity changes upon single mutation 
of protein-DNA binding, is the mCSM method [151] and its recent improved version 
mCSM-NA [285]. The mCSM was benchmarked against the ProNIT database [32] and 
was reported to result in a correlation coefficient of 0.673. However, the benchmarking 
was done on the entire ProNIT database without taking into consideration that in ProNIT 
database (a) some proteins interact with DNA as dimers and mutations could indirectly 
affect the binding by altering the quaternary structure of the corresponding protein dimer 
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instead of altering the binding; (b) in some cases, the binding affinity energy change upon 
mutations was experimentally measured using DNA which does not match the sequence of 
DNA in ProNIT database. This may indicate that mCSM is not very sensitive to the DNA 
sequence and may be over fitted, and thus alternative resources are needed. Its recent 
improved version, mCSM-NA method, enhanced the original method by including a 
pharmacophore modelling and information of nucleic acid properties into graph-based 
signatures and benchmarked against the new release of ProNIT database , achieving 
improved coefficient of 0.70 [285]. 
    In this work, we developed a new approach named SAMPDI, and benchmarked it against 
purged experimental data from the latest verison of ProNIT database and data from recent 
references. Comparing with existing mCSM and mCSM-NA approach, SAMPDI shows 
improvements in the accuracy and result in an improved correlation coefficient 0.72. The 
SAMPDI method was implemented in a user-friendly webservers, which shows good 
performance and capability for large-scale analysis. 
The SAMPDI applies the so-called rigid body approach, which is based on the assumption 
that the structures do not undergo conformational changes upon binding. It should be 
mentioned that in the development of the SAMPDI method we also tested a scenario such 
that, complex protein-DNA structure and unbound monomeric structures were separately 
minimized to take into account plausible structural changes induced by the binding, the 
final results indeed were worse and thus the rigid body approach was applied. In the 
standard MM/PBSA approach, long time-consuming MD simulations are required to 
explore the conformational space and intensive sampling of the entire conformation space 
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is still very challenging. The SAMPDI approach is a trade-off between extensive 
conformational sampling and execution time since one of the main goals of the SAMPDI 
method is to allow for large-scale analysis. Future expansion of the method could include 
fast conformation sampling method for protein and DNA to improve the accuracy of 
prediction. 
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CHAPTER FOUR 
 
RESCUING THE R133C RETT SYNDROME CAUSING MUTATION BY SMALL 
MOLECULE BINDING 
 
1. Introduction 
    Rett Syndrome (RTT) is another severe neurodevelopmental disease manifested by 
loss of hand skills, impaired mobility and speech, and development of stereotypical hand 
movement [300, 301]. RTT exclusively develops in females, affecting one in 10,000 to 
15,000 females with 50,000 RTT patients worldwide and no treatment is available now 
[302]. It was clinically demonstrated that vast majority of RTT cases are caused by 
mutations in MeCP2 gene [301, 303]. Particularly, the mutations in MeCP2 methyl-CpG-
binding (MBD) domain, which specifically binds to a methyl-CpG dinucleotide pair in 
DNA, were shown by us to affect MBD stability and interactions with DNA [46, 304] 
(Figure 4.1).  Many of the disease-associated mutations were shown to defect the MBD-
DNA binding [46] thus modulation of the protein-nucleic interaction could be a promising 
approach to seek treatment for RTT. 
      The interactions in biomacromolecule can be modulated via binding of small 
molecules [164, 305]. Such approaches can be either inhibition [306, 307] or stabilization 
of the interaction [308, 309]. In this chapter, we focused on rescuing one of the most 
frequently occurring mutation, R133C, demonstrated both computationally and 
experimentally that the mutation affects only MBD-DNA interactions[46, 304]. Thus, we 
are to seek a stabilizer which binding at the periphery of the MBD-DNA interface restores 
wild-type binding.  Structural based virtual screening was applied to screen a large database 
of compounds to identify potential drug-like compounds.  The crystal structure of MeCP2 
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MBD domain in complex with methylated DNA was used for the structurally-based 
screening [310]. However, proteins are well known to have highly flexibility and to adopt 
different conformational states. Such conformational changes should also be taken account 
into our screening. Thus, molecular dynamics simulations were performed to study the 
dynamics of the structures and generate the best representative structure for the docking. 
Three docking programs: Autodock4 [311], Autodock Vina [312] and Dock6 [313] were 
utilized to dock library of compounds to the structure. We analyzed and compared the 
docking results and eventually selected the common compound ranked in the top list of the 
different programs. Lastly, these selected potential compounds are to be subjected to 
experimental test in the future. 
 
 
 
Figure 4.1. Structure of MeCP2 MBD domain bound to DNA. RTT mutations are shown 
and marked.  
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2. Method and materials 
2.1 Molecular Dynamics simulation 
The crystal structure of MeCP2 MBD domain bound to methylated DNA (PDB:3C2i) [310] 
was used for the sampling of the protein conformations. MD simulations were performed 
with NAMD 2.11 [95] with Charmm36 force field [290]. The parameter files were prepared 
with VMD psfgen plugin [138]. Proteins were solvated with 0.15M NaCl in cubic water 
box with at least 10 Å from the protein to the edge of box. Langevin dynamics with periodic 
boundary conditions were applied in the simulation. VDW and electrostatic interactions 
were truncated at 12 Å with a switching function from 10 Å. Particle Mesh Ewald (PME) 
was applied for long-range electrostatic interaction calculations. First, the system 
underwent a 5000-step minimization with a fixed backbone, and then a subsequent 5000-
step minimization without constraint. Then, all atoms in the protein were fixed for 100 ps 
equilibration of the water. Harmonic constraint of 1 kcal∙mol-1∙Å-2 was applied to the 
protein alpha carbon atoms (CA), and the system was then gradually heated from 0K to 
310K with 1000-step/K in the NVT simulation. The system was maintained at 310K for 
1ns equilibration with CA constraints and another 2ns equilibration without constraints in 
NVT system. Finally, the system was switched to an NPT simulation and all constraints 
were removed for the 10 ns production run. 
 
2.2 Preparation of the compound library for virtual screening 
The diversity and size of compound library was critical for the virtual screening. To provide 
a high-quality library for virtual and vitro screening, we constructed a combined diverse 
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library using three large commercial libraries: Chembridge library (1159428 compounds), 
Chemdiv library (1638618 compounds) and LifeChemicals (544924 compunds). The 
merged compounds library was firstly subjected to the filtering to remove the molecules 
with undesired physico-chemical properties for a potential drug. We utilized FAF-Drgus4  
server [314] for the compounds filtering with the Drug like soft filter,  derived from 
published drug’s desired physico-chemical properties [315-319]. The details for the fileting 
ranges are: 100 < molecular weight < 600, -3 < LogP < 6, HBA (hydrogen bonds acceptors) 
<= 20, HBD (hydrogen bonds donors) <= 7, tPSA (topological Polar Surface Area) <= 180, 
Rotatable bonds < 11, Rings <=6.  Eventually, 1.34 million compounds remain for further 
analysis after the physico-chemical properties filtering. 
    To further enhance the compounds diversity in the merged library, the remaining 
compounds were further subjected to the clustering using Accelrys Pipeline Pilot [320] 
with the FCFP-4 fingerprint using similarity cut-off 0.7 and average cluster member size 
5. The clustering eventually leads to 0.31 million compounds with highly diversity. Lastly, 
we generated the 3D structures for the compounds using Corina [320] and further 
protonated at pH=7 using the ChemAxon.  
2.3 Structure-based Virtual Screening 
    Three popular docking programs were used for the virtual screening of the constructed 
diverse compound library.  
Autodock Vina and Audock4: 
Both Autodock Vina and Autodock4 reads PDBQT files as input for docking. We used 
Autodock tools to set up our systems and prepared the input files for both protein and 
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compounds. The sample parameter files used for Autodock Vina and Audock4 are shown 
in appendix Figure B-22 and Figure B-23. 
 
Dock6: 
Dock6 reads mol2 files of receptor and ligand for docking. We prepares the receptor mol2  
docking files using UCSF Chimera [82] and the input mol2 files for compounds are 
generated using ChemAxon. The receptor active sites for docking calculation are 
represented by a subset of spheres within the previous selected druggable pockets.  We 
used grid scores and gbsa hawkins score for primary and secondary ranking of the docking 
results. The sample parameters file used for docking is shown in Appendix Figure B-24. 
3. Results 
3.1 Identification of druggable pocket 
    Since our goal is to identify potential stabilizers to enhance the protein-DNA binding 
affinity, the small molecules are expected to bind at the periphery of the interface. Thus, 
we considered two cavities of the interface for the most potential druggable pockets for 
screening (Figure 4.2). One is located in the major groove of the DNA and in adjacent to 
the R133C mutation site (Pocket 1). Since the R133C causes loss of two salt bridges with 
the DNA bases, most promising drug-candidates are expected to form strong interactions 
to both protein and DNA, like a “clip” to enhance the binding affinity. Another potential 
druggable pockets are in the DNA minor groove but relatively far away from the mutation 
site (Pocket 2).  Such pocket is a small cavity expected to have small  conformational 
changes induced by the mutation, which was utilized as alternative pocket for our 
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screening.  To fully consider the conformational flexibility in the mutant structure, we 
perform clustering of the MD trajectory to identify the representative structure. The pockets 
were clustered via considering both the backbone and the side chain structural differences 
and the centroid structure from the most protonated cluster was retrieved as the 
representative structure for further docking analysis.  
 
Figure 4.2. Two potential druggable pocket subjected to virtual screening. 
3.2 Test of most suitable docking program for screening 
    The performance of docking programs vary with the targets and it is critical to select 
the most proper docking program for the screening[321]. Thus, we firstly tested different 
docking programs’ behavior over our systems and choose the best one for the screening 
over the large compound library.  Three docking programs:  Autodock4 [311], Autodock 
Vina [312] and Dock6 [313] were docked into 6000 compounds from the core library of 
the ChemBridge compound library. Then, the poses are ranked separately with the binding 
energy from each docking program. To evaluate the results, we took the top ranked 200 
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compounds from each program and manually compare the poses by considering characters 
such as charge complement, shape fitness, H-bonding, structural crashes and ligand 
conformations.  Eventually, the overall performance of Autodock4 is best among three 
docking programs while Autodock Vina ranked least top poses. Thus, we decide to use 
Autodock4 for the screening of the previous constructed large compound library. 
3.3 Virtual Screening 
    Autodock4 was applied for the docking of the constructed large diverse compound 
library into the two druggable pockets. For each compound, we retrieve the pose with 
lowest energy from all clusters. The median binding energy in pocket 1 is -8.08 kcal/mol 
and relative higher than pocket 2 (-7.44 kcal/mol), as shown in Figure 4.3. Since the 
R133C directly cause the loss of the H-bonds in the binding interface, compounds which 
forming H-bonds with both protein and DNA in the interface could have a higher chance 
to act as a successful stabilizer. Thus, for the first round of selection, we used two 
constrains: 1) Binding energy <= 8 kcal/mol;  2) Compounds forms at least one H-bond 
with both protein and DNA.  The selection leads to 163528 compounds for pocket 1 and 
113654 compounds for pocket 2. 
To  further reduce the number of candidates for final manual inspection and selection of 
the poses, we conduct rescoring and ranking using another docking program Dock6 [313]. 
Since free-energy based approach has been successfully applied in the rescoring of 
compounds in our previous study [164, 309],  we applied Hawkins GB/SA score, an 
Molecular Mechanics Generalized Born Surface Area (MM/GBSA) approach 
implemented in Dock6 [313], for the rescoring and reranking. The compounds with 
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GB/SA score less than -30 kcal/mol are selected, which results in 5543 compounds and 
1406 compounds for further analysis.  
 
Figure 4.3. The overall binding energy distribution from the virtual screening. 
3.4 Manual inspection and selection for the poses 
    Manual visualization and inspection of poses is very important at the final stage of the 
virtual screening to identify the best compounds. Thus, we used a visualization tool, 
PYMOL, to manually select the best poses. The major physico-chemical characteristics 
which would be critical to the potential stabilizer were fully considered based on our 
knowledge as shown in Figure 4.4. Besides manual selection, we also considered to 
eliminate the composes which would act as inhibitor via blocking the protein binding 
interface. Thus, we docked the selected compounds using a large searching box to include 
the entire protein and then to remove the compounds which most prefer to bind at the 
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interface and potentially block the binding (Figure 4.5). Eventually, 80 compounds are 
selected (shown in Appendix Table C-11) and to be subjected to experimental validation 
for their effects on the binding affinity.  
 
Figure 4.4. The major physico-chemical characteristics considered in manual pose 
selection. 
 
Figure 4.5. The overall binding energy distribution from the virtual screening. 
 136 
References： 
1. Alexov, E., Advances in Human Biology: Combining Genetics and Molecular 
Biophysics to Pave the Way for Personalized Diagnostics and Medicine. Advances 
in Biology, 2014. 2014: p. 1-16. 
2. Cargill, M., et al., Characterization of single-nucleotide polymorphisms in coding 
regions of human genes. Nat Genet, 1999. 22(3): p. 231-8. 
3. Goldstein, D.B., Common genetic variation and human traits. N Engl J Med, 2009. 
360(17): p. 1696-8. 
4. Niroula, A. and M. Vihinen, Classification of Amino Acid Substitutions in 
Mismatch Repair Proteins Using PON-MMR2. Hum Mutat, 2015. 
5. Suh, Y. and J. Vijg, SNP discovery in associating genetic variation with human 
disease phenotypes. Mutat Res, 2005. 573(1-2): p. 41-53. 
6. Altshuler, D., M.J. Daly, and E.S. Lander, Genetic mapping in human disease. 
Science, 2008. 322(5903): p. 881-8. 
7. Vihinen, M., Types and effects of protein variations. Hum Genet, 2015. 134(4): p. 
405-21. 
8. Schaafsma, G.C. and M. Vihinen, VariSNP, a benchmark database for variations 
from dbSNP. Hum Mutat, 2015. 36(2): p. 161-6. 
9. Sasidharan Nair, P. and M. Vihinen, VariBench: a benchmark database for 
variations. Hum Mutat, 2013. 34(1): p. 42-9. 
10. Song, C., et al., Large-scale quantification of single amino-acid variations by a 
variation-associated database search strategy. J Proteome Res, 2014. 13(1): p. 
241-8. 
11. Kucukkal, T.G. and E. Alexov, Structural, Dynamical, and Energetical 
Consequences of Rett Syndrome Mutation R133C in MeCP2. Comput Math 
Methods Med, 2015. 2015: p. 746157. 
12. Alexov, E. and M. Sternberg, Understanding molecular effects of naturally 
occurring genetic differences. J Mol Biol, 2013. 425(21): p. 3911-3. 
13. Zhang, Z., et al., A Y328C missense mutation in spermine synthase causes a mild 
form of Snyder-Robinson syndrome. Hum Mol Genet, 2013. 22(18): p. 3789-97. 
14. Casadio, R., et al., Correlating disease-related mutations to their effect on protein 
stability: a large-scale analysis of the human proteome. Hum Mutat, 2011. 32(10): 
p. 1161-70. 
15. Ramensky, V., Human non-synonymous SNPs: server and survey. Nucleic Acids 
Research, 2002. 30(17): p. 3894-3900. 
16. Niroula, A., S. Urolagin, and M. Vihinen, PON-P2: prediction method for fast and 
reliable identification of harmful variants. PLoS One, 2015. 10(2): p. e0117380. 
17. Vihinen, M., Proper reporting of predictor performance. Nat Methods, 2014. 
11(8): p. 781. 
18. Ng, P.C. and S. Henikoff, Predicting the effects of amino acid substitutions on 
protein function. Annu Rev Genomics Hum Genet, 2006. 7: p. 61-80. 
 137 
19. Kucukkal, T.G., et al., Computational and experimental approaches to reveal the 
effects of single nucleotide polymorphisms with respect to disease diagnostics. Int 
J Mol Sci, 2014. 15(6): p. 9670-717. 
20. Zhang, Z., et al., Predicting folding free energy changes upon single point 
mutations. Bioinformatics, 2012. 28(5): p. 664-71. 
21. Capriotti, E., R. Calabrese, and R. Casadio, Predicting the insurgence of human 
genetic diseases associated to single point protein mutations with support vector 
machines and evolutionary information. Bioinformatics, 2006. 22(22): p. 2729-34. 
22. Yang, Y., et al., Structure-based prediction of the effects of a missense variant on 
protein stability. Amino Acids, 2013. 44(3): p. 847-55. 
23. Vihinen, M., How to evaluate performance of prediction methods? Measures and 
their interpretation in variation effect analysis. BMC Genomics, 2012. 13 Suppl 
4: p. S2. 
24. Zhang, Z., et al., Computational analysis of missense mutations causing Snyder-
Robinson syndrome. Hum Mutat, 2010. 31(9): p. 1043-9. 
25. Ferrer-Costa, C., M. Orozco, and X. de la Cruz, Characterization of disease-
associated single amino acid polymorphisms in terms of sequence and structure 
properties. J Mol Biol, 2002. 315(4): p. 771-86. 
26. Petukh, M., T.G. Kucukkal, and E. Alexov, On human disease-causing amino acid 
variants: statistical study of sequence and structural patterns. Hum Mutat, 2015. 
36(5): p. 524-34. 
27. Guerois, R., J.E. Nielsen, and L. Serrano, Predicting Changes in the Stability of 
Proteins and Protein Complexes: A Study of More Than 1000 Mutations. Journal 
of Molecular Biology, 2002. 320(2): p. 369-387. 
28. Tokuriki, N. and D.S. Tawfik, Stability effects of mutations and protein 
evolvability. Curr Opin Struct Biol, 2009. 19(5): p. 596-604. 
29. Schreiber, G. and A.R. Fersht, Energetics of protein-protein interactions: Analysis 
ofthe Barnase-Barstar interface by single mutations and double mutant cycles. 
Journal of Molecular Biology, 1995. 248(2): p. 478-486. 
30. Petukh, M., M. Li, and E. Alexov, Predicting Binding Free Energy Change Caused 
by Point Mutations with Knowledge-Modified MM/PBSA Method. PLoS Comput 
Biol, 2015. 11(7): p. e1004276. 
31. Moal, I.H. and J. Fernandez-Recio, SKEMPI: a Structural Kinetic and Energetic 
database of Mutant Protein Interactions and its use in empirical models. 
Bioinformatics, 2012. 28(20): p. 2600-7. 
32. Kumar, M.D., et al., ProTherm and ProNIT: thermodynamic databases for proteins 
and protein-nucleic acid interactions. Nucleic Acids Res, 2006. 34(Database 
issue): p. D204-6. 
33. Peng, Y., et al., Predicting protein-DNA binding free energy change upon missense 
mutations using modified MM/PBSA approach: SAMPDI webserver. 
Bioinformatics, 2018. 34(5): p. 779-786. 
34. Getov, I., M. Petukh, and E. Alexov, SAAFEC: Predicting the Effect of Single Point 
Mutations on Protein Folding Free Energy Using a Knowledge-Modified 
MM/PBSA Approach. Int J Mol Sci, 2016. 17(4): p. 512. 
 138 
35. Lounnas, V., et al., Current progress in Structure-Based Rational Drug Design 
marks a new mindset in drug discovery. Comput Struct Biotechnol J, 2013. 5: p. 
e201302011. 
36. Hughes, J.P., et al., Principles of early drug discovery. Br J Pharmacol, 2011. 
162(6): p. 1239-49. 
37. Michel, J., Current and emerging opportunities for molecular simulations in 
structure-based drug design. Phys Chem Chem Phys, 2014. 16(10): p. 4465-77. 
38. Hung, C.L. and C.C. Chen, Computational approaches for drug discovery. Drug 
Dev Res, 2014. 75(6): p. 412-8. 
39. Sawicki, M.P., et al., Human Genome Project. The American Journal of Surgery, 
1993. 165(2): p. 258-264. 
40. Genomes Project, C., et al., A map of human genome variation from population-
scale sequencing. Nature, 2010. 467(7319): p. 1061-73. 
41. Peng, Y., et al., Revealing the Effects of Missense Mutations Causing Snyder-
Robinson Syndrome on the Stability and Dimerization of Spermine Synthase. Int J 
Mol Sci, 2016. 17(1). 
42. Li, L., et al., Forces and Disease: Electrostatic force differences caused by 
mutations in kinesin motor domains can distinguish between disease-causing and 
non-disease-causing mutations. Sci Rep, 2017. 7(1): p. 8237. 
43. Spellicy, C.J., et al., Key apoptotic genes APAF1 and CASP9 implicated in 
recurrent folate-resistant neural tube defects. Eur J Hum Genet, 2018. 26(3): p. 
420-427. 
44. Vaidyanathan, K., et al., Identification and characterization of a missense mutation 
in the O-linked beta-N-acetylglucosamine (O-GlcNAc) transferase gene that 
segregates with X-linked intellectual disability. J Biol Chem, 2017. 292(21): p. 
8948-8963. 
45. Chen, W.-T., et al., Amyloid-beta (Aβ) D7H mutation increases oligomeric Aβ42 
and alters properties of Aβ-zinc/copper assemblies. PloS One, 2012. 7(4): p. 
e35807. 
46. Yang, Y., et al., Binding Analysis of Methyl-CpG Binding Domain of MeCP2 and 
Rett Syndrome Mutations. ACS Chem Biol, 2016. 11(10): p. 2706-2715. 
47. Peng, Y., et al., Computational Investigation of the Missense Mutations in DHCR7 
Gene Associated with Smith-Lemli-Opitz Syndrome. International Journal of 
Molecular Sciences, 2018. 19(1). 
48. Peng, Y., et al., Mutations in the KDM5C ARID Domain and Their Plausible 
Association with Syndromic Claes-Jensen-Type Disease. Int J Mol Sci, 2015. 
16(11): p. 27270-87. 
49. Ferreira, L.G., et al., Molecular docking and structure-based drug design 
strategies. Molecules, 2015. 20(7): p. 13384-421. 
50. Bleicher, K.H., et al., Hit and lead generation: beyond high-throughput screening. 
Nat Rev Drug Discov, 2003. 2(5): p. 369-78. 
51. Acharya, C., et al., Recent Advances in Ligand-Based Drug Design: Relevance and 
Utility of the Conformationally Sampled Pharmacophore Approach. Current 
Computer Aided-Drug Design, 2011. 7(1): p. 10-22. 
 139 
52. Wilson, G.L. and M.A. Lill, Integrating structure-based and ligand-based 
approaches for computational drug design. Future Med Chem, 2011. 3(6): p. 735-
50. 
53. Drwal, M.N. and R. Griffith, Combination of ligand- and structure-based methods 
in virtual screening. Drug Discov Today Technol, 2013. 10(3): p. e395-401. 
54. Strahl, B.D. and C.D. Allis, The language of covalent histone modifications. 
Nature, 2000. 403(6765): p. 41-5. 
55. Jenuwein, T. and C.D. Allis, Translating the histone code. Science, 2001. 
293(5532): p. 1074-80. 
56. Martin, C. and Y. Zhang, The diverse functions of histone lysine methylation. Nat 
Rev Mol Cell Biol, 2005. 6(11): p. 838-49. 
57. Blair, L.P., et al., Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes 
in Cancer. Cancers (Basel), 2011. 3(1): p. 1383-404. 
58. Benevolenskaya, E.V., Histone H3K4 demethylases are essential in development 
and differentiation. Biochem Cell Biol, 2007. 85(4): p. 435-43. 
59. Iwase, S., et al., The X-linked mental retardation gene SMCX/JARID1C defines a 
family of histone H3 lysine 4 demethylases. Cell, 2007. 128(6): p. 1077-88. 
60. Outchkourov, N.S., et al., Balancing of histone H3K4 methylation states by the 
Kdm5c/SMCX histone demethylase modulates promoter and enhancer function. 
Cell Rep, 2013. 3(4): p. 1071-9. 
61. Grafodatskaya, D., et al., Multilocus loss of DNA methylation in individuals with 
mutations in the histone H3 lysine 4 demethylase KDM5C. BMC Med Genomics, 
2013. 6: p. 1. 
62. Patsialou, A., D. Wilsker, and E. Moran, DNA-binding properties of ARID family 
proteins. Nucleic Acids Res, 2005. 33(1): p. 66-80. 
63. Wilsker, D., et al., Nomenclature of the ARID family of DNA-binding proteins. 
Genomics, 2005. 86(2): p. 242-51. 
64. Huang, F., et al., The JmjN domain of Jhd2 is important for its protein stability, and 
the plant homeodomain (PHD) finger mediates its chromatin association 
independent of H3K4 methylation. J Biol Chem, 2010. 285(32): p. 24548-61. 
65. Mellor, J., It takes a PHD to read the histone code. Cell, 2006. 126(1): p. 22-4. 
66. Tzschach, A., et al., Novel JARID1C/SMCX mutations in patients with X-linked 
mental retardation. Hum Mutat, 2006. 27(4): p. 389. 
67. Goncalves, T.F., et al., KDM5C mutational screening among males with 
intellectual disability suggestive of X-Linked inheritance and review of the 
literature. Eur J Med Genet, 2014. 57(4): p. 138-44. 
68. By Robert L. Schalock, S.A.B.-D., Valerie J. Bradley,  Wil H.E. Buntinx, David L. 
Coulter,  Ellis M. (Pat) Craig, ; Sharon C. Gomez,  Yves Lachapelle, Ruth 
Luckasson, Alya Reeve,  Karrie A. Shogren,  Martha E. Snell, Scott Spreat, Marc 
J. Tassé, James R. Thompson,  Miguel A. Verdugo-Alonso,  Michael L. Wehmeyer, 
and Mark H. Yeager Intellectual Disability: Definition, Classification, and Systems 
of Supports 2010. 
69. Kaufman, L., M. Ayub, and J.B. Vincent, The genetic basis of non-syndromic 
intellectual disability: a review. J Neurodev Disord, 2010. 2(4): p. 182-209. 
 140 
70. Jensen, L.R., et al., Mutations in the JARID1C gene, which is involved in 
transcriptional regulation and chromatin remodeling, cause X-linked mental 
retardation. Am J Hum Genet, 2005. 76(2): p. 227-36. 
71. Tahiliani, M., et al., The histone H3K4 demethylase SMCX links REST target genes 
to X-linked mental retardation. Nature, 2007. 447(7144): p. 601-5. 
72. Abidi, F.E., et al., Mutations in JARID1C are associated with X-linked mental 
retardation, short stature and hyperreflexia. J Med Genet, 2008. 45(12): p. 787-93. 
73. Sherry, S.T., et al., dbSNP: the NCBI database of genetic variation. Nucleic Acids 
Res, 2001. 29(1): p. 308-11. 
74. Bullock, A.N., et al., Thermodynamic stability of wild-type and mutant p53 core 
domain. Proceedings of the National Academy of Sciences of the United States of 
America, 1997. 94(26): p. 14338-14342. 
75. Tan, K.P., et al., TSpred: a web server for the rational design of temperature-
sensitive mutants. Nucleic Acids Research, 2014. 42(Web Server issue): p. W277-
W284. 
76. Schaefer, C., et al., Disease-related mutations predicted to impact protein function. 
BMC Genomics, 2012. 13 Suppl 4: p. S11. 
77. Petukh, M., T.G. Kucukkal, and E. Alexov, On human disease-causing amino acid 
variants: statistical study of sequence and structural patterns. Hum Mutat, 2015. 
78. Kucukkal, T.G., et al., Structural and physico-chemical effects of disease and non-
disease nsSNPs on proteins. Curr Opin Struct Biol, 2015. 32: p. 18-24. 
79. Schuster-Bockler, B. and A. Bateman, Protein interactions in human genetic 
diseases. Genome Biol, 2008. 9(1): p. R9. 
80. Torkamani, A. and N.J. Schork, Distribution analysis of nonsynonymous 
polymorphisms within the human kinase gene family. Genomics, 2007. 90(1): p. 
49-58. 
81. Humphrey, W., A. Dalke, and K. Schulten, VMD: visual molecular dynamics. J 
Mol Graph, 1996. 14(1): p. 33-8, 27-8. 
82. Pettersen, E.F., et al., UCSF Chimera--a visualization system for exploratory 
research and analysis. J Comput Chem, 2004. 25(13): p. 1605-12. 
83. Li, C., et al., Continuous development of schemes for parallel computing of the 
electrostatics in biological systems: implementation in DelPhi. J Comput Chem, 
2013. 34(22): p. 1949-60. 
84. Li, L., et al., DelPhi: a comprehensive suite for DelPhi software and associated 
resources. BMC Biophys, 2012. 5: p. 9. 
85. Subhra Sarkar, S.W., Jie Zhang, Maxim Zhenirovskyy, Walter Rocchia, and Emil 
Alexov, DelPhi Web Server: A comprehensive online suite for electrostatic 
calculations of biological macromolecules and their complexes. Commun Comput 
Phys, 2013 January: p. 13(1): 269–284. 
86. Tu, S., et al., The ARID domain of the H3K4 demethylase RBP2 binds to a DNA 
CCGCCC motif. Nat Struct Mol Biol, 2008. 15(4): p. 419-21. 
87. Shoemaker, B.A., et al., Inferred Biomolecular Interaction Server--a web server to 
analyze and predict protein interacting partners and binding sites. Nucleic Acids 
Res, 2010. 38(Database issue): p. D518-24. 
 141 
88. van Stokkum, I.H., et al., Estimation of protein secondary structure and error 
analysis from circular dichroism spectra. Anal Biochem, 1990. 191(1): p. 110-8. 
89. Whitmore, L. and B.A. Wallace, DICHROWEB, an online server for protein 
secondary structure analyses from circular dichroism spectroscopic data. Nucleic 
Acids Res, 2004. 32(Web Server issue): p. W668-73. 
90. Koehler, C., et al., Backbone and sidechain 1H, 13C and 15N resonance 
assignments of the Bright/ARID domain from the human JARID1C (SMCX) 
protein. Biomol NMR Assign, 2008. 2(1): p. 9-11. 
91. Berman, H.M., The Protein Data Bank. Nucleic Acids Research, 2000. 28(1): p. 
235-242. 
92. Iwahara, J., et al., The structure of the Dead ringer-DNA complex reveals how AT-
rich interaction domains (ARIDs) recognize DNA. EMBO J, 2002. 21(5): p. 1197-
209. 
93. Lu, N. and D.A. Kofke, Accuracy of free-energy perturbation calculations in 
molecular simulation. I. Modeling. The Journal of Chemical Physics, 2001. 
114(17): p. 7303. 
94. Jorgensen, W.L. and L.L. Thomas, Perspective on Free-Energy Perturbation 
Calculations for Chemical Equilibria. J Chem Theory Comput, 2008. 4(6): p. 869-
876. 
95. Phillips, J.C., et al., Scalable molecular dynamics with NAMD. J Comput Chem, 
2005. 26(16): p. 1781-802. 
96. Pearlman, D.A., A Comparison of Alternative Approaches to Free Energy 
Calculations. The Journal of Physical Chemistry, 1994. 98(5): p. 1487-1493. 
97. MacKerell, A.D., et al., All-atom empirical potential for molecular modeling and 
dynamics studies of proteins. J Phys Chem B, 1998. 102(18): p. 3586-616. 
98. Liu, P., et al., A Toolkit for the Analysis of Free-Energy Perturbation Calculations. 
Journal of Chemical Theory and Computation, 2012. 8(8): p. 2606-2616. 
99. Lockwood, S., B. Krishnamoorthy, and P. Ye, Neighborhood Properties Are 
Important Determinants of Temperature Sensitive Mutations. Plos One, 2011. 
6(12). 
100. Ofiteru, A., et al., Structural and functional consequences of single amino acid 
substitutions in the pyrimidine base binding pocket of Escherichia coli CMP kinase. 
FEBS J, 2007. 274(13): p. 3363-73. 
101. Zhang, Z., et al., In silico and in vitro investigations of the mutability of disease-
causing missense mutation sites in spermine synthase. PLoS One, 2011. 6(5): p. 
e20373. 
102. Merz, K.M. and P.A. Kollman, Free energy perturbation simulations of the 
inhibition of thermolysin: prediction of the free energy of binding of a new 
inhibitor. Journal of the American Chemical Society, 1989. 111(15): p. 5649-5658. 
103. Bjørn O. Brandsdal, F.O.s., Martin Almlöf, Isabella Feierberg, Victor B. Luzhkov 
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Appendix B 
Supplementary materials: Figures 
 
 
 
 
Figure B-1. The side chain conformations of two disease-associated mutations 
mapped onto the KDM5C ARID domain: (a) part of the ARID domain zoomed at 
the WT position of A77; (b) part of thhe ARID domain zoomed at the MT position 
of T77; (c) part of the ARID domain zoomed at the WT position of D87; and (d) 
part of the ARID domain zoomed at the MT position of G87. 
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Figure B-2. The side chain conformation of non-classified mutations mapped onto 
the KDM5C ARID domain: (a) part of the ARID domain zoomed at the WT 
position of Arg108; (b) part of the ARID domain zoomed at the MT position of 
Try108; (c) part of the ARID domain zoomed at the WT position of Asn142; (d) 
part of the ARID domain zoomed at the MT position of Ser142; (e) part of the 
ARID domain zoomed at the WT position of Arg179; and (f) part of the ARID 
domain zoomed at the MT position of His179. 
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Figure B-3. Sequence alignment of human ARID-containing proteins. The 
mutation sites considered in this study are marked with grey bash line. The six 
most highly conserved residues are marked with a grey solid line. The helices 
from H0 to H7, and loops, are labeled at the top of the figure. The sequences are 
aligned with T-Coffee [207]. Similar results were obtained using the Clustal 
Omega webserver.  
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Figure B-4. A representative plot of ∆G for ARID WT, A77T, and D87G 
unfolding as a function of urea concentration.  
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Figure B-5. (a) Structural alignment between the KDM5C ARID domain and dead 
ringer ARID-DNA complex; and (b) part of structural alignment zoomed at DNA 
binding interface. Dead ringer ARID-DNA complex is marked with green and the 
KDM5C ARID domain is marked with blue. 
 
 
Figure B-6. (a) Thermodynamic cycle for folding free energy changes calculations; 
and (b) thermodynamic cycle for binding free energy changes calculations. 
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Figure B-7: (A) Four possible binding modes of ARID domain onto 5FWJ structure after 
applying constraint of linker length. (B) RMSD of ARID domain and JmjC domain. (C) 
RMSD of the interfacial residues. (D) Finalized model of ARID bound to KDM5C catalytic 
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core including JmjN, ARID, JmjC, ZF domains and the rest of inter domain regions marked 
with yellow, green, purple, orange and blue, respectively.  
 
Figure B-8: (A) Three possible binding modes after applying the constraint of linker length. 
(B) RMSDs of the complex of PHD1and JmjC domains. (C) Number of residues in PHD1 
domain, which have any atom within 6Å of H3K9me3 in the last 2.5ns simulation time. 
(D) The N-O distance of identified salt bridges (Glu375-H3R8 and Glu381-H3R2) between 
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PHD1 and substrate peptide. (E) Averaged RMSF of PHD1 domain residues calculated 
from model1 MD simulations. (F) Finalized model of PHD1 domain bound to KDM5C 
catalytic core including JmjN, PHD1, JmjC, ZF domains, inter domain region and histone 
peptide marked with yellow, green, purple, orange, blue and red, respectively 
 
Figure B-9: (A) Predicted interfacial region of ARID domain involved in domain 
interactions in the KDM5C quaternary structure. The interfacial region of ARID domain is 
marked with green while the rest of ARID domain is marked with pink. JmjN domain and 
DNA are marked with yellow and gray. Other regions, including JmjC and ZF domains, 
are marked with blue. The reside Asp87 side chain is shown with red. (B) The electrostatic 
potential map of ARID domain and KDM5C catalytic core. The electrostatic potential map 
of KDM5C catalytic core (including JmjN, JmjC and ZF domains) is shown on the left (the 
structure of ARID domain is marked with green). The electrostatic potential map of ARID 
domain is shown on the right (the structure of JmjN and JmjC domains are marked with 
purple). 
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Figure B-10: (A) The interfacial residues of PHD1 domain involved in the interaction in 
the KDM5C quaternary structure. The interfacial residues of PHD1 domain are marked 
with green while the rest of the PHD1 domain are marked with orange. The substrate 
histone peptide is marked with red while the rest of the region including JmjC and ZF 
domain are marked with blue. (B) The RMSD results for the KDM5B PHD1 domain bound 
to substrate peptide complex. (C) The RMSF results for the KDM5B PHD1 domain. (D) 
The predicted interfacial residues in ARID domain. The ARID domain, JmjC domain, 
 166 
DNA and inter-domain region are marked with pink, purple, gray, and blue, respectively. 
The predicted interfacial residues in ARID domain are colored with yellow. (E) The 
predicted interfacial residues in PHD and JmjC domains. The PHD domain, JmjC domain, 
histone substrate and inter-domain regions are marked with green, purple, red, and blue, 
respectively. Predicted interfacial residues in PHD and JmjC domains are colored with 
yellow. 
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Figure B-11. The side chain conformation of five disease-causing mutations 
mapped onto SpmSyn: (a) Part of SpmSyn zoomed at WT position of Met35; (b) 
Part of SpmSyn zoomed at MT position of Arg35; (c) Part of SpmSyn zoomed at 
WT position of Gly56; (d) Part of SpmSyn zoomed at MT position of Ser56; (e) 
Part of SpmSyn zoomed at WT position of Phe58; (f) Part of SpmSyn zoomed at 
MT position of Leu58; (g) Part of SpmSyn zoomed at WT position of Gly67; (h) 
Part of SpmSyn zoomed at MT position of Glu67; (i) Part of SpmSyn zoomed at 
WT position of Pro112; (j) Part of SpmSyn zoomed at MT position of Leu112; 
The side chain of WT and MT position is shown in red. Two different chains of 
the dimer are shown in blue and green. 
 
Figure B-12：The pathogenic and non-pathogenic mutation occurring sites mapping on 
the average RMSF of the WT DHCR7 protein. Pathogenic and non-pathogenic mutation 
sites are marked with red and green lines. The RMSF of transmembrane region are shown 
as blue. 
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Figure B-13：The changes in residue cross-correlation for mutation E288K and G303R. 
 
 
Figure B-14：Sequence alignment between DHCR7 and template 4QUV. 
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Figure B-15: Property distance for all types of amino acid pairs. 
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Figure B-16: Frequency patterns of ionizable residues in both Pfam and SCOP datasets. 
 
Figure B-17: Frequency patterns of ionizable interfacial residues in both Pfam and SCOP 
datasets. 
 172 
 
Figure B-18: Distribution of pKa shifts for different types of ionizable groups and 
different types of complexes in Pfam dataset. 
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Figure B-19: Distribution of pKa shifts for different types of ionizable groups and 
different types of complexes in SCOP dataset.  
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Figure B-20: Distributions of pKa shifts across the different binding modes in the Pfam 
dataset. 
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Figure B-21: Distributions of pKa shifts across the different binding modes in the SCOP 
dataset. 
 
Figure B-22: Docking parameter file used for Autodock Vina. 
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Figure B-23: Docking parameter file used for Autodock4. 
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Figure B-24: Docking parameter file used for Dock6. 
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Appendix C 
Supplementary materials: Tables 
 
 
 
Model1 Model2 Model3 Model4 
Model 1 0 2.20 2.64 1.80 
Model 2 2.20 0 3.46 3.06 
Model 3 2.64 3.46 0 2.93 
Model 4 1.80 3.06 2.93 0 
average 2.21 2.91 3.01 2.60 
 
Table C-1:  The RMSD of various ARID binding modes (in Å). The last row shows the 
average RMSD calculated with respect with other three models. 
 
 
 Salt bridge involved in the domain interactions 
ARID Arg80-Glu465, Arg80-Glu467, Arg80-Gu468, Asp87-Lys459, Asp87-Arg460 
Lys91-Glu465, Lys91-Glu466, Glu94-Arg390, Glu94-Lys459, Arg159-Glu399, 
Arg159-Asp402, Arg159-Glu419, Arg159-Glu422 
PHD1 Asp334-Lys551, Glu334-Lys550, Glu335-Lys551, Glu335-Arg635, Asp336-
Arg637, Asp337-Lys550, Asp347-Arg637, Asp347-Lys711 
 
Table C-2: Lists of identified salt bridges involved in interfacial ARID and PHD1 domains 
interactions. 
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Mutation SMS/GAPDH Ratio % Ctrl 
M35R 0.04 1.5 
G56S 0.07 2.6 
F58L 0.18 6.6 
G67E 0.13 4.8 
P112L 0.55 20.3 
Ctrl 2.71 100 
Table C-3. Densitometric analysis of bands present in denatured gel. 
 
Disease-causing missense mutations 
Mutation rSASA_mem CV score SAFFEC mCSM SDM DUET FOLDX ΔΔG_ave Polyphen 
T93M 0.21 0.62 0.53 0.10 0.30 -0.03 -0.52 0.08 Probably 
damaging 
G147D 0.01 1.00 3.30 -1.53 -0.35 -1.39 7.40 1.49 Probably 
damaging 
T154R 0.01 0.97 -3.55 -0.59 -1.45 -0.60 1.62 -0.91 Probably 
damaging 
S169L 0.31 0.85 1.39 -0.25 0.69 -0.25 0.62 0.44 Probably 
damaging 
R242H 0.02 1.00 0.17 -2.38 -0.05 -2.59 -0.20 -1.01 Probably 
damaging 
R242C 0.02 1.00 0.40 -1.96 0.39 -2.05 -3.95 -1.43 Probably 
damaging 
G244R 0.01 1.00 0.96 -1.39 -0.10 -1.20 4.72 0.60 Probably 
damaging 
V281M 0.02 0.91 -0.19 -0.28 -0.08 -0.30 0.40 -0.09 Probably 
damaging 
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E288K 0.10 1.00 -15.77 -0.27 -1.17 -0.24 0.78 -3.33 Probably 
damaging 
T289I 0.43 0.29 -0.60 -0.09 1.26 0.18 -0.70 0.01 Possibly 
damaging 
G303R 0.04 1.00 -1.48 -1.15 -2.73 -1.22 21.73 3.03 Probably 
damaging 
V326L 0.00 0.94 0.24 -1.08 0.20 -1.00 1.01 -0.13 Benign 
R352W 0.06 0.94 0.00 -0.37 2.57 -0.55 0.12 0.35 Probably 
damaging 
R352Q 0.06 0.94 -0.91 -0.81 -0.63 -0.81 0.60 -0.51 Probably 
damaging 
R404C 0.04 0.97 -0.05 -1.97 0.11 -2.18 3.00 -0.22 Probably 
damaging 
G410S 0.01 0.91 -2.71 -1.81 -0.55 -1.69 11.05 0.86 Probably 
damaging 
Missense mutations with unknown effects 
Mutatio
n 
rSASA_mem CV score SAFFEC mCSM SDM DUET FOLDX Average SD 
A41V 0.05 0.44 0.03 -0.28 -0.29 0.01 -0.30 -0.17 Benign 
I44T 0.18 0.76 0.69 -1.29 -2.79 -1.19 1.40 -0.64 Benign 
A67T 0.00 0.18 2.48 -1.59 -0.79 -1.66 5.65 0.82 Possibly 
damaging 
I75F 0.53 0.24 -0.47 -0.64 0.12 -0.61 -0.56 -0.43 Benign 
R81W 0.51 0.21 -0.55 -0.49 1.18 -0.58 -0.64 -0.22 Probably 
damaging 
A97T 0.24 0.80 0.18 -1.28 -2.29 -1.19 1.64 -0.59 Possibly 
damaging 
V126I 0.12 0.76 0.60 -0.78 0.74 -0.72 0.04 -0.02 Probably 
damaging 
V134L 0.28 0.32 1.36 -0.63 1.13 -0.43 -1.24 0.04 Benign 
A162V 0.13 0.76 1.18 0.00 0.68 0.19 -1.50 0.11 Possibly 
damaging 
R228Q 0.18 0.97 1.27 -1.01 -0.84 -1.13 -0.23 -0.39 Probably 
damaging 
V330M 0.58 0.85 -2.47 -0.52 -0.51 -0.45 -0.57 -0.90 Probably 
damaging 
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V338M 0.25 0.41 -0.92 -0.38 0.80 -0.19 -0.70 -0.28 Benign 
F361L 0.01 0.91 -0.16 -2.72 -0.17 -2.80 -0.90 -1.35 Probably 
damaging 
T364M 0.25 0.85 -0.63 -0.03 0.30 -0.32 -0.60 -0.26 Probably 
damaging 
R367C 0.56 0.32 4.01 -0.37 0.83 -0.30 0.30 0.89 Probably 
damaging 
G424S 0.08 0.35 -0.48 -0.48 2.60 -0.02 -0.03 0.32 Probably 
damaging 
G425S 0.12 0.56 -0.95 -0.68 2.54 -0.28 -0.10 0.11 Probably 
damaging 
R461C 0.54 0.71 3.02 -0.39 0.16 -0.31 1.25 0.75 Probably 
damaging 
Non-disease-causing missense mutations 
Mutatio
n 
rSASA_mem Conser SAFFEC mCSM SDM DUET FOLDX Average SD 
V43I 0.16 0.74 0.02 -0.32 0.59 -0.10 0.61 0.16 Benign 
G70S 0.00 0.12 0.67 -1.68 -2.79 -1.95 2.51 -0.65 Benign 
V76I 0.43 0.06 -1.00 -0.27 0.01 -0.19 0.75 -0.14 Benign 
A137S 0.68 0.97 0.39 -0.81 -1.42 -0.66 -0.19 -0.54 Possibly 
damaging 
V140M 0.37 0.53 -0.75 -0.49 -0.74 -0.59 -0.81 -0.67 Benign 
A162V 0.13 0.76 0.94 0.00 0.68 0.19 -1.47 0.07 Possibly 
damaging 
V191I 0.31 0.82 0.43 -0.45 0.59 -0.20 -1.11 -0.15 Possibly 
damaging 
A195T 0.03 0.85 0.37 -0.96 -0.79 -0.96 4.06 0.35 Probably 
damaging 
M196V 0.03 0.41 -0.37 -0.97 -1.11 -1.08 4.19 0.13 Benign 
A206T 0.29 0.59 2.01 -1.05 -1.72 -0.99 -0.16 -0.38 Probably 
damaging 
M220L 0.08 0.85 0.27 0.16 0.40 0.47 0.14 0.29 Benign 
R260Q 0.25 0.15 -1.37 -0.49 -0.26 -0.28 0.23 -0.43 Benign 
I295V 0.09 0.88 0.55 -1.04 -0.59 -0.97 0.50 -0.31 Possibly 
damaging 
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Table C-4: Folding free energy, rSASA and Polyphen predictions for the mutations in 
DHCR7 protein. ΔΔGs are shown in kcal/mol and average ΔΔG are also calculated using 
the results from multiple webservers. Mutations A206T and H390T are located on the 
loop, not present in the template, thus the rSASA is highlighted as red to indicate low 
confidence in our calculation for these two mutations.  
 
P335R 0.32 0.38 -3.49 0.15 1.18 0.40 1.85 0.02 Possibly 
damaging 
R363C 0.54 0.88 2.53 -0.17 0.16 -0.10 0.29 0.54 Benign 
R363H 0.54 0.88 2.00 -0.98 -0.41 -0.99 0.29 -0.02 Probably 
damaging 
T364M 0.25 0.85 0.59 -0.03 0.30 -0.32 -0.62 -0.02 Probably 
damaging 
R367C 0.56 0.32 3.65 -0.37 0.83 -0.30 0.28 0.82 Probably 
damaging 
H390T 0.36 0.85 0.49 1.55 1.47 1.48 -0.34 0.93 Benign 
G425S 0.12 0.56 1.13 -0.68 2.54 -0.28 -0.10 0.52 Benign 
A452T 0.32 0.32 1.32 -1.28 -2.72 -1.18 0.41 -0.69 Possibly 
damaging 
G456S 0.33 0.94 -0.43 -1.30 -2.55 -1.21 4.05 -0.29 Probably 
damaging 
R461C 0.54 0.71 3.71 -0.39 0.16 -0.31 1.25 0.88 Probably 
damaging 
Using rSASA, EC score, PD and ΔΔG  Using only rSASA, EC score, PD 
K TP TN Accuracy K TP TN Accuracy 
1 4 2 0.6 1 5 4 0.9 
2 4 2 0.6 2 5 4 0.9 
3 5 2 0.7 3 6 4 1 
4 4 2 0.6 4 6 3 0.9 
5 5 2 0.7 5 6 4 1 
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Table C-5. KNN classifications using different properties and K values. True positive 
(TP), true negative (TN) and accuracy are calculated for each K value. 
 
 
Residue 
Rotamer 
A 
1 
C 
3 
D 
18 
E 
54 
F 
18 
G 
1 
H 
36 
I 
9 
K 
81 
L 
9 
Residue 
Rotamer 
M 
27 
N 
36 
P 
2 
Q 
108 
R 
81 
S 
3 
T 
3 
V 
3 
W 
36 
Y 
18 
 
Table C-6. Max number of the rotamers for all types of amino acids taken from [322]. 
 
 CE PS VE NS S HB Y-intercept 
Coefficient 0.078 0.048 0.088 -0.0012 0.14 -0.043 0.445 
P-value 2E-05 1E-05 7.13E-08 0.4 0.041 0.10 8.92E-08 
Correlation coefficient 0.72 Number of cases 105 
 
Table C-7. The weight coefficients of the linear function for binding free energy changes 
determined from MLR. The corresponding p-values are shown as well.    
6 5 2 0.7 6 6 4 1 
7 5 2 0.7 7 6 4 1 
8 5 3 0.8 8 6 4 1 
9 5 2 0.7 9 6 4 1 
10 5 0 0.5 10 5 4 0.9 
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Root Mean 
Square of the 
Error 
(kcal/mol) 
Pearson 
correlation 
coefficient 
Fold 1 0.53 0.33 
Fold 2 0.57 0.7 
Fold 3 0.48 0.76 
Fold 4 0.64 0.6 
Fold 5 0.49 0.52 
Average 0.54 0.58 
 
Table C-8. 5-fold cross validation for the dataset used for the SAMPDI approach. 
 
 
Averaged weighting 
coefficients in 5-fold cross 
validation 
Standard Deviation 
of weighting 
coefficients in 5-fold 
cross validation 
Weighting coefficients 
from MLR in the 
training 
Y-Intercept 0.46 0.075 0.445 
NS -0.0025 0.0015 -0.0012 
VE 0.098 0.016 0.088 
CE 0.074 0.017 0.078 
PS 0.046 0.01 0.048 
S 0.14 0.068 0.14 
HB -0.045 0.025 -0.043 
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Table C-9: Average weighting coefficients and corresponding standard deviation in 5-fold 
cross validation for all the energy terms. The determined weighting coefficients from MLR 
was also shown for the comparison.  
 
 
Correlation matrixes calculated with Pearson correlation 
 
SASA VDW CE PS S HB 
SASA 1 
     
VDW 0.7 1 
    
CE 0.64 0.29 1 
   
PS 0.61 0.26 0.99 1 
  
S 0.32 0.41 0.2 0.2 1 
 
HB 0.31 0.44 0.17 0.15 0.44 1 
Variance inflation factors (VIF) 
 SASA VDW CE PS S HB 
VIF 3.31 2.43 47.72 45.03 1.35 1.38 
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Table C-10. Correlation matrixes and variance inflation factors (VIF) for the energy terms 
in SAMPDI. Terms with high correlation and VIF values (CC > 0.5 and VIF >4) are 
underlined. 
 
Compound ID Chemical NAME 
Chembridge:78356510 (2R*,3R*)-3-amino-1'-[(1-isopropyl-4-piperidinyl)methyl]-2,3-
dihydrospiro[indene-1,4'-piperidin]-2-ol 
Chembridge:63954502 N-[3-(4-methylpiperazin-1-yl)butyl]-1-piperidin-1-ylcyclohexanecarboxamide 
Chembridge:82584961 3-{[4-(3-phenylpropyl)-1,4-diazepan-1-yl]methyl}pyrrolidin-3-ol 
Chembridge:14214075 1-methyl-4-{[1-(2-piperidin-2-ylethyl)-1H-1,2,3-triazol-4-yl]carbonyl}-1,4,9-
triazaspiro[5.5]undecane 
Chembridge:51996641 N-[(3-methyl-5,6,7,8-tetrahydro-2,7-naphthyridin-4-yl)methyl]-2-(3-
pyrrolidinyl)benzamide 
Chembridge:16017655 1-ethyl-4-{[3-(3-methylphenyl)-1-(4-methylphenyl)-1H-pyrazol-4-
yl]methyl}piperazine 
Chembridge:60958399 N-(2,5-dimethylphenyl)-3-{4-[1-(4-methylpiperazin-1-yl)ethyl]piperidin-1-yl}-3-
oxopropanamide 
Chembridge:74091868 2-(dimethylamino)-N-[2-methyl-2-(4-methyl-1-piperazinyl)propyl]-2-(3-
methylphenyl)acetamide 
Chembridge:58607167 (2R*,3R*)-1'-(N,N-dimethylglycyl)-3-(4-morpholinyl)-2,3-dihydrospiro[indene-
1,4'-piperidin]-2-ol 
Chembridge:71823596 2-methyl-N-{2-[3-(3-pyridinyl)-1H-1,2,4-triazol-5-yl]ethyl}-2,8-
diazaspiro[4.5]decane-3-carboxamide 
Chemdiv:L295-0542 N-(4-ethylbenzyl)-2-[2-(4-methylphenyl)-4-oxo-2,4-dihydro-5H-pyrazolo[3,4-
d]pyrimidin-5-yl]acetamide 
Chembridge:54664387 N-(2-methoxyethyl)-2-methyl-3-{[(4-methyl-1,4-diazepan-1-
yl)acetyl]amino}benzamide 
Chembridge:17062855 2-oxo-N-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylmethyl)-1,2,3,4-
tetrahydroquinoline-6-sulfonamide 
Chembridge:41385842 8-(2-amino-6-methyl-4-pyrimidinyl)-2-[(3,5-dimethyl-4-isoxazolyl)methyl]-2,8-
diazaspiro[4.5]decan-3-one 
Chembridge:80203307 N-(1,2-diphenylethyl)-3-(4-methylpiperazin-1-yl)propanamide 
Chembridge:44531433 2-{1-benzyl-5-[(4-ethylpiperazin-1-yl)methyl]-1H-1,2,4-triazol-3-yl}acetamide 
Chembridge:48959062 (4R)-N-(1-ethylpiperidin-4-yl)-4-hydroxy-N-(2-pyridin-2-ylethyl)-D-prolinamide 
Chembridge:89707730 (1R,9aR)-1-({[2-(1H-indol-3-yl)ethyl]amino}methyl)octahydro-2H-quinolizin-1-
ol 
Chembridge:93839784 6-[(6-methyl-2-pyridinyl)methyl]-N-[(4-phenyltetrahydro-2H-pyran-4-
yl)methyl]-6-azaspiro[2.5]octane-1-carboxamide 
Chembridge:46845072 3-[(dimethylamino)methyl]-1-{[3-(2,5-dimethylphenyl)-1H-pyrazol-4-
yl]methyl}-3-piperidinol 
Chembridge:19371006 2-(1-phenylcyclohexyl)-6-piperidin-4-ylpyrimidin-4(3H)-one 
Chemdiv:G008-5368 5-(3,4-dimethylisoxazol-5-yl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-
methoxybenzenesulfonamide 
Chembridge:35311030 4-{2-[(4-thiomorpholin-4-ylpiperidin-1-yl)carbonyl]phenyl}morpholine 
Chembridge:81745001 4-{1-[2-(4-methylbenzyl)benzoyl]piperidin-4-yl}morpholine 
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Chembridge:15330541 N-[(1-ethyl-2-pyrrolidinyl)methyl]-N-{[1-(2-methoxyethyl)-4-
piperidinyl]methyl}-2-(3-methyl-1H-pyrazol-1-yl)acetamide 
Chembridge:9294680 N-[2-methoxy-5-({[2-(1-methyl-4-
piperidinyl)ethyl]amino}sulfonyl)phenyl]acetamide 
Chembridge:30440650 4-{[3-(3-methoxybenzoyl)-1-piperidinyl]methyl}-1,5-dimethyl-2-phenyl-1,2-
dihydro-3H-pyrazol-3-one 
Chembridge:61839572 N-(5-methyl-2,1,3-benzothiadiazol-4-yl)-3-(4,5,6,7-tetrahydropyrazolo[1,5-
a]pyrazin-2-yl)propanamide 
Chemdiv:D153-0063 1'-[(2,3,5,6-tetramethylphenyl)sulfonyl]-1,4'-bipiperidine 
Chembridge:40078167 2-(3,9-diazabicyclo[4.2.1]non-9-yl)-N-(2-methylbenzyl)acetamide 
Chembridge:10864439 N-[3-[(benzylamino)methyl]-5-(1-
piperidinylcarbonyl)phenyl]methanesulfonamide 
Chembridge:70812278 N-[(4-{[1-(cyclopropylmethyl)piperidin-4-yl]methyl}-5-oxomorpholin-2-
yl)methyl]-1H-pyrazole-4-sulfonamide 
Chembridge:52194258 5-{[{[3-(1-benzofuran-2-yl)-1-benzyl-1H-pyrazol-4-
yl]methyl}(isopropyl)amino]methyl}-2-pyrrolidinone 
Chembridge:38093279 9-{3-[(dimethylamino)methyl]benzoyl}-1-oxa-9-azaspiro[5.5]undecan-5-ol 
Chembridge:40889750 N-[(1R)-1-(3-methoxyphenyl)ethyl]-2-methyl-6-piperidin-4-ylpyrimidin-4-
amine 
Chembridge:64562297 N-[(3-methyl-5,6,7,8-tetrahydro-2,7-naphthyridin-4-yl)methyl]-2-phenyl-2-
(1H-tetrazol-1-yl)acetamide 
Chembridge:23511553 5-({[2-(1-benzylpiperidin-2-yl)ethyl]amino}sulfonyl)thiophene-3-carboxamide 
Chembridge:26076097 N-{2-[3-(2-methylphenyl)-1-pyrrolidinyl]ethyl}-2-oxo-1,2-dihydro-4-
quinolinecarboxamide 
Chembridge:80360739 5-{[3-(diphenylmethyl)-6,7-dihydroisoxazolo[4,5-c]pyridin-5(4H)-yl]carbonyl}-
1H-1,2,4-triazol-3-amine 
Chemdiv:C255-0943 2-methyl-N-(3-methylbutyl)-1-[2-(4-methylpiperazin-1-yl)ethyl]-5-
oxoprolinamide 
Chembridge:84959457 N-[(1-benzyl-1H-imidazol-2-yl)methyl]-N-methyl-5-(pyrrolidin-1-ylmethyl)-2-
furamide 
Chembridge:69031290 1'-{2-[(4-methylphenyl)thio]propanoyl}-1,4'-bipiperidine-4'-carboxamide 
Chemdiv:S591-1521 N-[1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-3-azetanyl]-N-ethyl-N-tetrahydro-
2H-pyran-4-ylamine 
Lifechem:F5017-0127 5-ethyl-N-((1-isopropylpiperidin-4-yl)methyl)thiophene-2-sulfonamide 
Chemdiv:1956-0061 1-[(4-methylphenyl)sulfonyl]-3-(pyrrolidin-1-ylacetyl)imidazolidine 
Chembridge:56480740 2-(2-pyridin-2-ylethyl)-8-(pyrimidin-5-ylmethyl)-2,8-diazaspiro[5.5]undecan-3-
one 
Chembridge:77982386 N-(cis-4-aminocyclohexyl)-3-(2-furyl)-4-phenylbutanamide 
Chembridge:66763532 N-(1-tert-butylpyrrolidin-3-yl)-2-methyl-5-(1H-pyrazol-1-
yl)benzenesulfonamide 
Chembridge:20528061 N-(1-methyl-4-piperidinyl)-N-(2-phenylethyl)-1-azepanesulfonamide 
Chembridge:78005408 N-{2,4-dimethyl-5-[(4-methylpiperazin-1-yl)methyl]benzyl}-3-(2-methyl-1H-
imidazol-1-yl)propan-1-amine 
Chembridge:39970175 2-(1-{[5-(pyrrolidin-1-ylmethyl)-2-thienyl]methyl}piperidin-4-yl)propan-2-ol 
Chembridge:91750483 N-({1-[2-(2-methylphenyl)ethyl]-4-piperidinyl}methyl)-N-(3-
pyridinylmethyl)ethanamine 
Chembridge:91245078 2-[(4-benzylpiperazin-1-yl)methyl]-N-(1H-imidazol-2-ylmethyl)-N-methyl-1,3-
oxazole-4-carboxamide 
Chembridge:43919158 5-[(2-{4-[(dimethylamino)methyl]phenyl}-1-piperidinyl)methyl]-N,N-dimethyl-
2-furamide 
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Chembridge:63028404 7-{2-[3-(dimethylamino)-2-hydroxypropoxy]-5-methoxybenzyl}-3,5,6,7,8,9-
hexahydro-4H-pyrimido[4,5-d]azepin-4-one 
Chemdiv:S720-1526 (2S,4S)-N-[3-(3,5-dimethyl-4-isoxazolyl)propyl]-4-phenoxy-1-tetrahydro-2H-
pyran-4-yltetrahydro-1H-pyrrole-2-carboxamide 
Chembridge:81027564 N-{[8-(3-methylbut-2-en-1-yl)-1-oxa-8-azaspiro[4.5]dec-2-yl]methyl}-3-(2-
oxoazepan-1-yl)propanamide 
Chembridge:45596927 N-{[1-(4-morpholinyl)cyclohexyl]methyl}-4,5,6,7-tetrahydro-1H-imidazo[4,5-
c]pyridine-4-carboxamide 
Chembridge:11156722 1-methyl-4-[3-(5-methyl-1H-tetrazol-1-yl)propanoyl]-1,4,9-
triazaspiro[5.6]dodecan-10-one 
Chembridge:65552572 3-{[({[1-(2-methoxyethyl)pyrrolidin-3-yl]methyl}amino)carbonyl]amino}-4-
methylbenzenesulfonamide 
Chembridge:61821585 N-[2-(dimethylamino)ethyl]-2-(2,4-dimethyl-6-oxo-1,6-dihydropyrimidin-5-yl)-
N-(2-methylbenzyl)acetamide 
Chembridge:97069383 7-(1H-imidazol-4-ylmethyl)-N-(2-phenylethyl)-6,7,8,9-tetrahydro-5H-
pyrimido[4,5-d]azepin-4-amine 
Chembridge:62154375 2-(3-{[3-(2-pyridinyl)-1-azetidinyl]methyl}phenoxy)acetamide 
Chembridge:31484474 8-[2-(dimethylamino)ethyl]-2-(2-phenylethyl)-2,8-diazaspiro[5.5]undecan-3-
one 
Chembridge:40851669 N-[3-(4-methylpiperazin-1-yl)butyl]-4-(4H-1,2,4-triazol-4-yl)benzamide 
Chembridge:76608419 2-(2-isopropyl-1H-benzimidazol-1-yl)-N-[(7S,8aS)-2-
methyloctahydropyrrolo[1,2-a]pyrazin-7-yl]acetamide 
Chembridge:89145681 N-ethyl-5-[(4-ethylpiperazin-1-yl)methyl]-N-(2-methylbenzyl)isoxazole-3-
carboxamide 
Chembridge:21627035 1-methyl-5-[N-methyl-N-(1-methylpiperidin-4-yl)glycyl]-4,5,6,7-tetrahydro-1H-
pyrazolo[4,3-c]pyridine-3-carboxamide 
Chembridge:75582364 N-[(3-methyl-5,6,7,8-tetrahydro-2,7-naphthyridin-4-yl)methyl]-2-(1H-tetrazol-
5-yl)benzamide 
Chembridge:98517584 5,7-dimethyl-6-[3-oxo-3-(4-pyridin-3-yl-1,4,6,7-tetrahydro-5H-imidazo[4,5-
c]pyridin-5-yl)propyl][1,2,4]triazolo[1,5-a]pyrimidine 
Chembridge:25787349 (1R,9aR)-1-{[bis(2-furylmethyl)amino]methyl}octahydro-2H-quinolizin-1-ol 
Chembridge:13033623 (2-{4-[2-(2,5-dimethylphenoxy)propanoyl]piperazin-1-yl}ethyl)dimethylamine 
Chembridge:88031006 N-[(4-{[1-(cyclopropylmethyl)piperidin-4-yl]methyl}-5-oxomorpholin-2-
yl)methyl]-5-oxo-4,5-dihydro-1H-1,2,4-triazole-3-carboxamide 
Chembridge:60618842 2-(1-isopropylpiperidin-4-yl)-N-(2-phenylethyl)-N-(pyridin-2-
ylmethyl)acetamide 
Chembridge:73314389 [1-(2,1,3-benzoxadiazol-4-ylmethyl)-3-(2-phenylethyl)-3-piperidinyl]methanol 
Lifechem:F6178-7296 N1-(2-cyanophenyl)-N2-((1-(tetrahydro-2H-pyran-4-yl)piperidin-4-
yl)methyl)oxalamide 
Chemdiv:SA46-2193 {7-[benzyl(methyl)amino]-5-oxa-2-azaspiro[3.4]oct-2-yl}(1H-indazol-3-
yl)methanone 
Chembridge:13675749 N-[(4-{[1-(cyclopropylmethyl)piperidin-4-yl]methyl}-5-oxomorpholin-2-
yl)methyl]-2-(3,5-dimethyl-1H-pyrazol-1-yl)acetamide 
Chembridge:19197720 (1R,9aR)-1-({[2-(2-methyl-1H-imidazol-1-yl)benzyl]amino}methyl)octahydro-
2H-quinolizin-1-ol 
Chembridge:76559661 2-morpholin-2-yl-N-[2-(2-phenoxyphenyl)ethyl]acetamide 
 
Table C-11. Final selected compounds for experimental verification. 
 
